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Abstract	  Organisms	   have	   evolved	   and	   diversified	   since	   the	   beginning	   of	   life.	   Although,	   generation	   and	  maintenance	   of	   diversity	   within	   ecosystems	   has	   been	   a	   central	   concern	   in	   ecology	   and	   evolutionary	  biology,	   little	   is	  known	  of	   the	  evolutionary	  processes	  driving	  diversification.	  Especially,	  diversification	  in	   relation	   to	   chronic	   infection	   is	   a	  major	   concern	   as	  high	  population	  diversity	  has	  been	  predicted	   to	  result	  in	  survival	  and	  persistence	  of	  the	  infecting	  microbe.	  	  Therefore,	  understanding	  within-­‐host	  dynamics	  and	  population	  diversification	  is	  necessary	  for	  optimal	  diagnosis	  and	  therapeutic	  treatment.	  Chronic	   Pseudomonas	   aeruginosa	   infections	   in	   the	   airways	   of	   patients	   with	   cystic	   fibrosis	   (CF)	   offer	  opportunities	   to	   study	   bacterial	   evolution	   and	   adaptation	   in	   natural	   environments.	   Significantly	  phenotypic	  and	  genomic	  changes	  of	  P.	  aeruginosa	  have	  been	  observed	  during	  chronic	  infection.	  While	  P.	  
aeruginosa	  diversity	   has	   been	   documented	   in	   contemporary	   respiratory	   specimens,	   it	   is	   less	   clear	   to	  what	   extent	  within-­‐patient	   diversity	   contributes	   to	   the	   overall	   population	   structure	   and	  whether	   the	  population	  is	  geographically	  or	  homogeneously	  distributed	  throughout	  the	  airways.	  The	   focus	  of	   this	   thesis	  has	  been	   to	  get	   a	  better	  understanding	  of	  how	  bacterial	  populations	  adapt	   to	  new,	   complex	   and	   heterogeneous	   environments	   with	  multiple	   selective	   pressures	   over	   long	   periods,	  and	   to	   analyse	   diversification	   during	   this	   adaptation.	   Using	   the	   P.	   aeruginosa	   chronic	   infection	   as	   a	  model	   system,	   and	   by	   combining	   bacterial	   genome	   sequencing,	   phenotypic	   profiling	   and	   unique	  sampling	   materials	   which	   included	   clonal	   bacterial	   isolates	   sampled	   for	   more	   than	   4	   decades	   from	  chronically	   infected	   CF	   patients,	   we	   were	   able	   to	   investigate	   the	   diversity	   generation	   of	   the	   clinical	  important	   and	   highly	   successful	   P.	   aeruginosa	   DK1	   clone	   type	   during	   chronic	   airway	   infection	   in	   CF	  patients.	  	  We	   show	   here	   that	   diversification	   of	   P.	   aeruginosa	   DK1	   occurs	   through	   the	   emergence	   of	   coexisting	  subpopulations	  with	  distinct	  phenotypic	  and	  genomic	  features	  and	  demonstrate	  that	  this	  diversification	  was	  a	  result	  of	  niche	  specialization	  as	  each	  subpopulation	  colonized	  separate	  geographical	  niches.	  This	  highly	  complex	  population	  diversity	  was	  observed	  to	  be	  stably	  maintained	  during	  long-­‐term	  evolution.	  	  Before	  diversification	  of	  the	  DK1	  clone,	  a	  regulatory	  mutation	  was	  found	  to	  be	  fixed	  in	  the	  population	  causing	  alteration	  of	  multiple	  phenotypes	  representing	  the	  chronic	  stage	  phenotype.	  	  	  Often	  chronic	  CF	  infections	  are	  polyclonal	  and	  therefore	  we	  investigated	  the	  population	  dynamics	  in	  a	  patient	  polyclonal	  infected	  with	  both	  DK1	  and	  DK2.	  We	  demonstrated	  that	  diversification	  was	  affected	  by	  the	  presence	  of	  other	  clones;	  interaction	  between	  the	  two	  clones	  resulted	  in	  horizontal	  DNA	  transfer	  that	  contributed	  to	  the	  observed	  population	  diversity	  by	  creating	  a	  novel	  strain	  DK1/2	  found	  to	  persist	  in	  the	  CF	  airways.	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These	  data	  indicate	  that	  spatial	  compartmentalization	  and	  transfer	  of	  DNA	  between	  infecting	  microbes	  can	   cause	   generation	   and	   maintenance	   of	   population	   diversity	   of	   infecting	   pathogens.	   Furthermore,	  fine-­‐tuning	  of	  global	  regulatory	  networks	  by	  modification	  of	  transcriptional	  regulators	  has	  fundamental	  roles	  in	  successful	  adaptation	  of	  P.	  aeruginosa	  to	  the	  CF	  environment.	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Dansk	  Resumé	  Organismer	   har	   udviklet	   sig	   og	   diversificeret	   siden	   livets	   begyndelse.	   Selvom	   generering	   og	  vedligeholdelse	   af	   diversitet	   i	   økosystemer	   har	   været	   et	   centralt	   anliggende	   i	   økologi	   og	   evolutionær	  biologi,	   vides	   der	   kun	   lidt	   om	   de	   evolutionære	   processer	   der	   ligger	   til	   grund	   for	   diversificering.	  Diversitet	   er	   især	   et	   stort	   problem	   i	   forhold	   til	   kronisk	   infektion	   hvor	   stor	   populationsdiversitet	   kan	  resultere	  i	  overlevelse	  og	  persistens	  af	  den	  inficerende	  mikrobe.	  Det	  er	  derfor	  vigtig	  at	  forstå	  dynamikken	  of	  populationsdiversiteten	  i	  patienten	  for	  optimal	  diagnose	  og	  terapeutisk	  behandling.	  Kroniske	  luftvejsinfektioner	  med	  Pseudomonas	  aeruginosa	  hos	  patienter	  med	  cystisk	  fibrose	  (CF)	  giver	  muligheden	  for	  at	  studere	  bakteriel	  evolution	  og	  tilpasning	  i	  naturlige	  miljøer.	  Signifikante	  fænotypiske	  og	   genomiske	   ændringer	   af	   P.	   aeruginosa	   er	   blevet	   observeret	   under	   kronisk	   infektion.	   Mens	   P.	  
aeruginosa	   diversitet	   er	   blevet	   dokumenteret	   i	   sputum	   prøver,	   er	   det	  mindre	   klart,	   i	   hvilket	   omfang	  diversiteten	  bidrager	  til	  den	  samlede	  populations	  struktur	  i	  patienten,	  og	  om	  populationen	  er	  geografisk	  eller	  homogent	  fordelt	  i	  luftvejene.	  Fokusset	   i	   denne	   afhandling	   har	   været	   at	   få	   en	   bedre	   forståelse	   af,	   hvordan	   bakteriepopulationer	  tilpasse	  sig	  nye,	  komplekse	  og	  heterogene	  miljøer	  med	  forskellige	  selektive	  pres	  over	  lange	  perioder,	  og	  at	  analysere	  diversiteten	  i	  løbet	  af	  denne	  tilpasning.	  Ved	  bruge	  af	  P.	  aeruginosa	  kroniske	  infektioner	  som	  modelsystem,	   og	   ved	   at	   kombinere	   bakteriel	   genomsekventering,	   fænotypiske	   profiler	   og	   unikke	  prøver,	  som	  inkluderer	  klonale	  bakterieprøver	  isoleret	  fra	  kronisk	  inficerede	  CF-­‐patienter	  for	  mere	  end	  4	  årtier,	  var	  vi	  i	  stand	  til	  at	  undersøge	  diversitet	  udviklingen	  af	  den	  klinisk	  vigtige	  og	  yderst	  succesfulde	  
P.	  aeruginosa	  DK1	  klon	  i	  kroniske	  luftvejsinfektioner	  hos	  CF-­‐patienter.	  Vi	   viser	   her,	   at	   diversificering	   af	   P.	   aeruginosa	   DK1	   sker	   gennem	   fremkomsten	   af	   sameksisterende	  subpopulationer	  med	  forskellige	  fænotypiske	  og	  genomiske	  funktioner	  og	  viser,	  at	  denne	  diversitet	  var	  et	   resultat	   af	   niche	   specialisering	   hvor	   hver	   subpopulation	   koloniserede	   adskilte	   geografiske	   nicher.	  Denne	   meget	   komplekse	   populationsdiversitet	   viste	   sig	   at	   være	   stabil	   under	   langvarig	   evolution.	  Før	  diversificering	  af	  DK1	  klonen	  fandt	  sted,	  blev	  en	  regulatorisk	  mutation	  fikseret	  i	  populationen	  som	  forårsagede	   ændringen	   til	   en	   fænotype	   der	   repræsenterede	   den	   kroniske	   fase	   fænotype.	  Kroniske	   CF	   infektioner	   er	   ofte	   polyklonale	   og	   derfor	   undersøgte	   vi	   populationsdynamikken	   hos	   en	  patient	   inficeret	  med	  både	  DK1	  og	  DK2.	  Vi	  viste,	   at	  diversificering	  var	  påvirket	  af	   tilstedeværelsen	  af	  andre	  kloner;	  samspillet	  mellem	  de	  to	  kloner	  resulterede	  i	  horisontal	  DNA	  overførsel,	  der	  bidrog	  til	  den	  observerede	  populationsdiversitet	  ved	  at	  skabe	  en	  ny	  stamme	  DK1/2	  der	  varerede	  ved	  i	  CF	  luftvejene.	  Disse	  data	  indikerer,	  at	  rumlig	  opdeling	  og	  overførsel	  af	  DNA	  mellem	  de	  inficerende	  mikroorganismer	  kan	   forårsage	   generering	   og	   vedligeholdelse	   af	   populationsdiversiteten	   af	   patogener.	   Derudover	   har	  finjustering	   af	   de	   globale	   regulatoriske	   netværk	   ved	   ændring	   af	   transskriptionsregulatorer	   en	  grundlæggende	  rolle	  i	  en	  vellykket	  tilpasning	  af	  P.	  aeruginosa	  til	  CF	  miljø.	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Chapter	  1	  	  
Introduction	  	  ince	   the	  beginning	  of	   life,	  organisms	  have	  evolved	  and	  diversified.	  The	  biological	  diversity	  on	  our	  planet	   is	   one	   of	   the	   most	   fascinating	   features	   we	   can	   address	   as	   scientists.	   Fossils	   or	   frozen	  organisms	  have	  made	  it	  possible	  to	  go	  back	  in	  time	  and	  study	  evolutionary	  processes	  and	  trajectories.	  	  In	  the	  case	  of	  bacteria,	  we	  are	  able	  to	  observe	  ‘real-­‐time’	  evolution	  as	  it	  progress,	  because	  of	  their	  short	  generation	   times	   and	   large	   population	   sizes	   in	   small	   spaces.	   Furthermore,	   transcriptomics,	  metabolomics,	   proteomics	   and	   next	   generation	   sequencing	   provide	   great	   tools	   for	   investigating	   the	  evolutionary	  trajectories	  and	  dynamics	  of	  an	  adapting	  population	  to	  a	  novel	  environment.	  Understanding	   the	   mechanisms	   and	   factors	   that	   promote	   and	   maintain	   genetic	   diversity	   within	  ecosystems	  remains	  a	  major	  topic	  in	  ecology	  and	  evolutionary	  biology.	  The	   central	   focus	   point	   in	   this	   thesis	   has	   been	   to	   document	   how	  bacterial	   populations	   adapt	   to	   new,	  complex	   and	   heterogeneous	   environments	   over	   long	   time	   periods,	   and	   to	   investigate	   the	   occurrence	  and	  maintenance	  of	  diversity	  in	  the	  evolving	  populations.	  To	   address	   this,	   we	   used	   long-­‐term	   chronic	   airway	   infection	   with	   Pseudomonas	   aeruginosa	   of	   cystic	  fibrosis	   (CF)	   patients	   for	   our	   model	   system.	   In	   this	   model	   system,	   we	   were	   able	   to	   investigate	  longitudinal	  evolutionary	  trajectories	  covering	  more	  than	  150,000	  bacterial	  generations	  [1]	  for	  different	  bacterial	  clones	  in	  distinct	  patients.	  Knowledge	   about	   evolutionary	   processes	   and	   dynamics	   is	   important	   in	   the	   treatment	   of	   chronic	  infections.	   Today,	   we	   only	   have	   limited	   information	   about	   long-­‐term	   evolutionary	   trajectories	   of	  pathogens	  in	  natural	  environments.	  	  
1.1|Outline	  of	  Thesis	  This	  thesis	  describes	  the	  evolutionary	  dynamics	  of	  adapting	  P.	  aeruginosa	  to	  natural	  environments	  that	  are	  characterized	  by	  complexity,	  spatial	  structures	  and	  dynamic	  that	  changes	  over	  time.	  While	  Chapter	  1	  gives	  an	  outline	  of	  this	  thesis,	  Chapter	  2	  summarizes	  some	  of	  the	  important	  knowledge	  about	  bacterial	  adaptation	   to	   novel	   environment	   based	   on	   in	   vitro	   evolutionary	   experiments.	   Chapter	   3	   gives	   an	  introduction	   to	   the	   model	   system	   used	   in	   this	   thesis:	   The	   chronic	   airway	   infection	   of	   cystic	   fibrosis	  patients	   and	   the	   lifestyle	   of	   P.	   aeruginosa	   in	   the	   CF	   airway.	   Present	   investigations	   are	   introduced	   in	  
Chapter	   4	   that	   gives	   the	   background	   and	   main	   objectives	   for	   this	   thesis.	   The	   conclusion	   and	   future	  perspective	  can	  be	  found	  in	  Chapter	  5	  and	  the	  papers	  presented	  in	  this	  thesis	  can	  be	  found	  in	  Chapter	  6.	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Chapter	  2	  
Bacterial	  adaptation	  and	  evolution	  	  or	   billions	   of	   years	   microorganisms	   have	   been	   adapting	   and	   evolving	   to	   many	   fluctuating	   and	  hostile	   environments	   and	   have	   practically	   colonized	   all	   available	   ecological	   niches	   on	   Earth.	  Experimental	   microbial	   evolution	   has	   provided	   great	   insight	   into	   the	   microbial	   dynamics	   of	  evolutionary	  adaptation	  by	  allowing	  researchers	  to	  test	  their	  theories	  directly.	  	  Microbes	  are	  ideal	  subjects	  for	  observe	  ‘real-­‐time’	  evolution	  as	  they	  reproduce	  quickly	  due	  to	  their	  short	  generation	  times	  and	  allow	  large	  population	  sizes	   in	  small	  places	  [2].	  Their	  ability	   to	  remain	  viable	  at	  frozen	   temperatures	   and	   resume	   proliferation	   when	   thawed	   provides	   the	   opportunity	   to	   compare	  ancestral	  and	  evolved	  populations.	  The	   experimental	   setup	   is	   mostly	   simple	   involving	   propagating	   populations	   from	   single	   clones	   in	   a	  defined	   laboratory	   environment.	   After	   growing	   for	   multiple	   generations,	   genotypic	   and	   phenotypic	  changes	   can	   be	   compared	   between	   ancestral	   and	   evolved	   populations.	   These	   kinds	   of	   evolution	  experiments	   have	   contributed	   with	   knowledge	   about	   the	   dynamics	   and	   genetic	   basis	   of	   adaptive	  processes	  during	  evolution.	  	  Evolution	   experiments	   with	   microorganisms	   have	   increased	   significantly	   during	   the	   recent	   years.	   In	  1988	   Richard	   Lenski	   and	   co-­‐workers	   initiated	   a	   long-­‐term	   evolutionary	   experiment	   (LTEE)	   with	  
Escherichia	  coli,	  where	  12	  parallel	  cultures	  were	  inoculated	  in	  a	  simple	  defined	  medium.	  Every	  day	  for	  the	  next	  26	  years	   (and	  still	  on-­‐going)	   the	  cultures	  were	  diluted	  and	  re-­‐inoculated	   in	   fresh	  medium	  to	  evolve	  more	  than	  50,000	  generation	  in	  a	  constant	  environment.	  During	  this	  period,	  samples	  extracted	  from	   the	   cultures	  have	  been	   stored	   regularly	   creating	   a	   fossil	   collection.	  This	   collection	  has	  provided	  great	  insight	  into	  the	  long-­‐term	  dynamics	  of	  adaptation	  including	  fitness	  kinetics	  and	  fitness	  trajectories	  [3].	  Furthermore,	  impacts	  of	  increased	  mutation	  rates	  [4],	  parallel	  evolution	  [5],	  evolution	  of	  innovative	  traits	   [6],	  and	  the	   importance	  of	  pleiotropic	  mutations	  [7]	  was	  demonstrated.	   In	   this	  chapter,	  some	  of	  these	  findings	  and	  theories	  behind	  adaptive	  evolution	  are	  presented.	  	  	  
2.1|Dynamics	  of	  evolutionary	  adaptation	  Most	  often,	  an	  organism	  needs	   to	  change	   its	  phenotype	   in	  order	   to	  adapt	   to	  a	  new	  environment.	  This	  evolutionary	  process	  where	  the	  reproductive	  success	  is	  improved	  has	  for	  long	  been	  of	  great	  interest	  to	  scientists.	  An	  organism	  may	  improve	  its	  fitness	  by	  either	  phenotypic	  acclimation	  or	  genetic	  alterations.	  Phenotypic	   acclimation	   refers	   to	   the	   change	   of	   phenotype	  without	   genetic	   changes	   [8].	   However,	   the	  metabolic	  cost	  linked	  to	  this	  may	  be	  unfavourable	  for	  long-­‐term	  adaptation	  to	  a	  changing	  and	  complex	  environment	  [9].	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Changing	   of	   genetic	   content	   can	   be	   achieved	   by	   either	  de	  novo	  mutations	   in	   already	   existing	  DNA	   or	  acquisition	  of	  new	  DNA	  from	  other	  organisms	  (see	  section	  2.2).	  	  
	  
2.1.1|Adaptive	  and	  nonadaptive	  mutations	  Adaptation	  through	  natural	  selection	  may	  improve	  the	  fitness	  relative	  to	  its	  ancestor	  by	  acquisition	  of	  mutations	   including	   single	   nucleotide	   polymorphisms	   (SNPs),	   indels	   (deletions	   and	   insertions),	   and	  gene	  rearrangements	  [2].	  Mutations	  can	  be	  divided	  into	  beneficial,	  neutral	  and	  deleterious	  based	  on	  the	  effect	  on	  the	  fitness.	  Beneficial	  mutations	  that	  drive	  adaptation	  by	  conferring	  an	  improved	  fitness	  in	  the	  environment	  are	  also	  referred	  to	  as	  adaptive	  mutations	  and	  are	  believed	  to	  be	  caused	  by	  the	  selective	  pressures	  rather	  than	  being	  random	  [10].	  Studying	  adaptive	  mutations	  can	  give	  better	  understanding	  of	  genetic	  events	  underlying	  the	  adaptation	  and	  can	  identify	  genes	  relevant	  for	  this	  adaptation.	  	  Adaptive	  benefits	  of	  a	  mutation	  are	  usually	  analysed	  by	  transferring	  the	  exact	  mutation	  to	  an	  isogenic	  strain	  and	  investigate	  fitness	  effects.	  [2].	  This	  is	  necessary	  since	  neutral	  or	  even	  deleterious	  mutations	  can	  hitchhike	  with	  beneficial	  mutations.	  Hitchhiking	  refers	  to	  the	  movement	  and	  increase	  of	  a	  neutral	  or	  a	   deleterious	   mutation	   in	   the	   population	   caused	   by	   its	   physical	   linkage	   with	   beneficial	   mutations	  elsewhere	  in	  the	  genome	  [2].	  	  Some	  mutations	  can	  appear	  nonadaptive	  meaning	  that	  they	  do	  not	  have	  a	  fitness	  effect.	  There	  may	  be	  several	  reasons	  for	  this	  observation:	  1) The	  mutations	  are	  neutral	  and	  either	  hitchhike	   to	  high	   frequency	  with	  beneficial	  mutations	  or	  drift	  randomly	  to	  high	  frequency	  [2,	  11].	  	  2) The	  mutations	   are	   adaptive,	   however,	   the	  methods	   to	   determine	   the	   fitness	   are	   not	   sensitive	  enough	  or	  not	  performed	  in	  the	  right	  conditions	  to	  detect	  the	  fitness	  increase	  [11].	  3) The	   fitness	   effects	   of	   mutations	   are	   epistatic,	   meaning	   that	   they	   are	   modified	   by	   their	  interactions	  with	  other	  mutations	  in	  the	  genome	  [11,	  12].	  In	  this	  way,	  some	  adaptive	  mutations	  can	  appear	  nonadaptive,	  but	  can	  increase	  fitness	  in	  combination	  with	  others.	  	  Even	   though	   neutral	   or	   deleterious	   mutations	   often	   occur,	   they	   will	   rarely	   become	   dominant,	   while	  beneficial	  mutations	  confer	  a	  fitness	  advantage	  in	  the	  given	  environment	  and	  may	  therefore	  be	  fixed	  in	  the	  population	   [13].	   If	   the	   rate	   of	   beneficial	  mutation	   appearance	   is	   low	  and	   the	   fitness	   advantage	  of	  each	  mutation	   is	   large,	   a	   beneficial	  mutation	   can	   completely	   replace	   all	   less	   fit	   variants	   and	   become	  fixed	   in	   the	   population,	   a	   phenomenon	   known	   as	   selective	   sweep	   [14,	   15]	   (Figure	   1).	   However,	   if	   the	  beneficial	  mutation	   rate	   is	   high	   and	  multiple	   lineages	   exist,	   each	  with	   different	   beneficial	  mutations,	  they	  will	  compete	  with	  each	  other,	  an	  effect	  known	  as	  clonal	  interference	  [15].	  The	  competition	  between	  these	  different	  lineages	  may	  slow	  down	  the	  rate	  of	  fixation,	  meaning	  that	  clonal	  interference	  can	  extent	  the	   time	  of	  genomic	  adaptation	  [16].	   If	   the	  environment	  remains	  constant,	  one	   lineage	  will	  eventually	  outcompete	  the	  others,	  a	  phenomenon	  called	  niche	  exclusion	  [17]	  (Figure	  1).	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  Figure	  1|Dynamics	  in	  an	  evolving	  bacterial	  population.	  Lineages	  with	  new	  beneficial	  mutations	  are	  represented	  as	  shaded	  wedges	  that	  originate	  in	  a	  previous	  genetic	  background	  and	  rise	  in	  frequency	  as	  they	  outcompete	  their	  ancestor	  and	  other	  lineages.	  The	  same	  shading	  indicates	  the	  presence	  of	  multiple	  competing	  beneficial	  mutations	  (clonal	  interference)	  and	  the	  light	  gray	  curve	  highlights	  the	  path	  to	  the	  final	  dominant	  genotype	  containing	  five	  mutations.	  (a)	  A	  beneficial	  mutation	  sweeps	  to	  fixation	  and	  generates	  a	  little	  diversity.	  Four	  lineages	  with	  different	  mutations	  coexist	  (b)	  before	  the	  offspring	  of	  one	  lineage	  become	  the	  majority	  (c)	  (niche	  exclusion).	  Figure	  is	  adapted	  from	  Barrick	  and	  Lenski	  (2009)	  [14].	  	  	  Experimental	  studies	  have	  shown	  that	  fitness	  gains	  initially	  are	  rapid	  but	  tend	  to	  decelerate	  over	  time	  [18].	   This	   may	   occur	   if	   mutations	   with	   large	   effects	   become	   fixed	   early	   and/or	   beneficial	   mutations	  become	   rarer	   as	   adaptation	  progress	  or	  have	   smaller	   effects	  on	   the	   fitness	   [2,	   18].	  This	  means	   that	   a	  population	   in	   a	   new	  environment	   evolves	   from	  a	   region	  of	   low	   fitness	   towards	   an	   adaptive	  peak	   [2],	  which	  can	  be	  achieved	  by	  several	  pathways	  depending	  on	  the	  fitness	  landscape	  and	  the	  acquirements	  of	  adaptive	  mutations	   (Figure	  2).	  When	  a	  population	   is	  near	  an	  adaptive	  peak	  only	  beneficial	  mutations	  will	  move	  it	  uphill,	  while	  deleterious	  mutations	  may	  move	  it	  downhill	  [19].	  When	  located	  at	  the	  top,	  the	  population	  is	  referred	  to	  as	  a	  specialist	  of	  the	  given	  niche.	  
	  Figure	   2|Climbing	   adaptive	   peaks	   in	   a	   rugged	   fitness	   landscape.	   Demonstration	   of	   a	   population	   (yellow)	   evolving	   in	   a	  heterogeneous	  environment	  with	  three	  distinct	  niches	  (peaks).	  Peaks	  represent	  optimal	  genotype	  for	  each	  niche	  and	  arrows	  represent	  different	  genotypic	  step	  that	  can	  lead	  to	  the	  top.	  The	  population	  may	  acquire	  distinct	  mutations	  moving	  it	  towards	  different	  peaks	  and	  therefore	  create	  diversity.	  Figure	  is	  modified	  from	  Elena	  and	  Sanjuan	  (2003)	  [19].	  	  What	  happens	  if	  the	  landscape	  changes	  or	  the	  population	  is	  moved	  to	  a	  new	  environment?	  It	  is	  a	  general	  concern	   in	   evolutionary	   biology	   that	   beneficial	   mutations	   conferring	   a	   fitness	   advantage	   in	   one	  environment,	   are	   presumed	   to	   have	   fitness	   cost	   in	   another	   environment	   [2,	   20].	   Such	   trade-­‐offs	   are	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often	  caused	  by	  antagonistic	  pleiotropy,	   in	  which	  a	  mutation	   that	   increase	   fitness	   in	  one	  environment,	  carry	   a	   cost	   and	   regress	  of	   fitness	   in	   a	   second	  environment.	   It	   can	  also	  be	   caused	  by	  accumulation	  of	  
mutations,	  in	  which	  neutral	  mutations	  in	  one	  environment	  are	  deleterious	  in	  a	  second	  environment	  [2,	  20,	   21].	   	   In	   this	   way,	   the	   same	   mutation	   that	   confers	   adaptation	   in	   one	   environment	   causes	   fitness	  decrease	  in	  different	  environment	  (Figure	  3).	  	  In	  contrast,	  generalists	  can	  tolerate	  a	  broad	  range	  of	  environmental	  conditions	  and	  are	  expected	  to	  arise	  in	  changing	  and	  variable	  environments	  because	  selection	  favours	  the	  genotype	  with	  the	  highest	  fitness	  across	  all	  environments	  [19,	  21].	  	  
	  Figure	  3|Trade-­‐offs	  and	  specificity	  of	  adaptation	  of	  genotype	  A,	  B,	  and	  C.	  Genotype	  A	  is	  a	  specialist	  adapted	  to	  environment	  A,	  but	  have	  acquired	  mutations	  with	  trade-­‐offs	  and	  therefore	  have	  reduced	  fitness	  in	  environment	  B.	  The	  opposite	  is	  true	  for	  genotype	  B,	  while	  genotype	  C	  is	  a	  generalist	  that	  performs	  moderately	  well	  in	  both	  environment	  A	  and	  B,	  but	  have	  lower	  fitness	  than	  the	  specialists	  in	  their	  preferred	  environment.	  The	  figure	  is	  adapted	  from	  Elena	  and	  Lenski	  (2003)	  [2].	  	  
2.1.2|Adaptive	  radiation	  and	  Niche	  specialization	  In	   spatially	   structured	   environments	   with	   distinct	   adaptive	   peaks	   (Figure	   2)	   acquisition	   of	   different	  mutations	  can	  generate	  genomic	  and	  phenotypic	  variation	  by	  moving	  the	  population	  towards	  different	  adaptive	  peaks.	   In	  doing	   so,	   subpopulation	  may	  occur	   that	   each	   climb	  different	   adaptive	  peaks	   in	   the	  fitness	   landscape	   leading	   to	   niche	   specialisation	   [19,	   22].	   This	   diversification,	   in	   which	   a	   genetically	  uniform	   population	   evolves	   into	   distinct	   subpopulations,	   each	   colonizing	   their	   own	   niches,	   is	   also	  referred	  to	  as	  adaptive	  radiation.	  	  Rainey	   and	  Travisano	  demonstrated	   that	   adaptive	   radiation	   increases	   as	   a	   function	   of	   environmental	  complexity	  and	  spatial	  heterogeneity	  [23]	  (Figure	  4).	  It	  was	  further	  showed	  that	  competition	  among	  the	  evolved	  niche-­‐specialist	  maintained	  variation	  [24].	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  Figure	   4|Adaptive	   radiation	   in	   microcosms.	   Experimental	   evolution	   of	   a	   single	   clone	   of	  Pseudomonas	   fluorescens	   in	   A)	   a	  heterogeneous	   environment	   and	   B)	   a	   homogeneous	   environment	   performed	   by	   Rainey	   and	   Travisano	   [24].	   A)	   In	   a	  heterogeneous	  environment	  a	  single	  clone	  gave	  rise	  to	  three	  subpopulations	  each	  occupying	  distinct	  niches	  within	  the	  spatially	  structured	   microcosms.	   B)	   In	   contrast,	   no	   diverse	   morphologies	   were	   observed	   in	   a	   homologous	   environment.	   Figure	   is	  adapted	  from	  Buckling	  et	  al.	  (2009)	  [23].	  
	  Another	  example	  of	  diversity	  generation	  was	  demonstrated	  by	  Singh	  and	  colleagues	  who	  showed	  that	  P.	  
aeruginosa	   rapidly	   undergoes	   extensive	   genetic	   diversification	   during	   short-­‐term	   growth	   in	   biofilm	  communities	  as	  a	  consequence	  of	  a	  heterogeneous	  environment	  with	  nutrient	  gradients	  [25,	  26].	  	  Hence,	   it	   appears	   that	   complex	   spatially	   environments	   drive	   the	   emergence	   of	   niche	   specialists	   [22].	  However,	   little	   is	  known	  about	   the	  diversity	  during	   long-­‐term	  evolution	  and	   in	  natural	  environments.	  An	  interesting	  question	  is	  if	  the	  diversity	  is	  stably	  maintained	  over	  extended	  periods	  and	  if	  geographical	  locations	   of	   the	   populations	   maintain	   this	   diversity.	  We	   have	   addressed	   this	   in	   paper	   1	   (Chapter	   6)	  where	   it	  was	  demonstrated	  that	   the	  geographical	   locations	   indeed	  play	  a	   fundamental	  role	   in	  shaping	  the	   population	   diversity	   in	   complex	   and	   spatially	   structured	   environments	   and	   that	   this	   generated	  diversity	  is	  stably	  maintained	  during	  long-­‐term	  evolution	  [27].	  	  	  
2.1.3|Rewiring	  of	  regulatory	  networks	  It	   has	   long	   been	   of	   great	   interest	   to	   understand	   the	   molecular	   mechanisms	   behind	   the	   phenotype	  changes	  during	  adaptation	  of	  an	  organism	  to	  a	  new	  environment.	  	  Studies	   on	  molecular	   evolution	   have	   proposed	   that	   it	   is	   the	   regulatory	   genes,	   rather	   than	   structural	  genes,	  that	  are	  important	  during	  the	  adaption	  [28].	  The	  reasons	  might	  be	  that	  mutations	  in	  transcription	  regulators	   can	   change	   the	   binding	   specificity	   or	   create	   or	   delete	   interactions	   and	   thereby	   shaping	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entirely	   new	   traits	   [29].	   In	   this	  way	  mutations	   in	   transcriptional	   regulation	   can	   alter	   the	   function	   or	  activity	   of	   one	   central	   protein	   involved	   in	   a	   complex	   regulatory	   network.	   Therefore,	   regulatory	  mutations	   often	   have	   widespread	   pleiotropic	   effects	   that	   are	   likely	   to	   have	   a	   fitness	   cost,	   and	  compensatory	  mutation	  may	   arise	   to	  modulate	   the	   regulatory	   network	   to	   reduce	   some	   of	   these	   side	  effects	  (Figure	  5)	  [30].	  	  Furthermore,	   several	   studies	   have	   shown	   that	   adaptive	  mutations	   in	   global	   regulatory	   genes	   involve	  major	   epistatic	   interactions	   [12,	   31,	   32].	   Damkiær	   and	   colleagues	   demonstrated	   that	   epistatic	  interactions	  of	  global	  regulators	  played	  a	  fundamental	  role	  in	  adaptation	  of	  the	  dominant	  P.	  aeruginosa	  DK2	  lineage	  to	  the	  cystic	  fibrosis	  environment	  [32].	  	  Because	   bacterial	   genes	   are	   regulated	   by	   multiple	   transcription	   factors	   working	   cooperatively	   or	  competitively,	   transcriptional	   rewiring	   caused	   by	  mutations	  may	   result	   in	   the	   establishment	   of	   novel	  combinational	   regulation	   [28].	   	  Likewise,	  we	  showed	   that	  mutation	   in	  a	  global	   regulator	  modified	   the	  regulon	   of	   this	   protein	   and	   resulted	   in	   significantly	   distinct	   gene	   expression	   profiles	   and	   catabolism	  compared	  to	  both	  a	  wild	  type	  and	  a	  knockout	  mutant	  (see	  Chapter	  6,	  paper	  2	  [33]).	  	  
	  Figure	  5|Evolution	  of	  regulatory	  networks.	  Example	  of	  a	  regulatory	  network	  (top).	  An	  early	  mutation	  in	  a	  central	  regulatory	  protein	  results	  in	  alteration	  of	  several	  other	  proteins	  where	  some	  are	  beneficial	  while	  others	  are	  not	  (middle).	  To	  account	  for	  this,	  later	  in	  evolution,	  compensatory	  mutation	  may	  arise	  (bottom).	  Figure	  is	  adapted	  from	  Hindre	  et	  al.	  (2012)	  [30].	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Evolution	   through	   bacterial	   transcription	   rewiring	   is	   mainly	   focused	   on	   the	   interaction	   between	  transcription	   factors,	   RNA	   polymerase	   and/or	   target	   promoters,	   however,	   other	   factors	   affecting	  transcription	   exist	   including	   secondary	  messengers,	   regulatory	  RNA	   and	   small	   RNAs	   [28].	  Due	   to	   the	  scope	  of	  this	  thesis,	  these	  factors	  will	  not	  be	  described	  here.	  	  
2.1.4|Hypermutators	  and	  their	  role	  in	  adaptation	  During	  adaptation	  hypermutators	  have	  been	  frequently	  found	  to	  arise	  both	  under	  laboratory	  conditions	  [4]	   and	   in	   natural	   environments	   [34].	   	   These	   hypermutators	   can	   have	   increased	  mutation	   rate	   up	   to	  1000-­‐fold	  caused	  by	  defects	  in	  DNA	  repair	  associated	  genes	  [35].	  	  The	   exact	   role	   of	   mutators	   in	   bacterial	   evolution	   is	   unclear,	   however,	   models	   have	   shown	   that	   the	  prevalence	  of	   strong	  mutators	   genes,	   that	   increase	   the	  mutation	   rate,	   can	  accelerate	   adaptation	   in	   an	  evolving	   population	   [35,	   36].	   Consequently,	   mutators	   can	   result	   in	   a	   rapid	   acquisition	   of	   beneficial	  mutations	  that	  enable	  them	  to	  specialize	  in	  the	  environment,	  but	  may	  have	  reduced	  capacity	  to	  survive	  elsewhere	  and	  therefore	  reduce	  the	  transmissibility	  of	  the	  strain	  [37].	  	  It	  has	  been	  described	  that	  mutators	  can	  spread	  and	  be	  fixed	  by	  hitchhiking	  with	  the	  beneficial	  mutations	  they	   generate	   [36,	   38].	   Likewise,	   in	   many	   studies	   the	   appearance	   of	   mutators	   have	   been	   linked	   to	  increased	  antibiotic	  resistance	  [34,	  39].	  Furthermore,	  complex	  and	  spatial	  habitats	  have	  been	  shown	  to	  promote	  evolution	  of	  mechanisms	  to	  enhance	  the	  rate	  of	  variation	  [34-­‐36].	  Under	  these	  conditions	  with	  strong	   selective	   challenges,	   bottlenecks	   are	   predicted	   to	   occur	   and	   thus	   giving	  mutators	   a	   significant	  role	  in	  bacterial	  evolution	  [34].	  While	  in	  a	  constant	  environment,	  mutation	  rates	  have	  been	  predicted	  to	  remain	  low	  [38].	  It	  has	  been	  shown	  that	  bacterial	  mutation	  rates	  change	  during	  adaptation	  so	  that	  a	  high	  mutation	  rate	  is	  beneficial	  at	  the	  beginning,	  but	  the	  benefit	  disappears	  when	  adaptation	  is	  reached	  [37].	  Thus	  in	  highly	  adapted	   populations,	   mutators	   are	   expected	   to	   be	   rare,	   as	   they	   frequently	   will	   generate	   lethal	   or	  deleterious	  mutations.	  While	   in	  an	  evolving	  population,	  mutators	  accelerate	  adaptation	  by	  generating	  beneficial	  mutations	  [37].	  
	  
2.2|Horizontal	  Gene	  Transfer	  in	  bacterial	  evolution	  Sequential	  modifications	  of	  gene	  function	  by	  accumulation	  of	  point	  mutations	  have	  indeed	  contributed	  to	  the	  diversification	  and	  adaptation	  of	  microorganisms	  as	  described	  above.	  This	  kind	  of	  adaptation	  to	  very	   hostile	   and	   novel	   environments	   can	   be	   assumed	   to	   be	   a	   slow	   evolutionary	   process.	   Instead,	  horizontal	   gene	   transfer	   (HGT)	   also	   known	   as	   lateral	   transfer	   represents	   a	   very	   fast	   evolutionary	  process	  in	  which	  the	  recipient	  cell	  rapidly	  acquires	  new	  traits.	  The	  widespread	  of	  antibiotic	  resistance	  and	   virulence	  have	   long	  been	   associated	  with	  HGT	  and	   are	   a	  major	   challenges	   in	   the	   clinical	   settings	  [40].	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There	  are	  two	  advantages	  with	  uptake	  of	  homologous	  DNA:	  the	  new	  DNA	  may	  repair	  damaged	  DNA	  on	  the	  host	  chromosome	  or	  the	  cell	  can	  acquire	  a	  new	  gene	  that	  confers	  a	  selective	  advantage.	  If	  the	  uptake	  is	   advantageous,	   the	   cell	   lineage	  may	  be	   spread	  and	  maintained	   in	   the	  population.	   Some	  HGT	  are	  not	  beneficial,	   but	   causes	   deleterious	   effects,	   resulting	   in	   eventual	   extinction	   of	   these	   cells.	   Finally,	   in	   a	  polymicrobial	  community	  HGT	  may	  contribute	  to	  the	  population	  diversity	  by	  generation	  of	  novel	  strains	  with	   mosaic	   genomes	   that	   blurs	   the	   boundaries	   between	   species	   [40]	   (Figure	   6).	   During	   a	   chronic	  infectious	  process,	  HGT	  may	  therefore	  result	  in	  the	  continuous	  generation	  of	  a	  cloud	  of	  new	  strains	  with	  novel	  combination	  of	  genes	  and	  distinct	  phenotypes.	  This	  may	  lead	  to	  increased	  disease	  severity	  as	  HGT	  provides	   the	  bacterial	  population	  with	  means	   to	   impede	   the	  adaptive	   immune	  response	  and	  generate	  high	  diversity	  [41,	  42].	  For	  this	  matter	  HGT	  has	  an	  important	  role	  in	  bacterial	  evolution	  and	  population	  dynamics	  and	   it	   is	   therefore	  of	  great	   importance	   to	  detect	  and	  study	  HGT	  for	  better	  understanding	  of	  evolutionary	  processes.	  	  	  
	  Figure	  6|Illustration	  of	  evolution	  of	  four	  species.	  The	  main	  lines	  show	  the	  vertical	  evolution	  of	  the	  species.	  During	  evolution	  genes	  in	  each	  of	  the	  species	  evolve.	  At	  some	  point	  a	  set	  of	  genes	  is	  transferred	  from	  species	  A	  to	  C	  (horizontal	  line)	  generating	  a	  novel	   strain	   with	   mosaic	   genome	   that	   may	   blur	   the	   boundaries	   between	   species.	   Figure	   is	   modified	   from	   Gogarten	   and	  Townsend	  (2005)	  [43].	  How	   can	   it	   be	   determined	   whether	   a	   new	   trait	   or	   genomic	   variation	   is	   a	   result	   of	   HGT?	   Outside	   of	  experimental	  settings,	  HGT	  are	  rarely	  detected.	  The	  most	  powerful	  tool	  to	  detect	  HGT	  is	  whole	  genome	  sequencing,	   since	  HGT	   creates	   an	   unusually	   high	   similarity	   between	   the	   donor	   and	   the	   recipient	   cell	  [44].	  Several	  methods	  for	  analysis	  of	  genome	  sequences	  to	  identify	  cases	  of	  HGT	  have	  been	  used.	  Beside	  from	   searching	   for	   uneven	   distribution	   patterns	   and	   comparing	   of	   phylogenetic	   trees,	   unusual	  nucleotide	   composition	   (e.g.	   codon	   usage,	   GC	   content)	   can	   give	   information	   of	   the	   donor	   origin,	   as	  sequences	  retain	  the	  characteristics	  of	  the	  donor	  genome	  [45].	  The	  availability	  of	  the	  increasing	  number	  of	  whole	  genomic	  sequences	  provides	  the	  opportunity	  to	  detect	  and	  determine	  the	  frequencies	  of	  lateral	  transfer	   in	  natural	  populations	  during	  adaptation.	  Likewise,	  we	  detected	  an	   in	  vivo	  HGT	  between	   two	  coexisting	   clones	   of	  P.	  aeruginosa	   sampled	   from	  a	   cystic	   fibrosis	   patient	   by	   identifying	  non-­‐randomly	  distributed	  SNPs	   in	   the	   recipient	   clone	  and	  mapping	   them	   to	   the	  a	  possible	  donor	  clone	   (see	  paper	  3	  Chapter	  6	  [46]).	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HGT	  can	  be	  considered	  a	  multistep	  process	  where	  several	  factors	  are	  necessary	  for	  the	  transfer	  to	  occur.	  First,	  there	  needs	  to	  be	  a	  supply	  of	  donor	  DNA.	  Second	  the	  DNA	  must	  be	  incorporated	  into	  the	  genome	  of	   the	  recipient	  cell.	  Third,	   the	   incorporated	  DNA	  must	  have	  reproductive	  advantage	   that	  benefits	   the	  recipient	   cell	   in	  order	   to	  persist.	  Delivery	  and	   incorporation	  of	   the	  DNA	   typically	   takes	  place	   through	  three	   mechanisms:	   transformation,	   transduction,	   or	   conjugation.	   Transformation	   is	   the	   uptake	   an	  incorporation	   of	   naked	   DNA.	   Conjugation	   is	   a	   cell	   contact-­‐dependent	   DNA	   transfer	   mechanism.	   The	  transfer	   can	   be	   mediated	   by	   self-­‐transmissible	   conjugative	   plasmid,	   mobilization,	   cointegration,	   or	  transposons.	  Transduction	  is	  mediated	  by	  bacteriophages	  that	  act	  as	  vector	  for	  injection	  of	  DNA	  into	  a	  recipient	  cell.	  	  For	  each	  of	  the	  described	  steps	  limitations	  and	  barriers	  exist,	  including	  supply	  of	  DNA,	  establishment	  of	  cell-­‐cell	  contact,	  cell	  competence,	  deleterious	  effects,	  etc.	  	  With	  these	  limitations	  in	  mind,	  it	  has	  been	  demonstrated	  that	  all	  necessary	  elements	  for	  successful	  HGT	  exists	   under	   chronic	   infectious	   conditions	   [47].	   Chronic	   bacterial	   infections	   are	   often	   associated	  with	  biofilms,	  where	  multiple	  species	  and	  phenotypes	  may	  coexist	  [41,	  48]	  and	  form	  close	  interactions	  [49].	  The	   surrounding	   protective	  matrix	   of	   the	   biofilm	   contains	   exopolysaccharides,	   proteins,	   lipids,	   and	   a	  high	  level	  of	  extracellular	  DNA	  (eDNA)	  from	  lysed	  or	  dead	  cells	  [50].	  Moreover,	  transformation	  has	  been	  demonstrated	  to	  be	  104-­‐fold	  higher	  in	  biofilms	  than	  in	  planktonic	  forms	  [51].	  These	  foundations	  make	  biofilm	  and	  chronic	  infectious	  conditions	  perfect	  settings	  for	  HGT	  [42].	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Chapter	  3	  	  
Evolution	  in	  natural	  environments	  ost	   knowledge	  we	   have	   today	   on	   bacterial	   adaptation	   and	   evolution	   to	   novel	   environments	   is	  based	  on	  experimental	  evolution	  studies	  performed	  under	  defined	  laboratory	  conditions.	  These	  studies	   have	   provided	   great	   insight	   into	   the	   adaptive	   evolution	   of	   bacterial	   populations.	   What	   is	  characteristic	   for	  these	  evolutionary	   laboratory	  experiments	  are	  the	   lack	  of	  environmental	  complexity	  and	  spatial	  structure.	  Even	  though	  specific	  polymorphisms	  occasionally	  occur,	  there	  is	  a	  general	  lack	  of	  population	  diversity	  in	  the	  adapting	  cultures.	  Therefore,	  it	  is	  uncertain	  how	  relevant	  these	  findings	  are	  for	   the	   evolutionary	   dynamics	   in	   natural	   environments	   where	   limited	   information	   is	   available.	  Mimicking	  a	  natural	  environment	  is	  very	  difficult	  because	  of	  multiple	  selective	  pressures	  that	  fluctuate	  in	  both	  time	  and	  space	  shaping	  the	  evolution	  of	  an	  adapting	  strain.	  	  For	   this	   reason,	   chronic	   infections	   with	   P.	   aeruginosa	   in	   cystic	   fibrosis	   patients	   give	   a	   unique	  opportunity	  to	  study	  the	  adaptation	  and	  evolution	  of	  a	  pathogen	  to	  the	  heterogeneous	  and	  fluctuating	  environment	  in	  the	  airway	  of	  patients	  with	  cystic	  fibrosis	  patients.	  Such	  studies	  may	  provide	  important	  information	  for	  future	  therapeutic	  strategies.	  	  	  
	  
3.1|Cystic	  Fibrosis	  Cystic	   fibrosis	   (CF)	   is	   the	   most	   common	   autosomal	   recessive	   disorder	   affecting	   Caucasians,	   with	   an	  incidence	   of	   approximately	   one	   in	   2,500	   individuls	   [52].	   It	   is	   caused	   by	   mutations	   in	   the	   CF	  transmembrane	   regulator	   (CFTR)	   gene	   that	   encodes	   a	   chloride	   channel	   [53,	   54].	   The	   CFTR	   protein	  belongs	   to	   the	  ABC	   transporter	   (ATP-­‐binding-­‐cassette	   transporter)	   super	   family	   and	   functions	   as	   the	  primary	   chloride	   channel	   of	   epithelial	   cells	   located	   in	   the	   respiratory,	   gastrointestinal,	   hepatobiliary,	  and	   reproductive	   system	   [55].	   CFTR	   and	   the	   epithelial	   Na+	   channel	   (ENaC)	   are	   very	   important	   for	  maintaining	  the	  salt-­‐water	  balance	  across	  the	  epithelial	  cell	  membranes.	  More	   than	   1800	  mutations	   in	   the	   CFTR	   gene	   have	   been	   identified	   [56].	   However,	   the	  most	   common	  mutation	   is	   ∆F508	   that	   accounts	   for	   approximately	   70%	  of	   CF	   chromosomes	  worldwide	   and	   80%	   in	  Danish	  CF	  patients	  [54,	  55,	  57,	  58].	  The	  mutation	  is	  a	  3-­‐bp	  deletion,	  resulting	  in	  loss	  of	  a	  phenylalanine	  at	  position	  508	   located	   in	   the	  nucleotide-­‐binding	  domain	  1	   [54,	  57].	  Due	  to	   this	  mutation,	   the	  protein	  formed	  after	  translation	  fails	  to	  mature	  properly	  and	  is	  subsequently	  tagged	  for	  degradation,	  resulting	  in	  the	  loss	  of	  CFTR	  [59].	  	  CFTR	   deletion	   or	   dysfunctionality	   results	   in	   abnormal	   transport	   of	   chloride	   and	   sodium	   across	   the	  epithelial	   cell	   membranes,	   dehydrating	   the	   airway	   surface	   liquid	   layer.	   As	   a	   consequence,	   thick	  dehydrated	   mucus	   is	   produced.	   The	   hyperviscous	   mucus	   is	   difficult	   to	   eradicate	   by	   mucociliary	  
M	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clearance	  and	  coughing	  [60].	  Due	  to	  this,	  opportunistic	  pathogens	  are	  able	  to	  evade	  and	  colonize	  the	  CF	  airways	   causing	   persistent,	   chronic	   infection.	   The	   deficient	   eradication	   of	   inhaled	   microbes	   by	  mucociliary	  clearance	  or	  coughing	  causes	  a	  continuously	  recruitment	  of	  polymorphonuclear	  leukocytes	  (PMNs)	  and	  thereby	  chronic	  inflammation	  [55].	  	  	  	  
3.1.1|Compartments	  of	  the	  CF	  airway	  The	  human	  respiratory	  system	  can	  be	  divided	  into	  upper	  and	  lower	  airways.	  The	  upper	  airways	  consist	  of	  the	  paranasal	  sinuses,	  which	  are	  a	  group	  of	  air-­‐filled-­‐spaces.	  The	  maxillary	  sinuses	  are	  located	  around	  the	  nasal	  cavity	  and	  the	  frontal	  sinuses	  are	  placed	  above	  the	  eyes.	  The	  ethmoidal	  sinuses	  are	  many	  small	  sinuses	  located	  between	  the	  eyes,	  and	  the	  sphenoid	  sinuses	  are	  placed	  behind	  the	  ethmoids	  [61]	  (Figure	  7).	  These	  small	  cavities	  facilitates	  the	  trapping	  of	  thick	  mucus	  in	  CF	  patients	  and	  it	  can	  be	  difficult	  to	  get	  access	  to	  the	  sinuses	  due	  to	  abnormal	  anatomy	  of	  CF	  patients.	  	  The	  lower	  airway	  can	  be	  divided	  into	  the	  conductive	  and	  respiratory	  zones	  (Figure	  7).	  The	  conductive	  zone	  refers	  to	  the	  trachea,	  bronchi,	  and	  terminal	  bronchioles.	  Cilia,	  submucosal	  glands	  and	  goblet	  cells	  are	   present	   in	   the	   conductive	   zone	   where	   also	   the	   mucus	   is	   produced	   [62].	   In	   the	   conductive	   zone,	  infecting	  microbes	  are	  found	  mainly	  inside	  sputum,	  where	  conditions	  are	  anaerobic.	  	  	  
	  Figure	  7|The	  airway	  of	  CF	  patients.	  The	  human	  respiratory	  system	  contains	  different	  anatomical	  compartments,	  including	  the	  paranasal	   sinuses,	   the	   conductive	   zone	   (tracheobronchial	   region),	   and	   the	   respiratory	   zone	   (alveolar	   region).	   Infecting	  microbes	   is	  removed	   in	  healthy	  subjects	  by	  the	  cilia	  of	   the	  epithelial	  cells,	  however,	   in	  CF	  patient	   thick	  dehydrated	  mucus	   is	  produces	   that	   enables	   bacteria	   such	   as	   P.	   aeruginosa	   to	   colonize.	   Continuous	   recruitment	   of	   PMNs	   results	   in	   increased	  inflammation	  and	  tissue	  damage.	  The	  airway	  mucus	  of	  the	  different	  compartment	  in	  the	  CF	  airway	  constitutes	  a	  reservoir	  for	  P.	  
aeruginosa	  growth.	  Figure	  is	  modified	  from	  Høiby	  et	  al.	  (2006)	  and	  Folkesson	  et	  al.	  (2012)	  [62,	  65].	  	  	  The	  respiratory	  zone	  contains	  no	  cilia	  and	  submucosal	  glands,	  but	  includes	  the	  bronchioles	  and	  alveolar	  ducts	  and	  sacs,	  where	  the	  O2	  and	  CO2	  exchange	  takes	  place	  [62].	  Therefore,	  bacteria	  in	  the	  respiratory	  zone	   are	   probably	   exposed	   to	   aerobic	   as	   well	   as	   microaerophilic	   growth	   conditions.	   The	   amount	   of	  PMNs	  is	  also	  higher	  here	  because	  of	  the	  blood	  vessels	  around	  alveoli	  [63,	  64].	  The	  presence	  of	  bacteria	  
Chapter	  3|Evolution	  in	  natural	  environments	  
	   13	  
is	   rare	   in	   the	   respiratory	   zones,	   but	   specific	   regions	   often	   becomes	   destroyed	   because	   of	   the	  inflammation	  surrounding	  infected	  areas	  [63].	  	  Several	   studies	   have	   suggested	   that	   the	   initial	   infection	   starts	   in	   the	   upper	   airways	   [66-­‐68].	   After	  several	  years	  with	  infection	  in	  the	  sinuses,	  the	  same	  organisms	  are	  thought	  to	  migrate	  and	  colonize	  the	  lower	  airways.	  The	  transmission	  from	  upper	  to	  lower	  airway	  is	  probably	  through	  the	  larynx	  and	  trachea	  [68].	  	  While,	   the	   small	   cavities	   of	   the	   sinuses	   facilitate	   trapping	   of	   the	   thick	  mucus,	   there	  may	   be	   a	   better	  clearance	   in	   the	   lung	   by	   breathing	   and	   coughing.	   It	   has	   been	   shown	   that	   the	   immune	   response	   is	  reduced	  in	  the	  sinuses	  compared	  to	  the	  lung	  [69,	  70].	  This	  means	  that	  the	  upper	  airway	  has	  less	  airflow,	  and	  less	  exposure	  to	  antibiotics	  and	  host	  immune	  cells	  than	  the	  lower	  airways.	  In	  this	  way,	  the	  sinuses	  may	  act	  as	  a	  reservoir	  for	  infecting	  bacteria	  and	  promote	  their	  adaptation	  [66,	  69].	  Consequently,	  early	  treatment	   of	   sinus	   infections	   may	   delay	   the	   development	   of	   significant	   chronic	   lung	   infection.	   Some	  hospitals	  require	  sinus	  surgery	  before	  lung	  transplantation	  to	  prevent	  infection	  in	  the	  lungs	  by	  bacteria	  colonizing	  the	  upper	  airway	  [68].	  
	  
3.1.2|CF	  airway	  ecology	  It	  is	  well	  documented	  that	  the	  major	  reasons	  for	  morbidity	  and	  mortality	  of	  CF	  patients	  is	  chronic	  lung	  infection	  caused	  by	  the	  colonizing	  microbes.	  The	  microbial	  community	  of	  CF	  patients	  has	  been	  found	  to	  change	  over	  time	  (Figure	  8).	  	  
	  Figure	  8|Prevalence	  of	  common	  human	  respiratory	  pathogens	  in	  patients	  with	  cystic	  fibrosis	  as	  a	  function	  of	  age.	  While	  
P.	  aeruginosa	  is	  the	  most	  common	  pathogen	  in	  CF	  adults,	  S.	  aureus	  and	  H.	  influenza	  infections	  are	  common	  in	  early	  childhood.	  Figure	  adapted	  from	  Folkesson	  et	  al.	  (2012)	  [65].	  	  As	  shown	  in	  Figure	  8,	  Staphylococcus	  aureus	  and	  Haemophilus	  influenza	  infections	  are	  common	  in	  early	  childhood.	   These	   organisms	   damage	   the	   epithelial	   surfaces	   leading	   to	   increased	   attachment	   by	   P.	  
aeruginosa,	  which	  is	  the	  major	  pathogen	  observed	  in	  adult	  CF	  patients	  [55].	  	  Most	   CF	   patients	   are	   initially	   infected	   with	   organisms	   found	   in	   their	   immediate	   environment,	   but	  patient-­‐to-­‐patient	   transmission	   have	   been	   detected	   [71,	   72].	   Contact	   to	   other	   CF	   patients	   therefore	  constitutes	  cross-­‐infection	  risk.	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As	  described	  above,	  each	  spatial	  site	  of	  the	  CF	  habitat	  is	  a	  very	  complex	  and	  dynamic	  ecosystem,	  where	  many	  factors	  contribute	  to	  the	  stressful	  environment.	  Microorganisms	  need	  to	  adapt	  to	  these	  multiple	  challenges,	   including	   antibiotic	   exposure,	   the	   immune	   system,	   nutrient	   availability,	   microbial	  interactions	  and	  heterogenous	  oxygen	   levels	   that	   fluctuate	  both	   in	   time	  and	  space	   in	  order	   to	  survive	  [73].	  Some	  of	  these	  will	  be	  described	  here.	  
Antibiotic	  treatment	  One	  of	  the	  major	  challenges	  for	  the	  bacteria	  to	  adapt	  to	  the	  CF	  airways	  is	  the	  fluctuating	  concentration	  of	  antibiotics	  that	  they	  are	  exposed	  to	  over	  time.	  CF	  patient	  are	  often	  treated	  early	  and	  aggressively	  with	  antibiotics	   to	   eradicate	   or	   prevent	   chronic	   infection	   [74].	   Inhaled	   antibiotics	   can	   result	   in	   high	  concentrations	  of	  the	  drug	  in	  the	  airway	  mucus,	  but	  low	  in	  the	  respiratory	  zone	  [62,	  73].	  The	  situation	  is	  reversed	   if	   the	   antibiotic	   is	   given	   intravenous	   [62,	   73].	   In	   this	   way,	   antibiotics	   can	   change	   the	  community	  structure	  and	  stability,	  but	  also	  promote	  the	  adaptation	  of	  strains	  with	  mutations	  conferring	  antibiotic	  resistance	  [73,	  75,	  76].	  	  
The	  immune	  system	  The	   immune	   response	   constitutes	   another	   significant	   selective	   force	   that	   shapes	   the	   adaptation	   of	  infecting	   microorganisms.	   The	   continuously	   recruitment	   of	   PMNs	   and	   neutrophils	   by	   the	   invading	  microorganisms	   results	   in	   inflammation	   and	   tissue	   damage	   [55].	   Furthermore,	   different	   eukaryotic-­‐specific	  receptors	  located	  on	  the	  surface	  of	  epithelium	  cells	  can	  recognize	  bacterial	  epitopes,	  including	  lipopolysaccharide	  (LPS)	  and	  flagellin,	  leading	  to	  killing	  of	  the	  bacteria	  [77,	  78].	  Moreover,	  phagocytosis	  of	  bacteria	  produces	  reactive	  oxygen	  species	  (ROS)	  and	  microorganisms	  are	  therefore	  also	  encountered	  with	  high	  oxidative	  stress	  [62].	  	  
Nutrient	  availability	  The	   physical	   and	   chemical	   properties	   of	   the	   CF	   environment	   are	   altered	   in	   comparison	  with	   healthy	  subjects.	  The	  availability	  of	  nutrients	  therefore	  constitutes	  another	  major	  selective	  force.	  The	  CF	  sputum	  is	  a	  complex	  substrate	   that	  provides	   the	   infecting	  bacteria	  with	  carbon	  and	  energy	  to	  support	  growth	  during	  colonization	  [79].	  For	  example,	  the	  sputum	  of	  CF	  patients	  is	  rich	  in	  different	  amino	  acids	  [80]	  and	  it	  has	  been	  shown	  that	  the	  preferred	  carbon	  sources	  of	  clinical	  P.	  aeruginosa	   isolates	  sampled	  from	  CF	  patients	  were	  proline,	  alanine,	  arginine,	   lactate,	  glutamate,	  and	  aspartate	   [81],	  demonstrating	   that	   the	  nutrient	  environment	  impacts	  adaptation	  of	  infecting	  microbes.	  	  
Microbial	  interactions	  Most	   CF	   infections	   are	   characterized	   by	   colonization	   of	   more	   than	   one	   species	   (Figure	   8)	   [55].	  Interactions	  between	  the	  different	  organisms	  of	  the	  microbial	  community	  also	  impose	  a	  major	  challenge	  for	  the	  adapting	  microbe.	  However,	  the	  effect	  on	  the	  individual	  behaviour	  and	  the	  population	  dynamic	  is	  very	  poorly	  understood.	  Because	  of	  the	  unavoidable	  competition	  for	  nutrients,	  antagonistic	  interactions	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are	   common	   within	   a	   community	   [82].	   Two	   examples	   of	   such	   antagonistic	   interaction	   are	   the	  production	  of	  bacteriocin	  (see	  section	  3.2.2)	  and	  the	  breakdown	  of	  cooperative	  behaviours	  due	  to	  the	  occurrence	  of	  cheaters	  [82,	  83].	  A	  cheater	  refers	  to	  a	  non-­‐cooperative	  strain	  that	  does	  not	  invest	  in	  the	  public	  good,	  but	  only	  utilize	  them.	  A	  classic	  example	  is	  the	  occurrence	  of	  siderophore-­‐deficient	  mutants	  in	  a	  P.	  aeruginosa	  population.	  These	  mutants	  do	  not	  produce	  siderophores	  but	  are	  still	  able	  to	  use	  them	  to	  acquire	  iron	  from	  the	  environment	  [84].	  	  Synergistic	  interactions	  have	  also	  been	  documented	  [85].	  For	  example	  it	  has	  been	  demonstrated	  that	  P.	  
aeruginosa	  show	  increased	  virulence	  when	  grown	  together	  with	  gram-­‐positive	  bacteria	  [86].	  Synergistic	  interaction	  can	  therefore	  result	  in	  increased	  disease	  severity	  [82].	  	  	  	  Other	  factors	  such	  as	  the	  heterogeneous	  distribution	  of	  oxygen	  also	  play	  important	  roles	  in	  shaping	  the	  evolution	   of	   adapting	   bacteria	   to	   the	   CF	   airway.	   To	   survive	   in	   this	   stressful	   environment,	  microorganisms	  therefore	  have	  to	  overcome	  these	  challenges	  by	  phenotypic	  and	  genomic	  adaptation.	  	  	  
3.1.3|Infection	  stages	  The	  morbidity	  and	  mortality	  of	  CF	  patients	  is	  a	  consequence	  of	  respiratory	  failure	  and	  chronic	  infection	  caused	   by	   the	   colonizing	   microorganisms	   [55].	   Two	   criteria	   are	   used	   to	   distinguish	   between	   the	  different	  phases	  of	  infection:	  the	  Copenhagen	  criteria	  and	  the	  Leeds	  criteria.	  Based	  on	  lower	  airway	  samples	  taken	  10-­‐12	  times	  per	  year,	  the	  Copenhagen	  criteria	  grades	  pulmonary	  infection	   into	   1)	   never	   been	   colonized,	   2)	   intermittently	   colonized	   and	   3)	   chronically	   infected.	   Most	  hospitals	  do	  not	   see	   the	  patients	  as	   regularly	  as	   in	  Copenhagen,	  and	   therefore	  uses	   the	  Leeds	  criteria	  where	  patients	  are	   seen	  every	   third	  month.	  The	  Leeds	   criteria	  grade	   the	   infection	   into	  1)	  never	  been	  infected,	  meaning	  that	  there	  has	  never	  been	  growth	  of	  any	  CF	  related	  Gram-­‐negative	  bacteria.	  2)	  Non-­‐infected	   where	   no	   growth	   of	   any	   CF	   related	   Gram-­‐negative	   bacteria	   is	   observed	   during	   a	   year.	   3)	  Intermittent	   colonization	  where	  growth	   is	  observed	   in	  >0%	  and	  ≤50%	  of	   the	   samples	  and	  4)	   chronic	  infection	  where	  growth	  is	  observed	  in	  >50%	  of	  a	  patient’s	  monthly	  lower-­‐airway	  samples.	  The	   chronic	   stage	   is	   characterized	   by	   constantly	   high	   serum	   levels	   of	   immunoglobulin	   G	   (IgG)	  antibodies	  and	  numerous	  PMNs	  in	  the	  lower	  airways	  [87].	  	  Early,	   aggressive	   antibiotic	   treatment	   is	   important	   to	   prevent	   or	   postpone	   chronic	   infection.	   Recent	  studies	   have	   demonstrated	   that	   sinus	   surgery	   can	   postpone	   chronic	   infection	   [88],	   confirming	   the	  importance	  of	  the	  sinuses	  as	  bacterial	  reservoirs	  and	  their	  role	  in	  establishment	  of	  chronic	  pulmonary	  infections.	  	  	  	  
3.2|Pseudomonas	  aeruginosa	  
P.	   aeruginosa	   is	   a	   gram-­‐negative,	   rod-­‐shaped	   bacterium	   that	   primarily	   lives	   in	   water,	   soil,	   and	  vegetation.	  It	  is	  an	  opportunistic	  pathogen	  capable	  of	  infecting	  a	  variety	  of	  different	  organisms	  including	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amoeba	  [89],	  plants	  [90],	  fruit	  flies	  [91],	  nematodes	  [92]	  and	  animals	  [93,	  94].	  P.	  aeruginosa	  infection	  in	  humans	  is	  generally	  restricted	  to	  immunocompromised	  patients	  such	  as	  patients	  suffering	  from	  burns,	  cancer,	  HIV	  and	  cystic	  fibrosis	  [95,	  96].	  	  
P.	  aeruginosa	  is	  a	  motile	  bacterium	  that	  is	  able	  to	  swim,	  swarm	  and	  twitch	  using	  a	  flagellum	  and/or	  pili.	  Its	  optimum	  growth	  temperature	  is	  37°C	  but	  is	  able	  to	  grow	  at	  42°C.	   	  The	  genome	  is	  5.2-­‐7.0	  Mbp	  with	  5,570	   open	   reading	   frames	  making	   it	   one	   of	   the	   largest	   genomes	   among	   bacteria	   [97].	  P.	  aeruginosa	  encodes	   a	   large	   number	   of	   regulatory	   proteins	   that	   reflect	   the	   broad	   adaptability	   and	   metabolic	  versatility	  of	  this	  organism.	  	  The	  minimal	  requirements	  of	  P.	  aeruginosa	  together	  with	  its	  large	  genome	  size	  and	  complex	  regulatory	  networks,	  makes	  it	  capable	  of	  growing	  in	  a	  diverse	  set	  of	  ecological	  habitats.	  Furthermore,	  P.	  aeruginosa	  has	  the	  ability	  to	  quickly	  switch	  lifestyle	  upon	  changing	  conditions.	  These	  abilities	  may	  have	  important	  consequences	  for	  humans,	  providing	  the	  possibility	  of	  contact	  and	  cross-­‐infections	  [98].	  	  The	  pathogenesis	  of	  P.	  aeruginosa	   rely	  on	  the	  production	  and	   interaction	  of	  multiple	  virulence	   factors	  such	   as	   cell-­‐associated	   factors	   (pili,	   flagella	   and	   LPS),	   secreted	   virulence	   factors	   (proteases,	  siderophores,	   pyocyanin,	   rhamnolipids,	   hydrogen	   cyanide,	   etc.),	   Type	   III	   secretion	   system,	   biofilm	  formation,	  alginate	  production	  and	  intrinsic	  resistance	  to	  a	  broad	  spectrum	  of	  antimicrobial	  agents.	  Due	  to	  the	  relevance	  of	  this	  thesis,	  only	  some	  of	  these	  virulence	  factors	  will	  be	  addressed	  here.	  	  
3.2.1|Cell-­‐to-­‐cell	  communication	  in	  pathogenesis	  of	  P.	  aeruginosa	  The	   success	   of	   P.	   aeruginosa	   to	   cause	   infections	   can	   be	   described	   to	   the	   ability	   of	   P.	   aeruginosa	   to	  produce	   a	   broad	   variety	   of	   different	   virulence	   factors	   required	   for	   acute	   infections	   (Figure	   9).	   The	  majority	   of	   these	   extracellular	   factors	   are	   not	   constitutive	   expressed	   but	   regulated	   in	   a	   cell	   density-­‐dependent	  manner	   termed	  quorum	   sensing	   (QS).	   QS	   is	  mediated	   by	   small	   diffusible	   signal	  molecules	  that	   interact	   and	   activate	   their	   transcriptional	   regulators	   when	   reaching	   a	   specific	   concentration	  correlated	  with	  specific	  cell	  densities	  of	  the	  population	  [99].	  	  	  	  	  
	  Figure	   9|Schematic	   overview	   of	   virulence	   factors	   of	   P.	   aeruginosa.	   P.	   aeruginosa	   express	   multiple	   virulence	   factors	  important	  for	  acute	  infection	  including	  cell-­‐associated	  factors,	  secreted	  virulence	  factors,	  and	  the	  Type	  III	  secretion	  system.	  The	  figure	  is	  adapted	  from	  Hauser	  and	  Ozer	  (2011)	  [100].	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  The	  P.	  aeruginosa	  QS	  system	  is	  mediated	  by	  two	  chemically	  distinct	  classes	  of	  signal	  molecules,	   the	  N-­‐acyl-­‐L-­‐homoserine	   lactones	   (AHLs)	   [101]	   and	   the	   4-­‐quinolones	   [102,	   103].	   There	   are	   two	   AHL-­‐dependent	  QS	  systems,	  namely	  the	  las	  system	  containing	  the	  transcriptional	  activator	  LasR	  and	  the	  AHL	  synthase	   LasI	   which	   directs	   the	   synthesis	   of	   N-­‐3-­‐oxo-­‐dodecanoyl-­‐homoserine	   lactone	   (oxo-­‐C12-­‐HSL)	  [104],	   and	   the	   rhl	   system	   consisting	   of	   RhlR	   and	   RhlI	   which	   directs	   the	   synthesis	   of	   N-­‐butanoyl-­‐L-­‐homoserine	  lactone	  (C4-­‐HSL)	  [105].	  	  Beside	  AHL	  signaling,	  P.	  aeruginosa	  produces	  another	  signal	  belonging	   to	   the	  4-­‐quinolones	  called	  3,4-­‐dihydroxy-­‐2-­‐heptylquinoline	  referred	  to	  as	  PQS.	  PQS	  function	  as	  a	  link	  between	   las	  and	  rhl	  systems	  as	  demonstrated	   in	   Figure	   10	   and	   adds	   a	   level	   of	   complexity	   to	   the	   QS	   network.	   The	   QS	   systems	   are	  hieratically	  organized	  so	  that	  las	  transcriptionally	  regulates	  the	  rhl	  system	  [101,	  106],	  and	  both	  las	  and	  
rhl	  regulates	  PQS	  [103].	  	  The	   QS	   system	   regulates	   multiple	   virulence	   factors	   through	   the	   regulation	   of	   these	   major	   systems,	  including	  production	  of	  elastase,	  exotoxin	  A,	  rhamnolipids,	  pyocyanin,	  hydrogen	  cyanide,	  siderophores,	  and	  biofilm	  formation	  [106,	  107].	  	  	  
	  Figure	   10|A	   simplified	   overview	   of	   the	   quorum	   sensing	   regulation	   in	   P.	   aeruginosa.	   Black	   arrows	   indicate	   positive	  regulation	  and	  red	  arrows	  indicate	  negative	  regulation.	  The	   las,	  rhl,	  and	  PQS	  QS	  system	  show	  a	  complex	  regulatory	  network.	  Adapted	  from	  Lazdunski	  et	  al.	  (2004)	  [108].	  To	   further	  add	  a	   level	  of	  complexity,	  various	  regulators	  have	  been	   found	  to	  modulate	   the	  QS	  circuitry	  [109].	  One	  of	  these	  is	  the	  virulence	  factor	  regulator	  (Vfr),	  an	  E.	  coli	  CRP	  homolog,	  which	  has	  been	  shown	  to	   control	   expression	   of	  more	   than	   200	   genes	   [110,	   111].	   Vfr	   directly	   activates	   lasR	   transcription	   by	  binding	   to	   Vfr-­‐binding	   sequences	   in	   the	   lasR	   promoter	   region	   [112].	   Moreover,	   Vfr	   has	   been	  demonstrated	  to	  directly	  regulate	  rhlR	   transcription	  by	  binding	  to	  several	  Vfr-­‐binding	  sites	  present	   in	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the	  rhlR	   promoter	   region,	  one	  of	  which	  negatively	   regulates	   rhlR	   [113].	   In	   this	  way,	  Vfr	   regulates	   the	  production	  of	  multiple	  virulence	  factors	  important	  for	  acute	  infection	  mainly	  through	  the	  regulation	  of	  the	  early	  steps	  of	  the	  QS	  signalling	  cascade.	  Furthermore,	  Vfr	  has	  been	  indicated	  to	  negatively	  regulate	  the	  PQS	  system	  [114].	  This	  complexity	  and	  the	   involvement	  of	  multiple	  regulatory	  proteins	  enables	  P.	  
aeruginosa	  to	  modify	  the	  QS	  circuitry	  upon	  environmental	  changes	  and	  allowing	  adaptation	  to	  different	  environmental	  conditions.	  	  
3.2.2|Lipopolysaccharides	  and	  pyocins	  
P.	   aeruginosa	   produces	   an	   arsenal	   of	   different	   virulence	   factors	   that	   contribute	   to	   survival	   and	  protection	  against	   the	   immune	   systems,	   competing	  bacteria	   and	  aggressive	   antibiotic	   therapy.	  One	  of	  these	  major	   virulence	   factors	   is	   the	   cell	  wall-­‐associated	   lipopolysaccharide	   (LPS).	   LPS	   is	   an	   essential	  component	  of	  the	  outer	  membrane	  and	  as	  the	  first	  line	  of	  defences	  it	  play	  fundamental	  roles	  for	  direct	  interaction	  with	  host	  cell	  receptors	  and	  antibiotics	  [115,	  116].	  	  	  	  
	  Figure	  11|Structures	  of	  LPS	  in	  P.	  aeruginosa.	  LPS	  consist	  of	  three	  regions:	  lipid	  A,	  which	  anchors	  the	  LPS	  to	  the	  membrane,	  an	  O-­‐antigen	  (O-­‐Ag),	  and	  a	  core	  oligosaccharide	  (OS),	  which	  links	  the	  O-­‐Ag	  to	  the	  lipid	  A.	  The	  OS	  can	  be	  either	  capped	  (O-­‐Ag	  is	  attached,	  structure	  1)	  or	  uncapped	  (no	  O-­‐Ag	  is	  attached,	  structure	  2-­‐5),	  while	  the	  O-­‐Ag	  can	  be	  expressed	  as	  two	  forms,	  namely	  A-­‐band	  (structure	  2)	  or	  B-­‐bands	  (structure	  3-­‐5).	  The	  figure	  is	  modified	  from	  Lam	  et	  al.	  (2011)	  [115].	  	  LPS	  of	  P.	  aeruginosa	  is	  composed	  of	  three	  distinct	  regions	  (Figure	  11):	  lipid	  A,	  core	  oligosaccharide	  (OS),	  and	  the	  long-­‐chain	  O	  antigen	  (O-­‐Ag).	  The	  lipid	  A	  domain	  anchors	  LPS	  in	  the	  bacterial	  outer	  membrane	  by	  several	  fatty	  acid	  chains	  attached	  to	  a	  disaccharide	  backbone.	  The	  core	  OS	  is	  the	  linker	  between	  O-­‐Ag	  and	   lipid	  A	  and	   it	   can	  be	  divided	   into	  an	   inner	  and	  an	  outer	   core.	  The	   inner	   core	   is	  highly	   conserved	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comparing	   to	   other	   gram-­‐negative	   bacteria	   and	   the	   composition	   of	   the	   sugars	   are	   identical	   among	  P.	  
aeruginosa	  strains	  [115].	  The	  outer	  core	  is	  divided	  into	  two	  structurally	  distinct	  glycoforms	  called	  ‘capped’	  and	  ‘uncapped’.	  	  The	  capped	  form	  is	  covalently	  bound	  to	  the	  O-­‐Ag,	  while	  the	  uncapped	  version	  prevents	  attachment	  of	  O-­‐Ag	  to	  the	  core	  OS	  [115,	  117]	  (Figure	  11).	  	  
P.	  aeruginosa	  is	  able	  to	  co-­‐express	  two	  forms	  of	  O-­‐Ag;	  the	  Common	  Polysaccharide	  Antigen	  (A-­‐band	  also	  known	   as	   CPA)	   and	   O-­‐Specific	   Antigen	   (B-­‐band	   also	   known	   as	   OSA)	   [118,	   119].	   The	   B-­‐band	  polysaccharides	  are	  the	  basis	  for	  the	  International	  Antigenic	  Typing	  Scheme	  (IATS)	  where	  P.	  aeruginosa	  is	   classified	   into	   20	  major	   serotypes	   (O1-­‐O20)	   based	   on	   the	   variation	   in	   B-­‐band	   structure	   and	   chain	  length.	  While	  A-­‐band	  LPS	  appears	  not	  to	  play	  a	  role	  in	  protecting	  the	  organism	  against	  serum-­‐mediated	  killing,	  the	  B-­‐band	  polysaccharides	  are	  highly	   immunogenic	   and	  have	  been	   found	   to	   confer	   serum	  resistance	  [120].	  The	  LPS	  of	  P.	  aeruginosa	   have	  been	   shown	   to	  undergo	  phenotypic	  modification	  during	   chronic	  infection,	   so	   that	   A-­‐band	   LPS	   becomes	   the	  major	   LPS	   antigen	   replacing	   the	   B-­‐band	   [121-­‐123].	   It	   has	  been	   implicated	   that	   prolonged	   antibiotic	   treatment	   has	   caused	   this	   conversion	   [124].	   Resistance	   to	  aminoglycosides	   is	   partly	   due	   to	   alterations	   in	   the	   LPS	   structure,	   resulting	   in	   decreased	   antibiotic	  passage	  across	  the	  outer	  membrane	  [125,	  126].	  	  Besides	   interaction	   with	   antibiotics	   and	   immune	   host	   cells,	   LPS	   has	   been	   described	   to	   function	   as	  receptor	  for	  R-­‐pyocins	  [127-­‐129].	  In	  particular	  the	  sugar	  residues	  of	  the	  outer	  core	  has	  been	  suggested	  to	  be	  involved	  in	  interaction	  with	  R-­‐pyocins	  [127,	  129]	  (Figure	  12).	  	  
	  Figure	  12|Overview	  of	  the	  sugar	  residues	  involved	  in	  R-­‐pyocin	  recognition.	  Arrows	  indicate	  the	  sugar	  residues	  involved	  in	  R-­‐pyocin	   interaction.	  R5	  pyocin	   seems	   to	   be	   able	   recognize	   two	   sugar	   residues,	   but	   favour	  α-­‐GlcIII	   over	   β-­‐GlcI	   (dashed	   line)	  [127].	  
Chapter	  3|Evolution	  in	  natural	  environments	  
	   20	  
	  Pyocins	   are	  bacteriocins	   and	  P.	  aeruginosa	   produces	   three	   types	   of	   pyocins:	   the	   soluble	   S-­‐pyocin,	   the	  flexible	  F-­‐pyocin	  and	  the	  non-­‐flexible	  and	  contractive	  R-­‐pyocin	  that	  resemble	  the	  tail	  of	  bacteriophages	  [130].	   R-­‐pyocins	   cause	   depolarization	   of	   the	   cytoplasmic	   membrane	   leading	   to	   cell	   lysis	   [119].	   The	  killing	  efficiency	  is	  very	  high	  for	  R-­‐pyocins	  as	  one	  pyocin	  molecule	  kills	  one	  bacterial	  cell.	  In	  comparison,	  100-­‐200	  molecules	  of	  F-­‐pyocins	  are	  required	  to	  kill	  one	  cell	  [130].	  Five	  different	  types	  of	  R-­‐pyocins	  have	  been	  identified	  based	  on	  their	  killing	  activities	  and	  difference	  in	  their	  amino	  acid	  sequence	  of	  the	  tail	  fiber	  protein	  Prf15	  (PA0621)	  [127,	  131].	  	  Pyocins	   are	   able	   to	   kill	   members	   of	   the	   same	   closely	   related	   species	   and	   in	   this	   way	   ensure	   the	  predominance	  of	  a	  given	  strain	  in	  a	  niche	  [130,	  132].	  In	   summary,	   LPS	   play	   a	   fundamental	   role	   both	   as	   a	   protective	   shield	   and	   as	   receptors	   for	   multiple	  foreign	  molecules	  including	  antibiotics,	  immune	  system,	  competing	  microbes,	  pyocins,	  etc.	  Thus,	  LPS	  in	  clinical	  isolates	  is	  often	  modified	  [122,	  133],	  conferring	  increased	  resistance	  and	  survival.	  	  	  
3.3|P.	  aeruginosa	  lifestyle	  and	  adaptation	  in	  CF	  airways	  The	   CF	   airway	   infection	   offers	   a	   unique	   opportunity	   to	   study	   the	   lifestyle	   and	   adaptation	   of	   P.	  
aeruginosa	  to	  a	  heterogeneous	  natural	  environment.	  Various	  factors	  contribute	  to	  the	  complexity	  of	  the	  ecosystem	   as	   discussed	   in	   section	   3.1.2	   that	   drives	   the	   evolution	   of	   P.	   aeruginosa	   to	   live	   in	   the	   CF	  ecosystem.	  Adaptation	   of	   P.	   aeruginosa	   often	   follows	   a	   characteristic	   pattern	   with	   the	   initial	   colonization	   of	   P.	  
aeruginosa	  strains.	  These	  strains	  often	  resemble	  environmental	  strains	  displaying	  wild-­‐type	  phenotypes	  i.e.	  non-­‐mucoid,	  fast	  growth,	  and	  susceptibility	  to	  antibiotics	  [134].	  However,	  in	  the	  complex	  and	  highly	  dynamic	   CF	   environment	   where	   multiple	   selective	   pressures	   act	   on	   the	   colonizing	   P.	   aeruginosa,	   it	  continuously	  need	  to	  adapt	  in	  order	  to	  survive.	  Therefore,	  P.	  aeruginosa	  undergoes	  significant	  genomic	  and	  phenotypic	  changes	  to	  adjust	  to	  the	  novel	  conditions	  of	  the	  CF	  airways.	  	  Parallel	   evolution	   towards	   some	   common	   traits	   referred	   to	   as	   ‘the	   chronic	   phenotypes’	   have	   been	  shown	  in	  different	  clinical	  settings	  [39,	  75,	  76].	  The	  genomic	  route	  to	  reach	  these	  end-­‐point	  phenotypes	  can	  be	  very	  distinct	  [135].	  	  	  
3.3.1|Phenotypic	  adaptation	  
P.	  aeruginosa	  is	  able	  to	  rapidly	  switch	   lifestyle	   in	  response	  to	  changing	  environmental	  conditions.	  The	  phenotype	  changes	  significantly	  as	  a	  consequence	  of	  the	  selective	  pressures	  present	  in	  the	  environment	  during	  long-­‐term	  evolution	  of	  P.	  aeruginosa	  in	  the	  CF	  airways.	  For	  example,	  estimations	  of	  P.	  aeruginosa	  growth	  rates	  in	  the	  CF	  airways	  show	  that	  P.	  aeruginosa	  populations	  have	  significantly	  decreased	  in	  vitro	  growth	   rate	   but	   are	   still	   actively	   growing	   in	   vivo	   [1,	   73].	   Furthermore,	   chronic	   infections	   with	   P.	  
aeruginosa	  are	  often	  characterized	  by	  a	  biofilm	  lifestyle	  [136].	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The	   biofilm	   serves	   as	   a	   protective	   physical	   barrier	   against	   the	   host	   immune	   response	   as	   well	   as	  antibiotic	   therapy	   and	   therefore	   display	   increased	   resistance	   to	   clearance	   and	   antibiotic	   resistance	  [137].	  Biofilms	  can	  be	  considered	  as	  a	  dynamic	  living	  organism	  in	  which	  multiple	  species	  may	  coexist	  in	  a	  spatially	  structured	  environment,	  where	  they	  can	  mutate	  and	  evolve	  to	  improve	  interaction	  with	  other	  species	   [42,	   138].	   Furthermore,	   it	   has	   been	   suggested	   that	   self-­‐generated	   diversity	   in	   biofilms	   may	  function	  as	  a	  form	  of	  biological	  insurance	  that	  protects	  the	  community	  unstable	  environments	  [25].	  The	   most	   common	   phenotypes	   associated	   with	   long-­‐term	   evolution	   in	   CF	   airways	   are	   antibiotic	  resistance	   [139],	   mucoidy	   [140],	   changed	   LPS	   [122],	   occurrence	   of	   ‘small	   colony	   variants’	   [141],	  increased	   mutation	   rate	   (mutators)	   [34],	   QS	   loss	   [142],	   auxotrophy	   [80],	   motility	   loss	   and	   reduced	  production	  of	  acute	  virulence	  factors	  [75].	  These	   phenotypes	   are	   remarkably	   different	   from	   the	   original	   invading	   strain	   and	   are	   observed	  repeatedly	  in	  different	  patients	  and	  in	  distinct	  clinical	  settings.	  The	  common	  reoccurrence	  of	  these	  traits	  suggests	  that	  there	  is	  a	  conserved	  pattern	  of	  evolution	  that	  P.	  aeruginosa	   follows	  in	  order	  to	  persist	  in	  the	  CF	  airways	  [75,	  143].	  Although	  there	  seem	  to	  be	  a	  parallel	  evolution	  toward	  chronic	  phenotypes,	  it	  does	  not	  exclude	  phenotypic	  diversity	  among	  clinical	  isolates.	  In	  fact,	  high	  phenotypic	  diversity	  has	  been	  observed	  even	  between	  isolates	  from	  the	  same	  sputum	  sample,	  where	  multiple	  phenotypes	  of	  the	  above	  mentioned	  variants	  could	  be	  isolated	  [69,	  144-­‐146].	  It	  is	  not	  known	  whether	  this	  adaptive	  radiation	  is	  a	  consequence	  of	  niche	  specialization	  or	  if	  the	  different	  subpopulations	  are	  homogenously	  distributed	  in	  the	  CF	  airway	  (Figure	  13).	  However,	  in	  paper	  1	  of	  this	  thesis,	  we	  addressed	  this	  important	  unanswered	  question	   and	   demonstrated	   that	   sub-­‐lineages	  were	   located	   at	   distinct	   geographical	   niches	  within	   the	  infected	  airways	  [27].	  	  	  
	  Figure	  13|Population	  heterogeneity	  of	  P.	  Aeruginosa	  within	  CF	  airways.	  	  Spatial	  and	  temporal	  heterogeneity	  may	  drive	  and	  maintain	  diversification	  of	  P.	  Aeruginosa	  population.	  It	  is	  not	  known	  whether	  the	  population	  is	  geographically	  isolated	  (left	  lung	  image)	  or	  homogeneous	  distributed	  throughout	  the	  airways	  (right	  side	  of	  the	  lung	  image).	  Figure	  is	  adapted	  from	  Bernier	  et	  al.	  (2014)	  [147].	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3.3.2|Genomic	  adaptation	  of	  P.	  aeruginosa	  Although	  the	  chronic	  phenotypes	  are	  commonly	  observed,	  the	  underlying	  genomic	  changes	  may	  be	  very	  different.	  Little	   is	  known	  about	  the	  evolutionary	  routes	  used	  by	  P.	  aeruginosa	   to	  reach	  the	  phenotypic	  fitness	   peak	   in	   the	   fitness	   landscape.	   Whole	   genome	   sequencing	   has	   made	   it	   possible	   to	   detect	   and	  identify	  adaptive	  mutations	  acquired	  during	   chronic	  CF	   infection.	   In	  doing	   so	  a	  number	  of	   repeatedly	  observed	   mutations	   have	   been	   found.	   Mutations	   are	   in	   particular	   identified	   in	   the	   regulatory	   genes	  
mucA	  and	  lasR	  [75,	  76].	  Inactivation	  of	  MucA	  results	  in	  overproduction	  of	  alginate	  leading	  to	  conversion	  to	   the	   mucoid	   phenotype	   [148].	   This	   slimy	   biofilm-­‐like	   phenotype	   is	   often	   observed	   in	   chronic	  infections	  and	  has	  several	  in	  vitro	  effects,	  including	  phagocytosis	  inhibition	  [149,	  150],	  protection	  from	  reactive	   oxygen	   intermediates	   [151],	   and	   is	   further	   suggested	   to	   improve	   resistance	   to	   the	   innate	  clearance	  mechanisms	  in	  the	  lung	  [152].	  	  Mutations	   in	  LasR	  influence	  the	  production	  of	  several	  virulence	  factors	  and	  confer	  growth	  advantages	  on	   certain	   amino	   acids	   [142].	   Furthermore,	   genes	   important	   for	   antibiotic	   susceptibility,	   such	   as	   the	  efflux	   pumps,	   are	   also	   commonly	  mutated	   [75,	   153].	   Epistatic	   interactions	   between	   these	  mutations	  play	  important	  roles	  in	  the	  adaptation	  of	  P.	  aeruginosa	  [32].	  	  Most	  studies	  identifying	  these	  adaptive	  mutations	  are	  based	  on	  few	  isolates	  from	  different	  time	  points	  representing	   the	   whole	   P.	   aeruginosa	   population	   [75,	   154]	   and	   therefore	   conclusions	   about	   the	  population	   structure	   should	   be	   considered	   with	   caution.	   The	   extent	   of	   diversity	   and	   the	   ecological	  dynamics	   within	   chronic	   infection	   are	   not	   fully	   understood.	   Two	   models	   have	   been	   suggested:	   the	  ‘dominant-­‐lineage’	   model,	   which	   suggests	   that	   little	   diversity	   is	   observed	   in	   the	   population,	   and	   a	  ‘diverse-­‐community’	  model,	  where	  several	  subpopulations	  may	  coexist	  and	  compete	  [155,	  156]	  (Figure	  14).	  	  
	  Figure	  14|Models	  of	  within-­‐patient	  evolution.	  A)	  In	  the	  ‘Dominant-­‐lineage’	  model	  beneficial	  mutations	  are	  fixed	  leading	  to	  one	  dominant	  lineage	  (green	  lines),	  while	  less	  fit	  ancestors	  are	  outcompeted	  (dashed	  lines).	  Polymorphic	  mutations	  will	  be	  rare	  in	  this	  model	  (magenta	  lines)	  [156].	  B)	  In	  the	   ‘Diverse-­‐community’	  model	  co-­‐existing	  subpopulations	  arise	  from	  the	  ancestor	  that	   may	   acquire	   distinct	   adaptive	   mutations	   leading	   to	   continuous	   diversification.	   Each	   subpopulation	   may	   climb	   local	  adaptive	  peaks	  resulting	  in	  niche	  specialisation.	  Figure	  is	  adapted	  from	  Lieberman	  et	  al.	  (2014)	  [156].	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  A	  heterogeneous	  environment	  with	  distinct	  niches	  have	  been	  shown	  to	  promote	  diversity	  [24].	  Indeed	  the	  CF	   airway	   constitute	   the	   complexity	   that	   generates	   diversity	   and	   ecologists	   have	   long	   recognized	  that	  population	  diversity	  can	  enhance	  survival	  and	  drive	  persistence	  in	  chronic	  infections	  [41].	  This	  is	  also	  known	  as	  the	  ‘insurance	  hypothesis’,	  which	  postulates	  that	  the	  presence	  of	  diverse	  subpopulations	  increases	  the	  range	  of	  conditions	  in	  which	  some	  will	  survive	  [157].	  Therefore,	  within-­‐patient	  population	  diversity	   has	   major	   implications	   for	   both	   for	   drug	   treatment	   and	   resistance	   [158],	   but	   also	   for	  understanding	  evolutionary	  processes	  and	  natural	  genetic	  microvariation	  [159].	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Chapter	  4	  	  
Present	  investigations	  tudying	   natural	   evolution	   is	   very	   complex.	   Various	   challenges	   exist	   including	   sampling	   of	  populations	   in	   an	   organized	   manner,	   the	   environment	   may	   be	   problematic	   to	   define	   or	   the	  population	   of	   interest	   is	   too	   small.	   Few	   systems	   are	   therefore	   suited	   for	   such	   studies.	   The	   airway	  infections	  of	  P.	  aeruginosa	  in	  patients	  suffering	  from	  CF	  constitute	  an	  ideal	  model.	  The	  work	  presented	  in	   this	   thesis	   has	   only	   been	   possible	   to	   perform	   due	   to	   an	   unique	   collection	   of	   frozen	   ‘fossils’	   of	   P.	  
aeruginosa	   isolates	  derived	  from	  CF	  patients	  since	  1973	  at	  the	  Copenhagen	  CF	  Clinic	  [160].	  This	  more	  than	  40	  year	  old	  strain	  collection	  provide	  an	  unique	  opportunity	  to	  design	  longitudinal	  investigations	  of	  evolutionary	  trajectories	  for	  different	  bacterial	  clones	   in	  distinct	  patients	  covering	  more	  than	  150,000	  bacterial	  generations	  [1].	  	  
	  
4.1|Background	  In	  a	  molecular	  epidemiological	  study	  it	  was	  shown	  that	  two	  dominant	  clones	  were	  repeatedly	  isolated	  from	  the	  CF	  patients	   in	  Copenhagen,	  namely	  DK1	  (formerly	  known	  as	  genotype	  r)	  and	  DK2	  (formerly	  known	  as	  genotype	  b)	   [161].	  These	  two	  clones	  have	  successfully	  colonized	  the	  airways	  of	  multiple	  CF	  patients	   since	   1973	   and	   were	   found	   to	   be	   transmissible	   between	   patients	   [161]	   (Figure	   15).	  Furthermore,	  in	  some	  patients	  the	  two	  clones	  appear	  to	  coexist,	  while	  in	  others,	  they	  seem	  to	  compete,	  because	   coexistence	  often	   resulted	   in	  niche	   exclusion	   and	  eradication	  of	   one	  of	   the	   clones	   [161].	  The	  specific	   mechanisms	   involved	   in	   this	   competition	   is	   not	   known,	   however,	   the	   nutritional	   conditions,	  antibiotic	   treatment,	   the	   immune	   system,	   and	   other	   stress	   factors	   might	   have	   contributed	   to	   this	  competitive	  effect.	  	  
	  Figure	  15|Simplified	  overview	  of	  the	  epidemiology	  of	   the	  DK1	  and	  DK2	  clones	  of	  P.	  aeruginosa	   in	  Danish	  CF	  patients	  
attending	   the	  Copenhagen	  CF	  Centre.	  The	  DK1	  and	  DK2	  clones	  was	  first	   isolated	  from	  CF	  patients	   in	  the	  early	  70’ties	  and	  have	  since	  then	  been	  transmitted	  and	  isolated	  from	  more	  than	  40	  patient	  each.	  Figure	  is	  adapted	  from	  [162].	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The	  evolutionary	  trajectories	  and	  dynamic	  of	  the	  DK2	  lineage	  has	  recently	  been	  investigated	  [76,	  163].	  Surprisingly,	   it	   was	   found	   that	   this	   dominant	   lineage	   evolved	   into	   a	   highly	   successful	   colonizer	   by	  acquiring	   few	   early	   pleiotropic	   mutations	   in	   regulatory	   genes	   that	   resulted	   in	   rewiring	   of	   global	  regulatory	  networks	  [32,	  76].	  The	  genomic	  signature	  indicated	  negative	  selection	  and	  it	  was	  observed	  that	   the	   adaptation	   leading	   to	   persistence	   of	   the	   DK2	   clone	   did	   not	   lead	   to	   increased	   population	  diversity.	  One	  dominant	  cell	  line	  has	  been	  able	  to	  colonize	  all	  major	  niches	  of	  the	  CF	  airways	  in	  several	  different	   hosts	   [76].	   These	   findings	  were	   indeed	   striking	   as	   they	   contradict	   previous	   observations	   of	  positive	   selection	   from	   long-­‐term	   in	   vitro	   evolution	   experiments	   [164]	   and	   generation	   of	   diversity	  reflected	  by	  the	  presence	  of	  multiple	  niches	  [22].	  A	  relevant	  and	  important	  question	  asked	  in	  this	  thesis	  is	  whether	   other	   clones	   of	  P.	  aeruginosa	   share	   this	   evolutionary	   path,	   or	   if	   alternative	   routes	   can	   be	  used.	  	  In	   many	   ways,	   the	   CF	   airway	   model	   resembles	   the	   Lenksi	   evolutionary	   experiment.	   However,	   the	  human	   airway	   constitute	   a	   far	   more	   complex	   natural	   environment	   with	   a	   spatially	   structure	   that	  fluctuates	  in	  both	  time	  and	  space	  compared	  to	  Lenski’s	  experimental	  setup	  [165].	  
	  
4.2|Thesis	  objectives	  and	  questions	  With	   the	   important	   and	   surprising	   findings	   of	   the	   evolutionary	   dynamics	   of	   DK2,	   we	   analysed	   the	  evolutionary	  dynamics	  of	  the	  DK1	  clone.	  	  The	   major	   objective	   of	   this	   thesis	   has	   therefore	   been	   to	   document	   how	   microbial	   populations	   use	  different	   evolutionary	   strategies	   when	   adapting	   to	   novel	   environments	   over	   long	   time	   periods.	  Furthermore,	   we	   investigated	   the	   underlying	   key	   mutational	   events,	   and	   mapped	   the	   subsequent	  functional	   progression	   of	   adaptation	   resulting	   in	   highly	   successful	   and	   transmissible	   cell	   lines	   with	  potential	  to	  persist	  indefinitely.	  	  A	   key	   motivation	   in	   this	   thesis	   was	   to	   document	   cases	   where	   generation	   of	   population	   diversity	   is	  evident	   and	   address	   a	   number	   of	   important	   questions	   in	   evolutionary	   biology,	   including:	   is	   spatial	  structure	  of	  the	  environment	  causing	  polymorphism?	  Is	  the	  diversity	  stably	  maintained	  over	  extended	  time	  periods?	  And	  is	  diversity	  maintained	  through	  interactions	  between	  variant	  subpopulations?	  	  The	   longitudinal	  collection	  of	   isolates	   from	  CF	  patients	  makes	  a	  perfect	   foundation	  to	  study	  this.	  With	  focus	  on	  DK1	  we	  aimed	  at	  addressing	  these	  and	  others	  important	  questions	  in	  evolutionary	  biology	  by	  the	  presented	  papers	  in	  Chapter	  6.	  
	  
4.2|Outline	  of	  studies	  
Paper	   1:	   In	   the	   first	   paper,	   we	   examined	   the	   temporal	   and	   spatial	   variations	   in	   the	   P.	   aeruginosa	  population	  diversity	   in	   a	   chronically	   infected	   individual	   during	   a	  32-­‐year	  period	   to	   gain	  new	   insights	  into	  the	  bacterial	  diversification	  processes.	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Genome	   sequencing	   and	   phenotypic	   assays,	   including	   transcriptome	   analysis	   (Affymetrix	   GeneChiP)	  and	   catabolic	   performance	   (BIOLOG	   Phenotype	   Microarrays)	   were	   used	   to	   characterize	   the	  evolutionary	   trajectories	   and	   demonstrated	   that	   multiple	   pathways	   for	   adaptation	   existed	   for	   the	  ancestral	  genotype.	  We	  observed	  that	  the	  original	  infecting	  clone	  rapidly	  diversified	  into	  three	  distinct	  sub-­‐lineages	   that	   co-­‐existed	   for	   decades	   each	  with	   their	   own	   functional	   and	   genomic	   signatures	   and	  rates	  of	  adaptation.	  Using	  unique	  sampling	  materials,	  we	  demonstrated	  that	  the	  subpopulations	  occupy	  separate	  geographical	  niches	  each	  with	  different	  selective	  pressures	  in	  the	  infected	  airways	  (Figure	  16).	  Based	   on	   our	   phenotypic	   and	   genomic	   data,	   we	   suggest	   that	   sinuses	   functioned	   as	   a	   reservoir	   for	  subsequent	  colonization	  of	  other	  available	  niches.	  These	   data	   indicated	   that	   there	   is	   an	   underlying	   complex	   population	   structure	   in	   P.	   aeruginosa	  infections	  not	  previously	  realized	  represented	  as	  the	  long-­‐term	  and	  stable	  intraclonal	  diversity.	  	  	  
	  Figure	  16|Geographical	  location	  of	  three	  distinct	  subpopulations	  of	  P.	  aeruginosa	  in	  the	  CF	  airways.	  The	  spatial	  structure	  were	   found	   to	  give	  rise	   to	   three	  different	  sub-­‐lineages	   (A,	  B,	  and	  C)	   that	  were	  stably	  maintained	  during	   long-­‐term	  evolution	  [27].	   Isolates	   from	   cluster	   A	   was	   found	   to	   colonize	   the	   sinuses,	   while	   isolates	   from	   cluster	   C	   was	   sampled	   from	   a	  bronchoalveolar	  lavage	  (BAL).	  Isolates	  from	  cluster	  B	  was	  found	  in	  sputum	  together	  with	  isolates	  from	  cluster	  A	  and	  C.	  
	  
Paper	  2:	   In	  the	  second	  study	  [33],	  we	  investigated	  one	  of	  the	  adaptive	  mutations	  observed	  in	  the	  DK1	  lineage.	  As	  mentioned,	  the	  DK2	  lineage	  was	  found	  to	  early	  acquire	  important	  regulatory	  mutations	  that	  rewired	   the	   regulatory	   network	   and	   played	   a	   fundamental	   role	   in	   adaptation.	   These	   important	  regulatory	  mutations	  were	  not	  observed	  in	  the	  DK1	  lineage	  (with	  the	  exception	  of	  mucA).	   Instead,	  we	  observed	   an	   early	   mutation	   in	   the	   global	   transcriptional	   regulator	   Vfr	   (vfrT163P).	   The	   mutation	   was	  predicted	  to	  occur	  before	  1973	  as	  all	  isolates	  with	  the	  exception	  of	  one	  1973	  isolate	  had	  the	  mutation.	  For	  this	  reason	  and	  with	  previously	  results	  from	  DK2	  in	  mind,	  this	  mutation	  was	  of	  great	  interest,	  and	  was	  hypothesized	  to	  have	  a	  central	  role	  in	  the	  adaptation	  of	  P.	  aeruginosa	  to	  the	  CF	  environment.	  	  To	   clarify	   the	   role	   of	   vfrT163P	   we	   transferred	   it	   to	   a	   PAO1	   background	   and	   characterized	   regulatory	  consequences	  and	  pleiotropic	  effects	  caused	  by	  the	  mutation	  compared	  to	  a	  wild	  type	  and	  a	  knockout	  mutant.	  We	  discovered	  that	  the	  mutation	  occurred	  in	  the	  RNA	  polymerase	  interaction	  region	  and	  that	  it	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resulted	   in	   modification	   of	   several	   phenotypes	   including	   transcriptional	   and	   catabolic	   profiles.	   The	  
vfrT163P	   phenotype	   resembled	   a	   chronic	   infection	   phenotype.	   This	   indicated	   that	   a	   single	   naturally	  occurring	  mutation	  caused	  completely	  alterations	  of	  multiple	  phenotypes	  reflecting	  the	  transition	  from	  an	  environmental	  strain	  to	  a	  host	  specific	  pathogen	  for	  CF	  patients.	  	  	  
Paper	  3:	  The	  CF	  airways	  are	  often	  colonized	  by	  multi-­‐species.	  Interactions	  between	  different	  clone	  types	  are	  one	  of	   the	   important	   selective	  pressures	   that	   shape	  bacterial	   evolution.	  The	  contribution	  of	   clone	  interaction	   to	   both	   population	   diversity	   and	   further	   evolution,	   but	   also	   patient	   morbidity,	   remains	  largely	  unelucidated.	  	  In	  study	  3,	  we	  identified	  an	  in	  vivo	  HGT	  via	  whole	  genome	  sequencing	  in	  a	  CF	  patient	  polyclonal	  infected	  with	  P.	  aeruginosa	  DK1	  and	  DK2	  clone.	  To	  gain	  new	  insight	   into	   the	  evolutionary	  roles	  of	  HGT	  during	  chronic	  polyclonal	  infections,	  we	  examined	  the	  population	  structure	  and	  dynamics	  of	  this	  CF	  patient.	  We	  elucidated	   that	   the	   two	   clones	   were	   colonizing	   the	   same	   niche	   in	   order	   for	   the	   HGT	   to	   occur	   and	  demonstrated	   that	   multiple	   subpopulations	   of	   both	   DK1	   and	   DK2	   co-­‐existed	   in	   the	   spatially	   and	  complex	   CF	   airway.	   The	   HGT	   contributed	   to	   this	   diversity	   by	   generating	   novel	   strains	   with	   mosaic	  genomes	  that	  was	  found	  to	  persist	  in	  the	  CF	  airways.	  	  Finally,	  we	  showed	  that	  the	  HGT	  resulted	  in	  altered	  intraclonal	  interactions	  by	  increasing	  the	  resistance	  to	  R5	  pyocin	  giving	  the	  recipient	  cell	  a	  selective	  advantage	  in	  bacterial	  warfare.	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Chapter	  5	  
Conclusion	  and	  future	  perspective	  	   he	   study	   of	   bacterial	   adaption	   to	   novel	   environments	   can	   provide	   great	   insight	   into	   the	  evolutionary	   processes	   and	   selective	   pressures	   driving	   the	   evolution.	   A	   major	   interest	   is	   to	  understand	  the	  mechanisms	  that	  promote	  and	  maintain	  genetic	  diversity	  within	  ecosystems.	  In	   this	   thesis,	  we	   investigated	   the	   diversity	   generation	   of	   evolving	  microbial	   populations	   using	   the	  P.	  
aeruginosa	   airway	   infection	   in	   CF	   patient	   as	   a	   model	   system.	   Although	   P.	   aeruginosa	   population	  diversity	   has	   been	   demonstrated	   by	   investigation	   of	   bacteria	   cultured	   from	   the	   same	   respiratory	  specimens,	   the	   understanding	   of	   how	   this	   diversity	   is	   generated	   and	  maintained	   is	   limited.	   Here	  we	  demonstrated	  two	  cases	  on	  how	  this	  diversity	  can	  be	  generated.	  	  With	  focus	  on	  the	  dominant	  and	  highly	  successful	  DK1	  clone,	  we	  presented	  a	  case	  in	  which	  DK1	  evolved	  in	  the	  highly	  complex	  and	  heterogeneous	  CF	  environment	  of	  one	  patient	  for	  32	  years.	  We	  demonstrated	  that	  not	  only	  did	  the	  ancestral	  clone	  diversify	  into	  several	  subpopulations	  rapidly	  after	  colonization,	  but	  we	  were	  also	  able	   to	   show	   that	   these	   subpopulations,	  with	  distinct	  genomic	  and	  phenotypic	   features,	  were	  stably	  maintained	  during	  long-­‐term	  infection.	  Therefore,	  sequencing	  a	  single	  isolate	  to	  represent	  the	   whole	   population	   would	   dramatically	   underestimate	   the	   intraclonal	   diversity	   and	   such	   results	  should	   be	   interpreted	   with	   caution.	   Moreover,	   it	   was	   clearly	   demonstrated	   that	   the	   subpopulations	  occupied	  distinct	  geographical	  locations	  within	  the	  CF	  airways.	  	  These	   data	   demonstrate	   that	   stable	   diversification	  within	  P.	  aeruginosa	   population	   can	   be	   caused	   by	  spatial	  compartmentalization	  in	  the	  complex	  CF	  environment.	  	  It	  was	  shown	  that	  before	  diversification,	  the	  DK1	  clone	  acquired	  an	  early	  regulatory	  mutation	  in	  a	  global	  transcriptional	   regulator	   (Vfr).	   The	   Vfr	   is	   implicated	   in	   the	   complex	   network	   of	   regulating	   acute	  virulence	   factors	   mainly	   through	   regulation	   of	   lasR.	   Mutation	   in	   this	   regulator	   lead	   to	   alteration	   of	  multiple	   phenotypes	   reflecting	   the	   transition	   from	   an	   environmental	   strain	   to	   a	   chronic	   strain.	   This	  indicated	  that	  mutation	  in	  vfr	  was	  the	  first	  step	  of	  becoming	  a	  successful	  colonizer.	  Another	   case	   of	   diversification	   was	   observed	   in	   a	   patient	   polyclonal	   infected	   with	   DK1	   and	   DK2	   for	  more	  than	  one	  decade.	  Via	  a	  genomic	  approach	  we	  identified	  an	  in	  vivo	  HGT	  between	  the	  two	  clones	  that	  significantly	  contributed	  to	  the	  generation	  of	  population	  diversity.	  The	  novel	  strain	  (termed	  DK1/2)	  was	  found	  to	  persist	  together	  with	  both	  DK1	  and	  DK2	  in	  the	  CF	  airways.	  Moreover,	  the	  transfer	  was	  shown	  to	  give	  the	  recipient	  cell	  an	  increased	  species-­‐specific-­‐antibiotic	  (pyocin)	  resistance.	  	  In	   conclusion,	   adaptation	   of	   DK1	   to	   the	   highly	   structured	   and	   heterogenous	   CF	   environments	   is	  facilitated	   by	   high	   intraclonal	   diversity	   and	   niche	   specialization.	   These	   results	   point	   toward	   an	  
T	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underlying	  complex	  population	  structure	  not	  previous	  realized,	  and	  show	  that	  the	  spatially	  structured	  CF	   environment	   and	   composition,	   and	   interaction	   between	   species	   within	   the	   community	   play	  significantly	  roles	  in	  diversification	  of	  the	  population.	  	  	  
5.1|Different	  evolutionary	  paths	  of	  DK1	  and	  DK2	  The	   investigation	  of	   the	  DK1	  clone	   revealed	  a	  distinct	   evolutionary	  path	   compared	   to	   that	  previously	  observed	   for	   the	  other	  dominating	   lineage,	  DK2.	  Although	   the	   two	   clones	  have	  evolved	  under	   similar	  selective	   pressures	   and	   antibiotic	   treatment	   and	   in	   some	   cases	   even	   in	   the	   same	   CF	   patients,	   it	   was	  demonstrated	   that	   the	   two	   clones	   evolved	   differently.	   Previous	   study	   documented	   limited	  diversification	  of	  the	  DK2	  lineage	  despite	  the	  stressful	  and	  fluctuating	  CF	  environment	  [76].	  	  In	  contrast,	  we	  observed	  high	  degree	  of	  diversification	  and	  niche	  specialization	  of	  the	  DK1	  clone	  in	  the	  case	  of	  isolates	  from	  patient	  P30M0	  (paper	  1).	  To	  further	  examine	  the	  DK1	  population	  dynamics	  and	  to	  exclude	   that	   the	   observed	   diversity	   in	   P30M0	   was	   a	   special	   case,	   we	   have	   genome	   sequenced	   12	  additional	   isolates	   from	   multiple	   patients	   infected	   with	   the	   DK1	   clone.	   These	   preliminary	   results	  confirm	   the	   high	   diversity	   within	   the	   DK1	   population	   (Figure	   17)	   and	   show	   a	   population	   with	   high	  genomic	  heterogeneity,	  occurrence	  of	  mutators,	  and	  deep	  branching	  resulting	   in	  phenotypic	  variation,	  co-­‐existing	  subpopulations	  and	  niche	  specialization.	  We	  therefore	  suggest	   that	   the	  two	  clones	  evolved	  through	   distinct	   evolutionary	   routes;	   DK1	   have	   evolved	   into	   a	   niche	   specialist	   where	   co-­‐existing	  subpopulations	   each	   climbed	   a	   distinct	   adaptive	   peak	   in	   the	   fitness	   landscape	   (illustrated	   as	   the	  ‘diverse-­‐community’	   model	   in	   Figure	   14b),	   while	   the	   DK2	   lineage	   reached	   an	   adaptive	   peak	   in	   the	  fitness	   landscape	   that	  made	   it	   possible	   to	   colonize	   all	  major	   niches	   of	   the	   CF	   airways	   and	   in	   several	  different	   hosts	   as	   a	   generalist.	   This	   type	   of	   evolutionary	   path	   may	   represent	   the	   ‘dominant-­‐lineage’	  model	  illustrated	  in	  (Figure	  14a).	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  Figure	  17|Evolutionary	  trajectories	  of	  P.	  aeruginosa	  DK1	  clone.	  Maximum-­‐parsimonious	  reconstruction	  of	  the	  DK1	  clones	  isolated	  from	  multiple	  patients.	  The	  phylogenetic	  tree	  is	  based	  on	  6,362	  SNPs	  identified	  from	  whole-­‐genome	  sequencing	  and	  length	   of	   branches	   are	   proportional	   to	   the	   number	   of	   mutations.	   Broken	   branches	   indicate	   hypermutators	   and	   the	   above	  number	  represent	  the	  number	  of	  accumulated	  SNPs	  in	  the	  given	  branch.	  Mutation	  detection,	  analysis	  and	  construction	  of	  the	  phylogenetic	  tree	  were	  performed	  as	  previously	  described	  [163].	  	  A	   limitation	   of	   the	   DK2	   study	   is	   that	   only	   one	   contemporary	   isolate	   from	   each	   sputum	   samples	   is	  sequenced	  and	  compared	  and	  major	  conclusions	  on	  the	  whole	  population	  structure	  should	  therefore	  be	  considered	  with	  caution.	  	  Other	  studies	  have	  demonstrated	   intraclonal	  population	  diversity	  of	  P.	  aeruginosa	   [69,	  159]	  but	   it	  has	  also	   been	   reported	   for	   other	   pathogens	   including	   Burkholderia	   cepacia	   complex	   [156,	   166]	   and	  
Helicobacter	   pylori	   [167]	   when	   adapting	   to	   the	   CF	   environment.	   This	   indicates	   that	   diversification	  within	  patients	  during	  adaptation	   is	   the	   rule	   rather	   than	   the	  exception,	  and	   that	  DK2	  might	  be	  a	   rare	  case.	  However,	   in	   a	   recent	   study	  by	  Marvig	  et	  al	   (2013),	   the	  possibility	   of	   intraclonal	  diversity	   in	   the	  DK2	  was	   indicated	   [163]	   and	  we	   further	   show	   a	   case	   in	   a	   polyclonal	   infection	  where	   the	   population	  structure	   of	   DK2	   is	   very	   complex	   [46].	   As	   a	   next	   step,	   we	   therefore	   suggest	   to	   study	   the	   intraclonal	  diversity	  in	  depth	  by	  sequencing	  multiple	  contemporary	  and	  temporal	  sputum	  samples	  of	  both	  DK1	  and	  DK2	  to	  confirm	  the	  observed	  diversity	  (DK1)	  or	  the	  lack	  of	  the	  same	  (DK2).	  Another	  intriguing	  question	  to	  ask	  is	  if	  one	  of	  the	  clones	  is	  more	  fit	  than	  the	  other,	  since	  we	  in	  several	  cases	   have	   observed	   coexistence	   of	   the	   two	   clones.	   Data	   indicate	   that	   they	   are	   colonizing	   the	   same	  niches	   [46,	  161]	  and	  most	  often	   this	  coexistence	  results	   in	  eradication	  of	  one	  of	   the	  clones,	   indicating	  that	  they	  are	  competing	  in	  the	  CF	  airways	  [161].	  Therefore,	  a	  head-­‐to-­‐head	  fitness	  experiment	  could	  be	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very	  interesting.	  Unfortunately,	  we	  lack	  an	   in	  vitro	  model	  system	  that	  can	  mimic	  the	  complexity	  of	  the	  CF	  environment	  and	  the	  selective	  pressures	  acting	  on	  the	  population.	  The	  use	  of	  synthetic	  cystic	  fibrosis	  sputum	   medium	   [79]	   have	   shown	   parallel	   selection	   of	   several	   mutations	   previously	   identified	   from	  patient	  isolates	  [168]	  and	  may	  therefore	  be	  a	  good	  way	  to	  start.	  	  
	  
5.2|Perspectives	  in	  relation	  to	  evolutionary	  microbiology	  It	   is	   now	   feasible	   via	   affordable,	   high-­‐throughput	   sequencing	   to	   uncover	   the	   underlying	   genetic	  mechanisms	   and	   changes	  during	   adaptation	   of	   evolving	  microbial	   populations	   in	   novel	   environments	  through	  the	  direct	  sequencing	  of	  clinical	  isolates.	  The	  Copenhagen	  strain	  collection	  provides	  the	  unique	  opportunity	   to	   study	   the	   longest	   natural	  microbial	   evolution	   ‘experiment’	   ever	   reported.	   It	   has	   been	  found	   that	   the	   evolutionary	   dynamics	   of	   P.	   aeruginosa	   resemble	   evolutionary	   dynamics	   documented	  from	  in	  vitro	  experiment	  [76,	  164,	  169].	  In	  this	  way,	  parallels	  can	  be	  drawn	  from	  laboratory	  studies	  and	  the	  real-­‐world	  evolution	  trajectories.	  	  	  Several	   parallels	   have	   been	   observed	   between	   the	   major	   pathogens	   of	   CF	   when	   adapting	   to	   the	   CF	  environment	  [170].	  Both	  P.	  aeruginosa	  [76,	  163]	  and	  Burkholderia	  dolosa	  [171]	  acquire	  mutations	  in	  an	  overlapping	   set	  of	   genes	   such	  as	  gyrA	  (drug	   resistance),	   global	   regulators,	   and	  genes	   involved	   in	   iron	  scavenging	  and	  outer	  membrane	  proteins	  [156,	  163].	  Besides	  this,	   intraclonal	  diversity	  and	  coexisting	  subpopulations	  have	  been	  observed	  for	  both	  pathogens	  [27,	  156].	  	  Studying	  how	  pathogens	  adapt	  to	  their	  human	  host	  can	  in	  this	  way	  provide	  unique	  information	  into	  the	  evolutionary	   trajectories	   of	   pathogens.	   These	   examples	   illustrate	   the	   importance	   of	   studying	   the	  molecular	   details	   of	   evolving	   populations	   in	   natural	   environments	   in	   addition	   to	   populations	   in	  laboratory	  systems.	  	  	  It	   is	   evident	   that	   most	   infections	   result	   from	   colonization	   by	   more	   than	   one	   microbe.	   How	   these	  pathogens	   and	   their	   evolved	  mutants	  may	   interact	  within	   the	   community	   is	   unclear.	   	  However,	  most	  laboratory	   studies	   have	   only	   been	   focusing	   on	   single	   bacterial	   species	   grown	   in	   isolation.	   With	   the	  identification	  of	  HGT	  between	   two	  dominant	   clones	  of	  P.	  aeruginosa	  we	  have	   seen	  a	   glimpse	  of	   these	  complex	   interactions	   between	   the	   infecting	   microbial	   communities.	   Therefore,	   it	   would	   be	   highly	  interesting	  to	  study	  the	  effect	  and	  interactions	  in	  the	  community	  not	  only	  between	  P.	  aeruginosa	  strains	  but	  also	  between	  the	  other	  infecting	  strains.	  This	  will	  give	  a	  better	  understanding	  of	  microbial	  evolution	  and	   allow	   deciphering	   inter-­‐species	   interactions	   that	   can	   help	   in	   the	   search	   for	   novel	   or	   improved	  treatments.	  	  The	  unique	  collection	  of	  P.	  aeruginosa	  isolated	  from	  Danish	  CF	  patients,	  were	  sampled	  after	  the	  onset	  of	  chronic	   infection.	  With	   the	   findings	   that	   the	   sinuses	  may	   act	   as	   a	   bacterial	   reservoir	  where	   they	   can	  adapt	   and	   evolve	   long	   before	   the	   onset	   of	   chronic	   pulmonary	   infections	   [27,	   66,	   69],	   it	   leads	   to	   the	  question	  what	  happens	  during	  early	  and	  intermittent	  infections	  both	  in	  the	  lung	  but	  also	  in	  the	  sinuses?	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The	  next	  step	  is	  to	  investigate	  the	  isolates	  from	  very	  young	  and	  intermittently	  colonized	  patients.	  This	  will	   lead	   to	   identification	   of	   mutations	   that	   are	   immediate	   important	   for	   colonization	   and	   transition	  from	  an	  environmental	  strain	  to	  a	  host	  specific	  pathogen	  for	  CF	  patients.	  
	  
5.3|Medical	  perspective	  Understanding	  how	  bacterial	  populations	  adapt	  to	  a	  novel	  environment	  and	  which	  underlying	  genetic	  changes	  occur	  may	  provide	  useful	  information	  in	  the	  design	  of	  new	  treatment	  strategies	  and	  therapeutic	  targets.	  	  The	   results	  presented	  here	  may	   therefore	   contribute	   to	   improve	   future	   therapeutic	   strategies	   since	   a	  clear	  understanding	  of	  the	  population	  diversity	  is	  important	  to	  target	  treatment.	  We	  show	  that	  there	  is	  high	   population	   diversity	   both	   contemporary	   and	   long-­‐term	   and	   that	   distinct	   subpopulations	   are	  spatially	  distributed	  in	  the	  CF	  airway.	  Designing	  treatments	  that	  target	  the	  different	  site	  are	  therefore	  needed.	   In	   order	   to	   specify	   and	   target	   treatments	   properly	   it	   is	   necessary	   to	   know	   the	   precise	  localization	  and	  diagnosis	  of	  the	  CF	  airway	  colonizations	  and	  infections.	  Our	  current	  study	  suggest	  that	  subpopulations	   found	   in	   the	   lower	   airways	   at	   some	   point	   originated	   from	   the	   sinus	   population	   and	  migrated	   to	   the	   lung.	  The	   importance	  of	   sinuses	  as	  bacterial	   reservoirs	  has	  previously	  been	   indicated	  [66,	  69].	  To	  prevent	  or	  delay	  transition	  to	  chronic	   lung	  infection	  and	  ultimately	  prolong	  the	   life	  of	  the	  patients,	  early	  diagnosis	  and	  treatment	  of	  P.	  aeruginosa	  colonizations	  in	  the	  paranasal	  sinuses	  could	  be	  an	  important	  therapeutic	  approach	  [69].	  	  With	   the	   realization	   that	   the	   intraclonal	   diversity	   is	   high,	   there	   need	   to	   be	   a	   better	   diagnosis	   and	  characterization	  of	  the	  strain	  variation	  especially	  in	  relation	  to	  antibiotics.	  When	  a	  clinician	  needs	   to	  decide	  how	  to	   treat	  a	  bacterial	   infection,	  knowledge	  about	  diversity	  and	   its	  impact	  on	  phenotypic	  variation	  is	  important	  and	  can	  provide	  better	  treatments.	  A	  clear	  understanding	  of	  within-­‐host	  population	  dynamics	  during	  the	  course	  of	  infection	  and	  generation	  of	  diversity	  is	  therefore	  necessary	  for	  optimal	  therapeutic	  interventions.	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  25	  
The	  opportunistic	  pathogen	  Pseudomonas	  aeruginosa	  chronically	  infects	  the	  airways	  of	  patients	  with	  cystic	  26	  
fibrosis	  (CF).	  A	  clear	  understanding	  of	  the	  within-­‐host	  population	  dynamics	  during	  the	  course	  of	  infection	  is	  27	  
necessary	   for	  optimal	   therapeutic	   interventions.	  While	  P.	  aeruginosa	  population	  diversity	  within	   infected	  28	  
individuals	  has	  been	  observed	  by	  inspection	  of	  bacteria	  cultured	  from	  the	  same	  respiratory	  specimens,	  our	  29	  
understanding	  of	   how	   this	   diversity	   is	   generated	   and	  maintained	   is	   limited.	   To	   gain	  new	   insight	   into	   the	  30	  
bacterial	  diversification	  processes,	  we	  examined	   the	   temporal	   and	   spatial	   variations	   in	   the	  P.	  aeruginosa	  31	  
population	  diversity	   in	   a	   chronically	   infected	  CF	  patient	  during	  a	  32-­‐year	  period.	  Genome	   sequence	  data	  32	  
and	  phenotypic	   profiling	   of	   clonal	   bacterial	   isolates	   sampled	   from	  different	   infection	   sites	   demonstrated	  33	  
that	  multiple	   pathways	   for	   adaptation	   existed	   for	   the	   ancestral	   genotype,	   and	   that	   the	  original	   infecting	  34	  
clone	   rapidly	   diversified	   into	   three	   distinct	   sub-­‐lineages,	   each	   with	   their	   own	   functional	   and	   genomic	  35	  
signatures	  and	  rates	  of	  adaptation.	  We	  further	  show	  that	  the	  three	  sub-­‐lineages	  co-­‐existed	  in	  the	  infected	  36	  
host	  for	  decades.	  We	  hypothesized	  that	  the	  observed	  diversification	  and	  stable	  maintenance	  of	  population	  37	  
polymorphisms	  was	  the	  result	  of	  partitioning	  of	  the	  sub-­‐lineages	  into	  different	  niches.	  Indeed,	  sampling	  of	  38	  
the	  paranasal	  sinuses	  and	  the	  lower	  airways	  clearly	  demonstrated	  that	  the	  sub-­‐lineages	  occupied	  separate	  39	  
geographical	   niches	   within	   the	   infected	   airways.	   The	   results	   point	   toward	   an	   underlying	   complex	  40	  
population	  structure	  not	  previously	  realized,	  and	  show	  that	  the	  highly	  structured	  CF	  host	  environment	  can	  41	  
contribute	  significantly	  to	  generation	  of	  intraclonal	  population	  diversity	  and	  its	  long-­‐term	  maintenance.	  	   	  42	  
	  3	  
Significance	  statement	  43	  
Within-­‐host	  pathogen	  evolution	  and	  diversification	  during	  the	  course	  of	  chronic	  infections	  is	  of	  importance	  44	  
in	  relation	  to	  therapeutic	  intervention	  strategies,	  yet	  our	  understanding	  of	  these	  processes	  is	  limited.	  Here	  45	  
we	   use	   chronic	   colonization	   of	   cystic	   fibrosis	   airways	   by	   the	   opportunistic	   pathogen	   Pseudomonas	  46	  
aeruginosa	  as	  a	  system	  for	  studying	  how	  evolution	  shape	  pathogen	  populations	  within	  hosts.	  We	  analyse	  47	  
clonal	  bacterial	  isolates	  sampled	  during	  a	  32	  year	  period	  from	  separate	  geographical	  niches	  within	  infected	  48	  
CF	  airways.	  We	  show	  that	   the	  original	   infecting	  strain	   immediately	  after	   initial	   colonization	  diverged	   into	  49	  
distinct	   sub-­‐lineages	   that	  co-­‐existed	   for	  decades,	  and	  occupied	  distinct	  niches.	  These	   results	   suggest	   that	  50	  
the	   spatial	   heterogeneity	   in	   CF	   airways	   plays	   a	   major	   role	   in	   relation	   to	   generation	   and	   stability	   of	  51	  
population	  diversity.	  	  52	  
	  53	  
Introduction	  54	  
Cystic	   fibrosis	   (CF)	   is	   a	   life-­‐shortening	   disease	   caused	   by	  mutations	   in	   the	   cystic	   fibrosis	   transmembrane	  55	  
conductance	  regulator	   (CFTR)	  gene.	  Although	  CF	   itself	   is	  a	  genetic	  disease,	  the	  morbidity	  and	  mortality	   is	  56	  
the	  result	  of	  life-­‐long,	  chronic	  bacterial	  airway	  infections	  and	  the	  resulting	  inflammation.	  The	  opportunistic	  57	  
pathogen	  Pseudomonas	  aeruginosa	  is	  a	  predominant	  pathogen	  in	  relation	  to	  the	  chronic	  airway	  infections.	  58	  
CF	  patients	  often	  acquire	   intermittent	  colonization	  of	   the	  airways	   from	  early	  childhood,	  which	  eventually	  59	  
proceeds	  into	  chronic	  infection	  where	  the	  same	  clonal	  P.	  aeruginosa	  lineage	  can	  persist	  for	  decades	  despite	  60	  
antibiotic	  therapy	  (1).	  Once	  the	  chronic	  infection	  has	  been	  established,	  lineage	  replacement	  is	  rare	  (2).	  CF	  61	  
airway	  infections	  are	  associated	  with	  genetic	  and	  phenotypic	  changes	  in	  P.	  aeruginosa,	  which	  contribute	  to	  62	  
its	   long-­‐term	   persistence	   in	   the	   airways.	   It	   is	   well	   established	   that	   the	   phenotype	   characteristics	   of	   P.	  63	  
aeruginosa	   isolates	   from	   chronically	   infected	   CF	   patients	   are	   most	   often	   remarkably	   different	   from	   the	  64	  
phenotypes	  displayed	  by	  the	  clonal	   isolates	  that	   initiated	  the	  infection	  in	  the	  same	  patients	  years	  before.	  65	  
Many	   phenotype	   characteristics	   of	   chronically	   infecting	   strains	   are	   consistently	   selected	   in	   different	   CF	  66	  
patients,	   suggesting	   that	  adaptation	  occurs	  with	   conserved	  patterns	  of	  evolution	   (3).	   This	   conclusion	  has	  67	  
been	   further	   substantiated	   by	   genome	   sequence	   analyses,	  which	   have	   led	   to	   the	   discovery	   of	   recurrent	  68	  
patterns	  of	  mutations	  in	  independent	  evolving	  P.	  aeruginosa	  lineages,	  and	  have	  furthermore	  provided	  new	  69	  
insight	  into	  the	  genetic	  changes	  underlying	  the	  phenotypic	  changes	  (4-­‐6).	  70	  
In	   parallel	   to	   these	   advances	   in	   characterizing	   the	   evolutionary	  pathways	   in	  P.	   aeruginosa,	   other	   studies	  71	  
have	  documented	  the	  existence	  of	  P.	  aeruginosa	  population	  diversity	  within	  individual	  hosts.	  For	  example,	  72	  
a	   significant	   level	   of	   phenotypic	   variability	   within	   the	   infecting	   P.	   aeruginosa	   population	   is	   commonly	  73	  
	  4	  
observed,	  and	  P.	  aeruginosa	  clones	  sampled	  from	  the	  same	  clinical	  specimen	  often	  display	  large	  differences	  74	  
in	   colony	   morphology,	   quorum	   sensing	   regulation,	   antibiotic	   resistance	   and	   other	   phenotypes	   typically	  75	  
associated	  with	  chronic	  CF	  infections	  (7-­‐11).	  Similarly,	  genome	  studies	  have	  provided	  evidence	  for	  genomic	  76	  
diversity	  among	  clonal	  isolates	  (12)	  and	  for	  clonal	  sub-­‐lineage	  replacements	  during	  long-­‐term	  infections	  in	  77	  
individual	   patients	   (4).	   Similar	   results	   have	  been	  obtained	   for	   other	   CF-­‐associated	  pathogens	   (13).	  While	  78	  
these	   studies	   add	   to	   an	   emerging	   picture	   of	   an	  underlying	   and	   complex	   population	  dynamics	  within	   the	  79	  
infected	  host,	   the	  specific	  causes	  of	  the	  observed	   intraclonal	  diversity	  are	  difficult	   to	  unravel	  and	  are	  not	  80	  
well	   understood.	   Since	   the	   CF	   airways	   is	   a	   highly	   structured	   environment	   with	   multiple	   connected	  81	  
compartments	  each	  with	  different	  environmental	  conditions,	  a	  possible	  model	  is	  that	  population	  diversity	  82	  
is	   the	   result	   of	   evolution	   of	   sub-­‐lineages	   that	   can	   efficiently	   occupy	   different	   niches	   available	   in	   the	   CF	  83	  
airways.	   Nevertheless,	   other	   processes	   such	   as	   interactions	   between	   variant	   sub-­‐populations	   (e.g.	  84	  
evolution	  of	  syntropic	  relationships)	  (14),	  and	  the	  evolution	  of	  variants	  with	  increased	  mutation	  rates	  (i.e.	  85	  
the	   hypermutator	   phenotype)	   (15)	   have	   been	   described	   for	   P.	   aeruginosa	   CF	   isolates	   and	   could	   also	  86	  
contribute	  to	  population	  diversification.	  	  87	  
Critically,	  it	  remains	  unknown	  how	  the	  observed	  intraclonal	  diversity	  is	  generated	  and	  if	  the	  environmental	  88	  
heterogeneity	  and	  structure	  of	  the	  CF	  airways	  contribute	  to	  diversity	  generation,	  how	  stable	  these	  variant	  89	  
populations	  are	  as	  a	  function	  of	  time,	  and	  whether	  the	  variant	  populations	  are	  geographically	  segregated	  in	  90	  
the	   airways.	   To	   address	   these	   issues,	   we	   analyzed	   clonal	   bacterial	   isolates	   sampled	   from	   a	   chronically	  91	  
infected	  individual	  during	  a	  32-­‐year	  period.	  Sampling	  and	  storage	  of	  P.	  aeruginosa	  isolates	  from	  chronically	  92	  
infected	  Danish	  CF	  patients	  has	  been	  carried	  out	  since	  1973,	  which	  has	  resulted	  in	  a	  strain	  collection	  that	  93	  
represents	  40	  years	  of	  ‘infection	  history’	  from	  a	  large	  number	  of	  infected	  individuals.	  These	  frozen	  stocks	  of	  94	  
P.	  aeruginosa	  can	  easily	  be	  revived	  and	  analyzed.	  In	  our	  initial	  examination	  of	  the	  clonal	  relationship	  among	  95	  
the	  stored	  isolates	  using	  low-­‐resolution	  molecular	  typing	  methods	  we	  identified	  two	  distinct	  and	  dominant	  96	  
P.	  aeruginosa	   lineages	  that	  were	  observed	  repeatedly	  because	  of	  transmission	  among	  patients	  (16).	  Here,	  97	  
we	   focus	  on	  one	  of	   these	   transmissible	   lineages	   called	  DK1	   and	  demonstrate	   rapid	  diversification	  of	   the	  98	  
original	   infecting	   strain	   into	   three	   distinct	   sub-­‐lineages,	   each	   with	   their	   own	   functional	   and	   genomic	  99	  
signatures.	   We	   show	   that	   this	   functional	   and	   genomic	   diversification	   remained	   stable	   for	   decades,	   and	  100	  








Genomic	   evolution	   of	   the	  DK1	   lineage	   and	  within-­‐patient	   diversity.	   The	  DK1	   lineage	   has	   been	   isolated	  108	  
from	  more	  than	  40	  CF	  patients	  since	  the	  start	  of	  the	  sampling	  program	  in	  1973.	  We	  first	  sought	  to	  identify	  109	  
patients	  with	  a	  long	  clonal	  infection	  history	  with	  DK1,	  and	  from	  whom	  both	  contemporary	  DK1	  isolates	  as	  110	  
well	  as	  historical	  isolates	  from	  lung	  expectorates	  were	  available.	  We	  found	  one	  such	  patient	  (P30M0),	  and	  111	  
sequenced	   the	   genomes	   of	   18	   isolates	   sampled	   between	   1980	   and	   2012	   from	   this	   patient	   (Figure	   1).	  	  112	  
Furthermore,	  to	  characterize	  the	  evolution	  of	  the	  DK1	  lineage	  from	  its	  entry	  into	  the	  CF	  environment	  until	  113	  
present	  day,	  we	  also	   identified	  and	  sequenced	  the	  four	  oldest	  DK1	   isolates	   in	  the	  strain	  collection.	  These	  114	  
four	  isolates	  were	  sampled	  from	  four	  different	  patients	  in	  1973	  (Figure	  1).	  	  115	  
Following	   sequencing,	   we	   identified	   high-­‐quality	   single	   nucleotide	   polymorphisms	   (SNPs)	   in	   the	   non-­‐116	  
repetitive	  parts	  of	  the	  genomes	  by	  mapping	  sequence	  reads	  for	  each	   isolate	  against	  the	  DK1-­‐P33F0-­‐1973	  117	  
genome	  sequence	  as	  previously	  described	  (4),	  and	  found	  a	  total	  of	  160	  SNPs	  that	  had	  appeared	  since	  the	  118	  
isolates	  diverged	  from	  their	  common	  DK1	  ancestor	  before	  1973.	  	  119	  
The	   identification	   of	   SNPs	   enabled	   us	   to	   determine	   the	   evolutionary	   relationship	   among	   the	  DK1	   clones	  120	  
(Figure	   2A).	   Focusing	   on	   the	   isolates	   from	   P30M0,	   we	   observed	   that	   relatively	   few	   SNP	   changes	   had	  121	  
occurred	   during	   32	   years	   of	   colonization	   of	   the	   patient	   (Table	   S1).	   For	   example,	   only	   19	   SNP	   changes	  122	  
separate	   isolates	  DK1-­‐P30M0-­‐1980	  and	  DK1-­‐P30M0-­‐2012c,	  and	  DK1-­‐P30M0-­‐2012c	  had	  only	  accumulated	  123	  
24	  SNP	  changes	  in	  total	  since	  it	  diverged	  from	  the	  common	  ancestor	  of	  all	  DK1	  isolates	  (Figure	  2A).	  Despite	  124	  
this	  moderate	  genomic	  evolution,	   the	  phylogenetic	   tree	   revealed	  a	  divergent	  population	  structure	  of	   the	  125	  
P30M0	   isolates,	   and	   the	   deeply	   branched	   topology	   of	   the	   tree	   provided	   evidence	   for	   three	   distinct,	  126	  
coexisting	  sub-­‐lineages	  (cluster	  A,	  B,	  and	  C	  in	  Figure	  2A).	  We	  performed	  a	  Bayesian	  analysis	  to	  estimate	  the	  127	  
divergence	  dates	  and	  mutation	  rate.	  Based	  on	  the	  Bayesian	  phylogenetic	  reconstruction,	  we	  estimated	  that	  128	  
the	   infecting	   population	   first	   diverged	   in	   1979	   (95%	   highest	   posterior	   density	   (HPD):	   1976-­‐1982)	   (Figure	  129	  
2A).	  This	  estimate	  coincides	  with	  the	  first	  DK1	  culture	  from	  P30M0	  which	  was	  sampled	  in	  1980,	  suggesting	  130	  
that	   the	   DK1	   population	   diverged	   soon	   after	   initial	   colonization.	   The	   population	   further	   diverged	   into	  131	  
cluster	   A	   and	   C	   a	   decade	   later	   (Figure	   2A).	   Importantly,	   bacterial	   isolates	   from	   the	   three	   clusters	   were	  132	  
identified	  in	  contemporary	  samples	  (from	  2012/2013)	  demonstrating	  their	  co-­‐existence	  for	  decades	  in	  the	  133	  
same	  CF	  patient	  (see	  below).	  	  134	  
Overall,	   the	   DK1	   lineage	   accumulated	   1.3	   SNPs/year,	   and	   the	   relative	   rates	   of	   nonsynonymous	   and	  135	  
synonymous	   substitutions	   (dN/dS=0.56)	   implied	   that	   the	   long-­‐term	   evolution	   of	   the	   DK1	   lineage	   was	  136	  
dominated	   by	   negative	   selection	   (P	   <	   4.72×10-­‐10).	   Nonetheless,	   isolates	   from	   cluster	   C	   had	   a	   higher	  137	  
	  6	  
evolutionary	   rate	   than	   the	   two	   other	   clusters	   (Figure	   2B).	   The	   mean	   mutation	   rate	   for	   cluster	   C	   was	  138	  
estimated	  to	  be	  2.7	  SNPs/year,	  while	  the	  rates	  for	  cluster	  A	  and	  B	  were	  found	  to	  be	  0.9	  and	  1.2	  SNPs/year,	  139	  
respectively.	   The	   elevated	   rate	   in	   cluster	   C	   was	   not	   a	   consequence	   of	   horizontally	   acquired	   SNPs	   as	  140	  
observed	   in	   other	   CF	   isolates	   (4)	   or	   a	   hypermutator	   phenotype	   caused	   by	   mutations	   in	   DNA	  mismatch	  141	  
repair	   systems	   (17).	   Instead,	   we	   speculated	   that	   the	   elevated	   mutation	   rate	   was	   due	   to	   selection	   and	  142	  
fixation	   of	   adaptive	  mutations.	   In	   support	   of	   this	   hypothesis,	   we	   found	   a	   stronger	   signature	   of	   positive	  143	  
selection	  (i.e.	  a	  larger	  fraction	  of	  nonsynonymous	  mutations)	  among	  the	  SNPs	  in	  the	  C	  cluster	  (branches	  PD,	  144	  
PF,	   PG,	  XB,	   and	  XC	   in	   Figure	  2A)	   relative	   to	   the	  A	  and	  B	   cluster	   (39/13	  vs.	   37/29;	   Fisher's	   exact	   test,	  P	  =	  145	  
0.026).	  	  146	  
We	   have	   previously	   identified	   a	   set	   of	   65	   pathoadaptive	   genes	   in	   P.	   aeruginosa	   involved	   in	   CF	   host	  147	  
adaptation	   (i.e.	   genes	   that	   undergo	   adaptive	   evolution	   under	   the	   pressure	   of	   natural	   selection	   during	  148	  
chronic	   CF	   infections)	   (4).	  We	   reasoned	   that	   the	   prevalence	   of	   pathoadaptive	  mutations	   in	   each	   of	   the	  149	  
three	  sub-­‐lineages	  would	  provide	  an	  independent	  measurement	  of	  the	  level	  of	  positively	  selected	  SNPs.	  In	  150	  
agreement	  with	  our	  finding	  of	  enhanced	  positive	  selection	  in	  cluster	  C,	  we	  found	  that	  most	  pathoadaptive	  151	  
mutations	  were	  found	  in	  this	  cluster,	  whereas	  cluster	  A	  contained	  fewest	  (Figure	  2C).	  	  152	  
	  153	  
Phenotype	  analysis	  supports	  the	  existence	  of	  different	  sub-­‐lineages.	  We	  hypothesised	  that	  the	  existence	  154	  
of	   three	   divergent	   sub-­‐lineages	   each	   with	   different	   evolutionary	   trajectories	   would	   result	   in	   observable	  155	  
functional	   diversification.	  We	   first	   analysed	   the	   genotype/phenotype	   relationship	  within	   each	   cluster	   by	  156	  
measuring	   the	   catabolic	   performance	   of	   the	   isolates	   on	   125	   informative	   substrates	   of	   both	   carbon	   and	  157	  
nitrogen	   sources	   using	   Biolog	   Phenotype	   Microarrays.	   Hierarchical	   clustering	   (Ward’s	   Linkage,	   Euclidian	  158	  
distance)	   of	   the	   data,	   resulted	   in	   four	   principal	   clusters,	   each	   containing	   isolates	   with	   related	   catabolic	  159	  
profiles	  (Figure	  3C).	   It	  was	  observed	  that	  early	   isolates	  (from	  1973)	  clustered	  together	  with	  P.	  aeruginosa	  160	  
laboratory	   reference	   strain	   PAO1,	   and	   that	   the	   later	   isolates	   from	   P30M0	   grouped	   in	   three	   different	  161	  
clusters	  identical	  to	  the	  clusters	  derived	  from	  the	  genome	  sequence	  data	  (cf.	  Figure	  2A).	  	  162	  
P.	  aeruginosa	  isolates	  from	  chronically	  infected	  patients	  often	  display	  common	  phenotypic	  traits	  including	  163	  
conversion	   into	   alginate	   overproducing	  mucoid	   variants	   (18,	   19),	   reduced	   growth	   rates	   (20),	   and	   loss	   of	  164	  
virulence	   factor	   production	   (5),	   quorum	   sensing	   (21)	   and	  motility	   (22).	  We	  measured	   variations	   in	   these	  165	  
phenotypes	  for	  isolates	  from	  the	  three	  clusters.	  All	  isolates	  had	  reduced	  or	  abolished	  motility,	  but	  lineage-­‐166	  
specific	   differences	   in	   other	   traits	   were	   observed	   (Figure	   3A).	   For	   example,	   cluster	   B	   isolates	   had	  167	  
maintained	   production	   of	   quorum-­‐sensing	   (QS)	   molecules	   and	   had	   reduced	   protease	   secretion,	   while	  168	  
isolates	   from	   cluster	   A	   produced	   QS	   molecules	   but	   no	   proteases.	   Cluster	   C	   isolates	   had	   lost	   both	   QS	  169	  
production	   and	   protease	   secretion	   (Figure	   3A).	   Furthermore	   isolates	   from	   this	   cluster	   had	   a	   significantly	  170	  
	  7	  
longer	   in	  vitro	  doubling	   time	   than	   isolates	   from	  cluster	  A	  and	  B	   (Figure	  3B).	  All	  P30M0	   isolates	  contain	  a	  171	  
nonsense	  mutation	  (C349T)	  in	  the	  anti-­‐sigma	  factor	  mucA.	   Inactivation	  of	  MucA	  leads	  to	  activation	  of	  the	  172	  
AlgT	   sigma	   factor,	   expression	   of	   the	   alg	   operon	   (encoding	   enzymes	   for	   alginate	   biosynthesis),	   and	  173	  
overproduction	   of	   the	   alginate	   exopolysaccharide.	   As	   expected	   from	   the	  mucA	   mutation,	   isolates	   from	  174	  
cluster	   A	   and	   C	   were	   mucoid.	   However,	   isolates	   from	   cluster	   B	   were	   non-­‐mucoid	   most	   likely	   due	   to	  175	  
missense	  mutations	  in	  algT	  (Table	  S1).	  176	  
Overall,	  the	  unique	  phenotypic	  profiles	   in	  relation	  to	  both	  catabolic	  capacities	  and	  CF-­‐related	  phenotypes	  177	  
found	   for	   each	   cluster	   supported	   the	   genomic	   SNP-­‐based	   evidence	   for	   co-­‐existing	   sub-­‐populations.	  178	  
Furthermore,	  we	  note	  that	  the	   isolates	  from	  cluster	  C	  showed	  more	  phenotype	  traits	  typically	  associated	  179	  
with	  chronic	  infections	  than	  the	  other	  two	  clusters.	  	  180	  
	  181	  
Correlation	  between	  genomic	  evolution	  and	  phenotype	  diversity.	  Long-­‐term	  colonization	  of	  CF	  airways	  is	  182	  
often	  associated	  with	  significant	  changes	  in	  global	  gene	  expression	  profiles	  of	  the	  infecting	  isolates	  (23,	  24),	  183	  
and	  to	  examine	  the	  level	  of	  diversity	  and	  its	  variation	  as	  a	  function	  of	  time	  within	  each	  of	  the	  three	  clusters,	  184	  
we	  measured	  whole-­‐genome	  transcript	  abundance	  on	  two	  temporally	  separated	  isolates	  from	  each	  cluster.	  185	  
The	   two	   isolates	   (DK1-­‐P30M0-­‐2001b	   and	   DK1-­‐P30M0-­‐2007b)	   from	   cluster	   A	   showed	   very	   similar	   gene	  186	  
expression	   profiles	   as	   indicated	   by	   the	   high	   Pearson	   correlation	   (r	   =	   0.9944)	   (Figure	   4A)	   and	   their	   close	  187	  
clustering	  in	  singular	  value	  decomposition	  (SVD)	  analysis	  shown	  in	  Figure	  4D.	  In	  fact,	  only	  two	  genes	  with	  188	  
significant	   expression	   changes	   (Student’s	   t-­‐test,	   P	   <	   0.05)	   were	   identified	   in	   isolate	   DK1-­‐P30M0-­‐2001b	  189	  
relative	  to	  DK1-­‐P30M0-­‐2007b.	  In	  contrast,	  temporally	  separated	  isolates	  from	  both	  cluster	  C	  and	  B	  showed	  190	  
a	  more	  diverse	  gene	  expression	  profile	   (r	  =	  0.9632	  and	  r=	  0.9450,	  respectively).	  78	  genes	  with	  significant	  191	  
expression	  changes	  were	  identified	  when	  comparing	  isolates	  from	  cluster	  C	  (Figure	  4C)	  and	  298	  genes	  with	  192	  
significant	  expression	  changes	  were	  identified	  when	  comparing	  the	  two	  non-­‐mucoid	   isolates	  DK1-­‐P30M0-­‐193	  
2001a	   and	   DK1-­‐P30M0-­‐2009	   from	   cluster	   B	   (Figure	   4B).	   The	   differences	   in	   the	   extent	   of	   phenotypic	  194	  
diversity	  developing	  over	  time	  within	  the	  three	  clusters	   is	  consistent	  with	  a	  hypothesis	  that	   isolates	  from	  195	  
cluster	   B	   and	   C	   evolved	   in	   environments	   different	   from	   cluster	   A	   with	   stronger	   selective	   pressures	  196	  
mediating	  higher	  levels	  of	  both	  genomic	  evolution	  and	  phenotypic	  diversity.	  	  197	  
Limited	   parallel	   evolution	   among	   coexisting	   sub-­‐lineages.	   The	   long-­‐term	   coexistence	   of	   distinct	   sub-­‐198	  
lineages	  enabled	  us	  to	  investigate	  the	  extent	  of	  parallelism	  among	  three	  evolutionary	  pathways	  within	  the	  199	  
same	   individual.	   We	   examined	   the	   genome	   data	   for	   mutations	   that	   accumulated	   independently	   in	   the	  200	  
different	  sub-­‐lineages	  (Table	  S1).	  As	  anticipated	  such	  parallel	  evolution	  was	  observed	  in	  genes	  known	  to	  be	  201	  
involved	  in	  antibiotic	  resistance,	  and	  included	  mutations	  in	  DNA	  gyrases	  gyrA	  (cluster	  B	  and	  cluster	  C),	  gyrB	  202	  
(cluster	   A	   and	   C),	   as	   well	   as	   fusA1	   (cluster	   B	   and	   C)	   encoding	   elongation	   factor	   G	   (25,	   26)	   (Table	   S1).	  203	  
	  8	  
Unexpectedly,	  no	  other	  examples	  of	  parallel	  genomic	  evolution	  were	  found	  which	  suggests	  that	  the	  three	  204	  
sub-­‐lineages	  exist	  in	  separate	  niches	  each	  with	  different	  selective	  conditions	  by	  which	  evolution	  is	  directed.	  205	  
Importantly,	   this	   conclusion	   is	   in	   agreement	   with	   the	   observed	   lineage-­‐specific	   distribution	   of	  206	  
pathoadaptive	  mutations	  (Figure	  2C).	  207	  
	  208	  
Mapping	   co-­‐existing	   sub-­‐population	   to	   different	   spatial	   sites.	   Patient	   P30M0	   went	   through	   paranasal	  209	  
sinus	   surgery	   in	   2012	   during	   which	   expectorated	   sputum,	   bronchoalveolar	   lavage	   (BAL)	   and	   all	   sinus	  210	  
material	  (from	  both	  left	  and	  right	  sinuses)	  was	  sampled	  and	  stored.	  This	  provided	  a	  unique	  opportunity	  to	  211	  
determine	   the	   distribution	   of	   the	   three	   sub-­‐lineages	   at	   different	   sites	   in	   the	   infected	   CF	   airways	   (sinus	  212	  
versus	   lower	   airways).	   Sub-­‐lineage-­‐specific	   primers	  were	  designed	  on	   the	  basis	   of	   the	   genome	   sequence	  213	  
data,	   and	   a	   cross-­‐sectional	   analysis	   of	   multiple	   bacterial	   isolates	   from	   each	   sample	   was	   done	   by	   PCR	  214	  
screening	  (Materials	  and	  Methods).	   	  We	  found	  that	  all	  analysed	  isolates	  from	  the	  sinus	  samples	  belonged	  215	  
to	  cluster	  A	  (64	  isolates	  in	  total),	  while	  all	  isolates	  from	  the	  BAL	  sample	  belonged	  to	  cluster	  C	  (64	  isolates	  in	  216	  
total).	   Both	   clusters	   could	   be	   detected	   in	   the	   sputum	   sample	   as	   well	   as	   in	   additional	   sputum	   samples	  217	  
available	  from	  2010,	  2011	  and	  2012.	  However,	   in	  these	  samples	  cluster	  A	  isolates	  were	  found	  only	  in	  low	  218	  
numbers	  and	  constituted	   less	   than	  2%	  of	   the	   total	  population.	  Bacterial	   isolates	   from	  cluster	  B	  were	  not	  219	  
found	   in	   the	   samples	   related	   to	   the	   upper	   airways	   (sinus	   surgery),	   and	   were	   infrequently	   detected	   in	  220	  
sputum	  samples	  from	  2010	  to	  2013,	  where	  they	  were	  present	  at	  low	  numbers	  (less	  than	  1%).	  Nevertheless,	  221	  
cluster	  B	  isolates	  had	  previously	  been	  consistently	  detected	  in	  sputum	  samples	  from	  the	  patient.	  Genome	  222	  
sequencing	   of	   one	   isolate	   from	   the	  BAL	   sample	   and	   two	   isolates	   sampled	   from	  each	   side	   of	   the	   sinuses	  223	  
verified	  that	  they	  belonged	  to	  cluster	  C	  (BAL	  isolate	  DK1-­‐P30M0-­‐2012a)	  and	  cluster	  A	  (sinus	  isolates	  DK1-­‐224	  
P30M0-­‐2012b	  and	  DK1-­‐P30M0-­‐2012c).	  Together,	   these	  findings	  confirmed	  that	  the	  three	  co-­‐existing	  sub-­‐225	  
populations	  evolved	   in	   spatially	   separated	  niches	  of	   the	  CF	  airway:	   isolates	   from	  cluster	  A	   colonizing	   the	  226	  
sinuses	  of	  this	  patient,	  and	  isolates	  from	  cluster	  B	  and	  C	  colonizing	  and	  evolving	  in	  the	  lower	  airways.	  	  	  227	  
	  228	  
Discussion.	  	  229	  
Although	  P.	  aeruginosa	  population	  heterogeneity	   in	   relation	  to	  chronic	  CF	   infections	  has	   frequently	  been	  230	  
documented	   by	   microbial	   culturing,	   our	   understanding	   of	   the	   temporal	   and	   spatial	   dynamics	   of	   this	  231	  
diversity	   is	   limited.	   In	   this	   study	   we	   combined	   current	   genome	   sequencing	   technologies,	   phenotypic	  232	  
profiling	  and	  unique	  sampling	  materials	  which	   included	  clonal	  bacterial	   isolates	  sampled	  during	  a	  32-­‐year	  233	  
period	  from	  both	  sputum	  and	  from	  material	  obtained	  from	  paranasal	  sinus	  surgery	  in	  a	  chronically	  infected	  234	  
CF	  patient	  to	  gain	  new	  insight	  into	  the	  bacterial	  diversification	  processes	  in	  chronic	  CF	  infections.	  	  235	  
The	   phylogenomic	   analysis	   demonstrated	   that	   the	   initial	   infecting	   DK1	   strain	   diversified	   into	   three	   sub-­‐236	  
	  9	  
populations	   (clusters	   A,	   B	   and	   C)	   each	   with	   their	   individual	   genetic	   signature	   of	   mutations	   and	   limited	  237	  
parallel	   genomic	   evolution.	  Our	   phenotype	   profiling	   of	   strains	   from	   the	   different	   clusters	   supported	   this	  238	  
result	  and	  showed	  that	  the	  accumulation	  of	  mutations	  shaped	  their	  phenotype	  in	  such	  ways	  that	  the	  three	  239	  
clusters	  were	  clearly	  distinguishable	  with	  respect	  to	  mucoidy,	  doubling	  time,	  metabolic	  performance,	  and	  240	  
global	  gene	  expression	  profiles.	  Although	  diversity	  has	  often	  been	  observed	   in	  P.	  aeruginosa	  populations	  241	  
from	  the	  same	  CF	  respiratory	  specimen,	  we	  show	  here	  that	  such	  diversity	  can	  have	   long-­‐term	  stability	  as	  242	  
demonstrated	  by	  the	  decade	  long	  co-­‐existence	  of	  the	  three	  different	  sub-­‐lineages.	  	  243	  
From	   an	   ecological	   perspective,	   these	   findings	   indicate	   population	   diversification	   as	   a	   result	   of	   adaptive	  244	  
radiation	   processes	   and	   niche	   partitioning.	   Evolutionary	   theory	   and	   experimental	   evolution	   studies	   –	   in	  245	  
which	   microbial	   populations	   evolve	   under	   defined,	   artificial	   conditions	   in	   the	   laboratory	   -­‐	   have	   clearly	  246	  
established	   a	   connection	   between	   heterogeneous	   environments	   (i.e.	   introduction	   of	   distinct	   and	   vacant	  247	  
niches,	  each	  with	  different	  selective	  conditions)	  and	  the	  evolution	  and	  maintenance	  of	  population	  diversity	  248	  
(27-­‐29).	  Indeed,	  this	  explanation	  has	  been	  used	  to	  rationalize	  the	  observed	  population	  diversity	  in	  relation	  249	  
to	  chronic	  CF	  infections,	  but	  since	  most	  studies	  on	  P.	  aeruginosa	  population	  diversity	  rely	  on	  inspection	  of	  250	  
isolates	  from	  sputum	  or	  BAL	  samples	  which	  lack	  spatial	  resolution,	  conclusions	  about	  niche	  partitioning	  has	  251	  
been	   difficult.	   In	   this	   study	   we	   obtained	   parallel	   samples	   from	   different	   compartments	   in	   the	   infected	  252	  
individual,	  including	  material	  sampled	  from	  the	  paranasal	  sinuses,	  which	  enabled	  us	  to	  demonstrate	  a	  clear	  253	  
spatial	   distribution	   of	   the	   sub-­‐lineages	   in	   different	   niches.	  We	   found	   cluster	   A	   to	   inhabit	   the	   paranasal	  254	  
sinuses,	   whereas	   we	   identified	   cluster	   B	   and	   C	   in	   samples	   from	   the	   lung	   environment	   (i.e.	   in	   sputum	  255	  
samples	  and	  in	  BAL	  samples).	  Because	  of	  the	  striking	  absence	  of	  parallel	  genomic	  evolution	  between	  cluster	  256	  
B	  and	  C,	  which	  clearly	  indicate	  that	  they	  populate	  niches	  with	  different	  selective	  pressures,	  we	  suggest	  that	  257	  
clusters	  B	  and	  C	  occupy	  distinct	  niches	  in	  the	  lungs	  of	  the	  patient.	  A	  distribution	  of	  the	  three	  sub-­‐lineages	  in	  258	  
different	   niches	  would	   result	   in	   lineage-­‐specific	   sets	   of	   genes	   being	   under	   positive	   selection,	   which	  was	  259	  
indeed	  observed	  (Figure	  2C).	  Importantly,	  recent	  documentations	  of	  spatial	  distributions	  of	  microorganisms	  260	  
in	   CF	   lungs	   further	   support	   this	   model.	   For	   example,	   spatial	   heterogeneity	   of	   microbial	   communities	   in	  261	  
infected	   CF	   lungs	   has	   been	   demonstrated	   recently	   by	   culture-­‐independent	   analysis	   of	   CF	   lung	   tissue	  262	  
samples	  (30),	  and	  microscopy	  analysis	  of	  explanted	  CF	  lungs	  has	  furthermore	  shown	  that	  mucoid	  and	  non-­‐263	  
mucoid	  variants	  of	  P.	  aeruginosa	  are	  located	  in	  different	  niches	  such	  as	  the	  sputum	  in	  the	  conductive	  zone	  264	  
of	  the	  bronchi	  and	  the	  respiratory	  zones	  of	  the	  alveoli	  and	  respiratory	  bronchioles	  in	  the	  infected	  CF	  lung,	  265	  
respectively	  (31).	  Interestingly,	  cluster	  B	  and	  C	  are	  different	  with	  respect	  to	  the	  mucoid	  phenotype	  (isolates	  266	  
from	  cluster	  C	  are	  mucoid	  as	   a	   consequence	  of	  mutations	   in	  mucA,	   and	   isolates	   from	  cluster	  B	  are	  non-­‐267	  
mucoid	  as	  a	  consequence	  of	  mutations	  in	  both	  mucA	  and	  algT),	  and	  it	  is	  possible	  that	  a	  related	  distribution	  268	  
is	  present	  in	  the	  patient	  studied	  here.	  The	  observation	  that	  the	  faster	  growing	  cluster	  B	  isolates	  consistently	  269	  
	  10	  
constituted	  only	  a	  small	   fraction	  of	   the	  population	  sampled	  recently	   from	  the	   lung	  environment	  and	  was	  270	  
even	  absent	  from	  the	  population	   in	  some	  cases,	  could	  be	  related	  to	  difficulties	   in	  sampling	  the	  particular	  271	  
lung	  niche	  occupied	  by	  cluster	  B.	  This	  is	  in	  accordance	  with	  observations	  from	  CF	  autopsies	  and	  explanted	  272	  
lungs,	  which	   showed	   that	   the	  non-­‐mucoid	  phenotype	  was	  actually	  phagocytosed	  by	  PMNs	   in	   contrast	   to	  273	  
the	   biofilm-­‐growing	  mucoid	   phenotype	   (34).	   Alternatively,	   or	   complementary,	   it	   is	   possible	   that	   isolates	  274	  
from	   cluster	   C	   are	   better	   adapted	   than	   cluster	   B	   to	   the	   stressful	   and	   selective	   conditions	   in	   the	   lung	  275	  
environment.	  Indeed,	  cluster	  C	  isolates	  exhibited	  a	  larger	  panel	  of	  phenotypes	  often	  found	  in	  isolates	  from	  276	  
chronic	  infections,	  and	  had	  a	  larger	  number	  of	  pathoadaptive	  mutations	  than	  cluster	  B.	  The	  prevalence	  of	  277	  
pathoadaptive	  mutations	  has	  previously	  been	  shown	  to	  be	  an	   indicator	  of	  ecological	  success	   (4),	  and	  the	  278	  
observation	   that	   cluster	   C	   had	  more	   pathoadaptive	  mutations	   in	   total	   than	   cluster	   B,	   provide	   a	   possible	  279	  
explanation	  to	  the	  differences	  in	  their	  population	  sizes	  in	  lung	  samples.	  	  280	  
Our	  phylogenomic	  analysis	  furthermore	  showed	  that	  cluster	  B	  diverged	  from	  the	  population	  soon	  after	  or	  281	  
coinciding	   with	   initial	   colonization,	   and	   that	   the	   DK1	   population	   further	   diverged	   ten	   years	   later.	   By	  282	  
combining	   this	   phylogeny	   with	   the	   spatial	   location	   of	   each	   of	   the	   three	   clusters	   it	   is	   now	   possible	   to	  283	  
reconstruct	  the	  evolutionary	  history	  of	  DK1	  in	  the	  patient	  studied	  here.	  We	  propose	  that	  the	  patient	  was	  284	  
first	   colonized	   in	   the	  paranasal	   sinuses	  with	   isolates	  belonging	   to	  cluster	  A.	  Following	   initial	   colonization,	  285	  
isolates	  from	  the	  infected	  sinuses	  migrated	  to	  the	  lungs	  in	  two	  distinct	  events	  (separated	  by	  a	  decade)	  and	  286	  
evolved	   into	   highly	   successful	   colonizers	   of	   the	   lungs	   (i.e.	   cluster	   B	   and	   C).	   Based	   on	   observations	   of	  287	  
extensive	  overlap	  in	  colony	  morphotypes	  between	  clonal	  isolates	  sampled	  from	  the	  paranasal	  sinuses	  and	  288	  
BAL	   samples,	  we	  have	  previously	  demonstrated	  migration	   from	   the	   sinuses	   to	   the	   lung	  environment	   (9).	  289	  
The	  genomic	  data	  presented	  here	  provide	  further	  evidence	  for	  this	  hypothesis,	  and	  highlight	  the	  dynamic	  290	  
nature	   of	   the	   infecting	   population	   as	   well	   as	   the	   significance	   of	   the	   paranasal	   sinuses	   as	   functional	  291	  
pathogen	  reservoirs.	  	  292	  
Interestingly,	  the	  amount	  of	  evolutionary	  changes	  was	  different	  in	  the	  three	  clusters.	  Isolates	  from	  cluster	  B	  293	  
and	   C	   accumulated	  more	   pathoadaptive	  mutations	   and	   demonstrated	  more	   phenotypic	   alterations	   as	   a	  294	  
function	   of	   time	   than	   the	   sinus-­‐associated	   population	   in	   cluster	   A.	   We	   speculate	   that	   the	   observed	  295	  
differences	   are	   related	   to	  mutation	   pathways	   activated	   by	   stress	   responses	   (i.e.	   induced	  when	   cells	   are	  296	  
maladapted	   to	   their	   environment)	   (32,	   33),	   differences	   in	   in	   vivo	   growth	   rates,	   or	   due	   to	   oxygen	   radical	  297	  
damage	  as	  a	  result	  of	  the	  inflammatory	  response	  which	  differs	  in	  different	  niches	  of	  the	  respiratory	  tract.	  298	  
Although	   the	   sinus	   and	   lung	  environments	   share	   some	  physiological	   properties	   such	  as	   thick	  mucus	   that	  299	  
can	   function	   as	   sites	   for	   bacterial	   growth,	   there	   are	   also	   significant	   differences	   that	   may	   explain	   the	  300	  
different	   evolutionary	   trajectories	   associated	   with	   each	   compartment.	   For	   example,	   the	   inflammatory	  301	  
response	   is	   reduced	   in	   the	   paranasal	   sinuses	   and	   polymorphonuclear	   leukocytes,	  which	   produce	   oxygen	  302	  
	  11	  
radicals	  (34)	  dominates	  in	  the	  lungs	  and	  sputum	  whereas	  they	  are	  rare	  in	  the	  paranasal	  sinuses	  where	  the	  303	  
inflammation	   is	   less	   pronounced	   due	   to	   high	   production	   of	   Immunoglobulin	   A	   (35).	   Further,	   antibiotic	  304	  
penetration	   and	   hence	   the	   achievement	   of	   therapeutic	   levels	   is	   hypothesized	   to	   be	   less	   efficient	   in	   the	  305	  
sinuses	  than	  in	  the	  lungs	  (35,	  36).	  	  306	  
We	   have	   previously	   shown	   a	   much	   more	   pronounced	   evolutionary	   response	   in	   sinus-­‐associated	   P.	  307	  
aeruginosa	   populations	   in	   intermittently	   colonized	  patients	   than	  what	  we	   show	  here	   for	   cluster	  A	   (9).	   In	  308	  
addition,	   studies	   have	   shown	   extensive	   overlaps	   in	   evolved	   phenotypes	   such	   as	   colony	  morphology	   and	  309	  
global	   gene	  expression	  profiles	  between	   isolates	   from	  sinus	  and	   lung	   samples	   from	   the	   same	  chronically	  310	  
infected	  patients	  (9,	  36),	  which	  was	  clearly	  not	  observed	  here.	  These	  observational	  differences	  suggest	  that	  311	  
generalizing	   conclusions	   concerning	   evolution	   of	   P.	   aeruginosa	   in	   the	   paranasal	   sinuses	   should	   be	  312	  
considered	   with	   caution,	   and	   that	   our	   understanding	   of	   the	   factors	   that	   influence	   the	   evolutionary	  313	  
trajectories	  of	  sinus-­‐associated	  P.	  aeruginosa	  populations	  is	  incomplete.	  	  314	  
Our	  results	  show	  that	  the	  environmental	  heterogeneity	  of	  the	  CF	  airways	  contribute	  to	  the	  generation	  and	  315	  
stability	  of	   intraclonal	  diversity,	   and	   it	   is	  possible	   that	   similar	  processes	  underlie	   the	  population	  diversity	  316	  
observed	  in	  other	  CF-­‐associated	  pathogens	  (13).	  More	  broadly,	  our	  study	  demonstrates	  that	  P.	  aeruginosa	  317	  
isolated	   from	   chronic	   CF	   patients	   are	   representatives	   of	   an	   underlying	   complex	   and	   dynamic	   population	  318	  
structure	  comprised	  of	  distinct	  clonal	  variants	  that	  are	  distributed	   in	  different	  niches.	  Our	  results	  suggest	  319	  
that	  assuming	  that	  one	  isolate	  in	  sputum	  and	  BAL	  samples	  is	  representative	  of	  the	  entire	  population	  may	  320	  
lead	  to	  an	  inaccurate	  description	  of	  therapy-­‐relevant	  phenotypes	  such	  as	  antibiotic	  resistance	  profiles,	  and	  321	  
that	   treatment	   strategies	   targeting	   the	  dominant	   population	  need	  not	   be	   effective	   in	   other	   areas	   of	   the	  322	  
airways,	  or	  against	  other	  sub-­‐populations.	  A	  more	  complete	  understanding	  of	  the	  spatial	  heterogeneity	  and	  323	  
population	  diversity	  could	  therefore	  have	  positive	  implications	  for	  efficient	  therapy	  and	  disease	  outcome.	  	  324	  
	  325	  
Materials	  and	  methods	  326	  
	  327	  
Ethics	   Statement.	   No	   patient	   samples	   were	   taken	   specifically	   for	   this	   study.	  	  Isolation	   and	   storage	   of	  328	  
bacterial	   isolates	   was	   part	   of	   the	   established	   routine	   at	   the	   Department	   of	   Clinical	   Microbiology,	  329	  
Rigshospitalet.	   The	   bacterial	   isolates	   used	   in	   the	   study	   included	   isolates	   from	   the	   bacterial	   collection	  330	  
available	   at	   the	   Department	   of	   Clinical	   Microbiology,	   Rigshospitalet	   as	   well	   as	   bacteria	   isolated	   during	  331	  
Functional	   Endoscopic	   Sinus	   Surgery	   (FESS)	   on	   patient	   P30M0	   in	   2012.	   The	   use	   of	   bacterial	   isolates	  was	  332	  
approved	  by	  the	  local	  ethics	  committee,	  Region	  Hovedstaden.	  All	  samples	  were	  anonymized.	  333	  
Bacterial	  strains.	  The	  investigated	  strains	  of	  the	  P.	  aeruginosa	  DK1	  clone	  type	  consisted	  of	  18	  longitudinal	  334	  
isolates	  from	  patient	  P30M0	  and	  four	  historical	  isolates	  from	  1973	  from	  patient	  P33F0,	  P50F0,	  P13F1,	  and	  335	  
	  12	  
P43M1.	  Patient	  P30M0	  was	  chosen	  based	  on	  the	  long	  clonal	  infection	  history	  with	  DK1	  and	  the	  availability	  336	  
of	   stored	   isolates	   and	   new	   lung	   expectorates.	   Additional	   clinical	   strains	   from	  P30M0	  were	   isolated	   from	  337	  
either	  sinus	  or	  bronchoalveolar	   lavage	  (BAL)	  samples	   from	  2012.	  The	  samples	   from	  the	  paranasal	  sinuses	  338	  
were	   taken	  during	  Functional	  Endoscopic	   Sinus	  Surgery	   (FESS)	  as	  previously	  described	   (37).	   Isolation	  and	  339	  
identification	   of	  P.	   aeruginosa	  was	   done	   as	   previously	   described	   (38).	   The	   isolates	  were	   grown	   in	   Luria-­‐340	  
Bertani	  (LB)	  medium	  and	  stored	  at	  -­‐80°C	  with	  10%	  glycerol.	  The	  P.	  aeruginosa	   isolates	  investigated	  in	  this	  341	  
study	  were	  confirmed	  to	  belong	  to	  the	  DK1	  lineage	  by	  two	  independent	  genotyping	  methods:	  pulsed-­‐field	  342	  
gel	   electrophoresis	   and	   SNP	   genotyping	   using	   AT	   biochips	   (Clondiag	   Chip	   Technologies,	   Germany)	   as	  343	  
described	  previously	  (39).	  	  344	  
Genome	  sequencing.	  Genomic	  DNA	  was	  prepared	  from	  P.	  aeruginosa	  isolates	  using	  Wizard	  Genomic	  DNA	  345	  
Purification	  Kit	  (Promega).	  Genomes	  were	  sequenced	  to	  an	  coverage	  depth	  of	  90	  fold	  (range	  17	  to	  207	  fold)	  346	  
on	   either	   an	   Illumina	   GAIIx	   platform	   generating	   75-­‐bp	   single-­‐end	   reads	   (6	   isolates),	   or	   on	   a	   HiSeq2000	  347	  
platform	  generating	  either	  75-­‐nt	  single-­‐end	  reads	  (7	   isolates)	  or	  100-­‐nt	  paired-­‐end	  reads	  (9	   isolates).	  The	  348	  
genome	  of	  DK1-­‐P33F0	  was	  de	  novo	   assembled	   into	  6,156,016	  bp	   (252	   contigs,	  N50=49,984	  bp)	  with	   the	  349	  
assistance	   of	   P.	   aeruginosa	   genome	   sequences	   of	   PAO1,	   PA14,	   and	   LESB58,	   respectively,	   using	   the	  350	  
Columbus	  module	  of	  Velvet	  version	  1.0.16	   (40).	  The	  genome	  assembly	  of	  DK1-­‐P33F0	  was	   then	  used	  as	  a	  351	  
reference	   for	   alignment	  of	   sequence	   reads	   from	  each	  of	   the	   isolates	   to	   identify	   high-­‐quality	   SNPs	   in	   the	  352	  
non-­‐repetitive	  parts	  of	  the	  genome.	  353	  
Mutation	   detection,	   analysis	   and	   construction	   of	   the	   phylogenetic	   tree	   were	   performed	   as	   previously	  354	  
described	  (4).	  Calculation	  of	  the	  dN/dS	  ratio	  was	  based	  on	  the	  assumption	  that	  a	  random	  mutation	  in	  the	  355	  
total	   number	   of	   possible	   SNP	   mutation	   would	   cause	   a	   synonymous	   change	   25%	   of	   the	   time	   (41,	   42).	  356	  
Bayesian	   analysis	   of	   evolutionary	   rates	  was	  performed	  using	  BEAST	   v1.7.2	   (43)	  with	   a	   lognormal	   relaxed	  357	  
molecular	   clock	  model	   and	  a	  general	   time-­‐reversible	  	  substitution	  model.	  Mutation	   rates	  were	   calculated	  358	  
from	  a	  chain	  length	  of	  50	  million	  steps,	  sampled	  every	  5,000	  steps.	  The	  first	  5	  million	  steps	  were	  discarded	  359	  
as	  a	  burn-­‐in.	  A	  maximum	  clade	  credibility	  tree	  was	  generated	  using	  the	  TreeAnnotator	  program	  from	  the	  360	  
BEAST	  package),	  and	  the	  effective	  sample-­‐sizes	  (ESS)	  of	  all	  parameters	  were	  >1,000	  as	  calculated	  by	  Tracer	  361	  
v1.5	   (available	   from	  http://beast.bio.ed.ac.uk/Tracer),	   which	   was	   also	   used	   to	   calculate	   95%	   HPD	  362	  
confidence	  intervals	  of	  the	  divergence	  times	  (i.e.	  an	  interval	  in	  which	  the	  modeled	  parameter	  resides	  with	  363	  
95%	  probability).	  364	  
Biolog	   Phenotype	   MicroArrayTM.	   Phenotype	   MicroArray	   (Biolog,	   Hayward,	   CA)	   experiments	   were	  365	  
performed	  in	  duplicate	  according	  to	  manufacturer	  instructions	  (44,	  45).	  Bacterial	  strains	  were	  streaked	  on	  366	  
LB	  agar	  plates	  and	  incubated	  at	  37°C	  until	  colonies	  appeared	  on	  plates	  (23-­‐48	  h).	  Cells	  were	  swabbed	  from	  367	  
	  13	  
the	   plates	   and	   suspended	   in	   IF-­‐0	   GN	   Base	   (inoculation	   fluid)	   at	   a	   density	   corresponding	   to	   42%	  368	  
transmittance	   in	   the	   Biolog	   turbidimeter.	   The	   cell	   suspensions	  were	   diluted	   1:6	   in	   IF-­‐0	  minimal	  medium	  369	  
containing	   Biolog	   redox	   dye	  mixture	   D	   (tetrazolium),	   and	   100	   µL	   aliquots	  were	   added	   to	   carbon	   source	  370	  
plates	   (PM1).	  Nitrogen	   plates	   (PM3)	  were	   prepared	  with	   ferric	   citrate	   and	   glucose	   supplemented	   to	   the	  371	  
inoculation	  mixture.	  In	  total	  190	  substrates	  were	  available	  on	  the	  two	  plates.	  Of	  these,	  125	  were	  found	  to	  372	  
be	   informative	   by	   showing	   consistent	   growth	   between	   replicates.	  OmniLog	  OL_FM/Kin	  1.20.02	   software	  373	  
(Biolog)	  was	  used	  to	  export	  the	  OmniLog	  data	  and	  the	  average	  area	  beneath	  each	  kinetic	  curve	  was	  used	  374	  
for	  analysis.	  Total	  catabolic	  function	  was	  calculated	  as	  previously	  described(46).	  Further	  data	  and	  statistical	  375	  
analysis	  was	  performed	  using	  R	  version	  2.10.1	  (R	  Development	  Core	  Team	  2009).	  376	  
Affymetrix	  GeneChip.	   Strains	  were	   grown	  aerobically	   at	   37°C	   in	   LB	  medium	  starting	   at	  OD600	   =	  0.01	  and	  377	  
harvested	  at	  OD600	  =	  0.5.	   Immediately	  after	  harvesting,	  cells	  were	  mixed	  with	  either	  RNAprotect	  Bacteria	  378	  
Reagent	  (Qiagen)	  if	  non-­‐mucoid	  cells,	  or	  mixed	  with	  STOP	  solution	  (95%	  ethanol,	  5%	  phenol)	   if	  cells	  were	  379	  
mucoid	   to	   avoid	   clumping.	   After	   10	   minutes	   of	   centrifugation	   at	   7000	   g	   at	   4°C	   the	   supernatant	   was	  380	  
discarded	   and	   cell	   pellet	   was	   stored	   at	   -­‐80°C.	   RNA	   extraction,	   cDNA	   preparation	   and	   labelling,	   and	  381	  
hybridization	   were	   performed	   as	   previously	   described	   (42).	   The	   raw	   CEL	   files	   were	   obtained	   by	   the	  382	  
Affymetrix	  GeneChip	  Operating	  System	  1.4	  and	  the	  analysis	  was	  performed	  by	  using	  BioConductor	  tools	  in	  383	  
R	  environment	  (47).	  Strains	  were	  tested	  in	  triplicates.	  384	  
Motility	  assays.	  The	  motility	  of	  all	  isolates	  was	  tested	  on	  ABT	  agar	  supplemented	  with	  0.5%	  casamino	  acids	  385	  
and	  0.5%	  glucose	  as	  previously	  described	  (48).	  Briefly,	  ABT	  plates	  were	  inoculated	  with	  single	  colonies	  on	  386	  
the	   top,	   in	   the	  middle	   or	   on	   the	   bottom	  of	   the	   plates	   to	  measure	   swarm,	   swim,	   or	   twitch,	   respectively.	  387	  
Swim	  and	  swarm	  were	  measured	  on	  0.3%	  (wt/vol)	  agar	  and	  0.6%	  (wt/vol),	  respectively	  and	  incubated	  24	  h	  388	  
at	   30°C.	   Twitching	  motility	   was	   determined	   on	   1.5%	   (wt/vol)	   agar	   and	   incubated	   48	   hours	   at	   37°C.	   The	  389	  
motility	  zones	  were	  calculated	  in	  triplicates	  relative	  to	  the	  reference	  strain	  PAO1.	  	  390	  
Detection	  of	  quorum	  sensing	  signals.	  For	  detection	  of	  QS	  signals	  P.	  aeruginosa	  strains	  were	  cross-­‐streaked	  391	  
against	  two	  E.	  coli	  MH155	  and	  MH205	  monitor	  strains	  as	  previously	  described	  (48).	  After	  48	  h	  of	  incubation	  392	  
at	  37°C	  the	  AHL	  production	  was	  detected	  by	  inspecting	  the	  fluorescence	  of	  the	  monitor	  strains	  with	  a	  Zeiss	  393	  
Axioplan	  2	  microscope	  with	  a	  2.5/0.075×	  neofluar	  plan	  objective.	  394	  
Skim	   milk	   protease	   assay.	   The	   production	   of	   protease	   was	   determined	   by	   applying	   one	   colony	   of	   the	  395	  
isolate	  grown	  on	  LB	  agar	  to	  skim	  milk	  plates	  (LB	  agar	  with	  10%	  skim	  milk).	  The	  plates	  were	  incubated	  for	  24	  396	  
h	  at	  37°C	  and	  the	  clearing	  zones	  were	  measured.	  397	  
Determination	  of	  hypermutable	  phenotypes.	  The	  isolates	  were	  grown	  overnight	  in	  LB	  broth	  at	  37°C.	  The	  398	  
hypermutability	  of	  the	  isolates	  was	  determined	  by	  plating	  aliquots	  of	  serial	  dilutions	  of	  bacteria	  cells	  on	  LB	  399	  
plates	  with	  and	  without	  Rifampicin	  (300	  µg/mL)	  or	  Streptomycin	  (500	  µg/mL).	  The	  plates	  were	  incubated	  at	  400	  
	  14	  
37°C	  for	  24	  or	  48	  hours	  and	  the	  number	  of	  colonies	  was	  counted.	  An	  isolate	  was	  considered	  hypermutable	  401	  
if	   it	   had	   20	   times	   higher	   mutation	   frequency	   after	   exposure	   to	   rifampicin	   and	   streptomycin	   than	   the	  402	  
reference	  strain.	  403	  
Growth	  rate	  measurement	  and	  estimation	  of	   in	  situ	  bacterial	  generations.	  LB	  broth	  was	  inoculated	  with	  404	  
the	  isolate	  and	  incubated	  at	  37°C	  overnight.	  A	  cell	  culture	  volume	  was	  transferred	  into	  50	  mL	  LB	  in	  a	  250	  405	  
mL	  shaking	  flask	  with	  baffles	  generating	  an	  OD600nm	  of	  0.01.	  The	  flask	  was	  incubated	  at	  37°C	  with	  shaking	  at	  406	  
240	  rpm	  in	  a	  New	  Brunswick	  Scientific	  incubator.	  Growth	  rates	  were	  measured	  by	  monitoring	  the	  OD600nm	  407	  
during	  growth.	  The	  measurements	  were	  done	  at	  least	  in	  duplicates.	  	  408	  
Growth	  rates	  were	  calculated	   from	  the	  exponential	  part	  of	   the	  growth	  curves	  and	  expressed	  as	  doubling	  409	  
times	  in	  minutes	  (ln(2)/minutes).	  410	  
PCR	  screening.	  A	  multiplex	  PCR	  strategy	  was	  constructed	  for	  determination	  of	  different	  sub-­‐lineages	  of	  P.	  411	  
aeruginosa	  from	  patient	  P30M0.	  Sub-­‐lineage-­‐specific	  primers	  were	  designed	  including	  an	  internal	  positive	  412	  
control	   for	   all	   lineages	   (Table	   S3).	   PCR	   amplifications	   were	   performed	   with	   the	   following	   optimized	  413	  
parameters:	  pre-­‐denaturation	  for	  5	  min	  at	  95°C;	  25	  cycles	  of	  95°C	  for	  30	  s,	  66°C	  for	  30	  s,	  and	  72°C	  for	  25	  s;	  414	  
post-­‐extension	   for	  3	  min	  at	  72°C;	  and	  soaking	  at	  4°C.	  PCR	  products	  were	   resolved	   in	  a	  2%	  agarose	  gel	   in	  415	  
1XTBE	  buffer	  at	  100	  V	  and	  visualized	  with	  ethidium	  bromide.	   In	   total	  3*64	   isolates	  were	  tested	   from	  the	  416	  
sinus,	  BAL,	  and	  sputum	  sample	  from	  2012.	  Furthermore,	  isolates	  sampled	  from	  sputum	  samples	  from	  2010,	  417	  
2011,	  and	  2012	  were	  tested.	  	  418	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Figure	   1.	   Patient	   origin	   and	   sampling	   time	   of	   genome	   sequenced	   P.	   aeruginosa	   DK1	   isolates.	   DK1	   P.	  543	  
aeruginosa	  isolates	  were	  sampled	  from	  five	  different	  CF	  patients	  between	  1973	  and	  2012.	  Bacterial	  isolates	  544	  
from	   different	   patients	   are	   specified	   by	   symbols.	   Stacked	   symbols	   indicate	   that	   multiple	   isolates	   were	  545	  
sampled	   the	   same	  year	   from	   the	   same	  patients.	   The	   isolates	   are	  named	  by	   their	   clone	   type,	   and	  by	   the	  546	  
patient	  from	  whom	  they	  were	  isolated	  and	  their	  isolation	  year	  (e.g.	  DK1-­‐P30M0-­‐1980).	  	  547	  
	   	  548	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  549	  
Figure	   2.	   Evolutionary	   trajectory	   of	   the	   DK1	   lineage.	   A)	   Maximum-­‐parsimonious	   reconstruction	   of	   the	  550	  
phylogeny	  of	  DK1	  clones	   isolated	   from	  CF	  patients	  P30M0,	  P33F0,	  P50F0,	  P13F1,	  and	  P43M1.	  The	  tree	   is	  551	  
based	   on	   160	   SNPs	   (identified	   from	   genome	   sequencing)	   which	   accumulated	   in	   a	   highly	   parsimonious	  552	  
fashion	  (parsimonious	  consistency	  of	  0.99).	  Capital	  letters	  indicate	  branch	  names,	  and	  lengths	  of	  branches	  553	  
are	  proportional	  to	  the	  number	  of	  SNPs.	  The	  specific	  mutations	  that	  have	  accumulated	  during	  each	  specific	  554	  
branch	  are	   listed	   in	  Table	  S1.	  The	   three	  phylogenetic	  clusters	   in	  P30M0	  are	   labelled	  A,	  B,	  and	  C.	  Median	  555	  
estimates	  of	  divergence	  dates	  (in	  calendar	  years)	  are	  given	   in	  red	  for	  the	  major	  nodes.	  B)	  Mutation	  rates	  556	  
(SNPs	   per	   year)	   for	   each	   of	   the	   three	   clusters	   and	   for	   all	   DK1	   isolates.	   C)	   Prevalence	   of	   pathoadaptive	  557	  
mutations	   in	   the	  three	  DK1	  sub-­‐lineages.	  The	  genes	  hit	  by	  nonsynonymous	  SNPs	  are	   indicated	  with	   filled	  558	  
circles	  for	  each	  of	  the	  three	  DK1	  sub-­‐lineages	  in	  P30M0.	  	  559	  
	   	  560	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Figure	  3.	  Phenotypic	  characterization	  of	  DK1	  isolates.	  A)	  anm,	  non-­‐mucoid;	  m,	  mucoid.	  bMotility	  relative	  to	  562	  
PAO1.	  cProduction	  of	  AHLs	  detected	  by	   inspection	  of	  bioluminescence	  of	  monitor	  strain;	  ++,	  high	  level;	  +,	  563	  
low	  level;	  -­‐,	  not	  detectable.	  dDetection	  of	  proteases	  on	  skim	  milk	  plates;	  +++,	  high	  level;	  +,	  low	  level;	  -­‐,	  not	  564	  
detectable.	   B)	   Doubling	   time	   of	   historical	   isolates	   and	   P30M0	   isolates	   measured	   in	   LB	   medium.	   C)	  565	  
Dendrogram	   showing	   the	   hierarchical	   cluster	   analysis	   (Wards	   linkage,	   Euclidean	   Distance)	   of	   global	  566	  
catabolic	  function.	  Colours	  represent	  each	  cluster;	  cluster	  A,	  blue;	  cluster	  B,	  green;	  and	  cluster	  C,	  purple.	  567	  
	   	  568	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Figure	  4.	  Transcriptome	  analysis.	  A)	  Comparison	  of	  gene	  expression	  of	  the	  two	  mucoid	  isolates	  DK1-­‐570	  
P30M0-­‐2001b	  and	  DK1-­‐P30M0-­‐2007b	  from	  cluster	  A.	  B)	  Comparisons	  of	  the	  two	  non-­‐mucoid	  isolates	  DK1-­‐571	  
P30M0-­‐2001a	  and	  DK1-­‐P30M0-­‐2009a	  from	  cluster	  B.	  C)	  Comparison	  of	  gene	  expression	  of	  the	  two	  mucoid	  572	  
isolates	  DK1-­‐P30M0-­‐2006	  and	  DK1-­‐P30M0-­‐2011	  from	  cluster	  C.	  The	  red	  dots	  represent	  genes	  with	  573	  
significantly	  increased	  expression	  (fold	  change	  ≥	  2,	  P	  ≤	  0.05),	  and	  green	  dots	  indicate	  genes	  with	  decreased	  574	  
expression.	  The	  r	  (Pearson	  correlation)	  values	  indicate	  the	  strength	  and	  direction	  of	  linear	  relationship	  575	  
between	  the	  expression	  levels	  of	  the	  isolates.	  D)	  Single	  value	  decomposition	  showing	  the	  gene	  expression	  576	  
relationships	  among	  isolates	  from	  cluster	  A,	  B	  and	  C.	  Each	  circle	  represents	  the	  mean	  of	  duplicates.	  Blue	  577	  
circles	  represent	  isolates	  from	  cluster	  A,	  green	  circles	  represent	  isolates	  from	  cluster	  B,	  and	  isolates	  from	  578	  
cluster	  C	  are	  shown	  as	  purple	  circles.	  	  579	  
	  580	  
Table	  S1:	  SNP	  changes	  observed	  in	  the	  P30M0	  lineage.	  
Branch Position Type	  of	  mutation Product PseudoCAP	  Function	  Class
Independt	  mutations	  
observed	  within	  the	  gene	  
listA T163P Missense PA0652 vfr transcriptional	  regulator	  Vfr Transcriptional	  regulators 1
listA L7L Silent PA4695 ilvH 1
listA R12L Missense PA1430 lasR transcriptional	  regulator	  LasR 1
listA G476S Missense PA0928 gacS sensor/response	  regulator	  hybrid Two-­‐component	  regulatory	  systems 1
listA A19P Missense PA2020 probable	  transcriptional	  regulator Transcriptional	  regulators 1
listB G505A Missense PA3545 algG alginate-­‐c5-­‐mannuronan-­‐epimerase	  AlgG 2
listB G10G Silent PA4755 greA transcription	  elongation	  factor	  GreA Transcription,	  RNA	  processing	  and	  degradation 1
listC P515P Silent PA14_03220 Hypothetical	  protein Hypothetical,	  unclassified,	  unknown 2
listC S480S Silent PA0262 conserved	  hypothetical	  protein Hypothetical,	  unclassified,	  unknown 1
listC 31 Not	  annotated 0
listC A28P Missense PA3897 hypothetical	  protein Membrane	  proteins 1
listC Y59C Missense PA0762 algU sigma	  factor	  AlgU Transcriptional	  regulators 5
listC R527H Missense PA3257 prc periplasmic	  tail-­‐specific	  protease 1
listC T57T Silent PA3399 hypothetical	  protein Hypothetical,	  unclassified,	  unknown 1
listD G73G Silent PA4286 hypothetical	  protein Hypothetical,	  unclassified,	  unknown 1
listD A380A Silent PA1238 1
listD K55K Silent PA3127 hypothetical	  protein Hypothetical,	  unclassified,	  unknown 1
listD A168V Missense PA0021 conserved	  hypothetical	  protein Membrane	  proteins 1
listD L10Q Missense PA5537 hypothetical	  protein Hypothetical,	  unclassified,	  unknown 1
listD L435L Silent PA2840 probable	  ATP-­‐dependent	  RNA	  helicase Transcription,	  RNA	  processing	  and	  degradation 1
listE I65I Silent PA1192 conserved	  hypothetical	  protein Hypothetical,	  unclassified,	  unknown 1
listI L117F Missense PA2196 probable	  transcriptional	  regulator Transcriptional	  regulators 1
listI 11717 Intergenic PA1566/PA1567/ 15	  upstream	  conserved	  hypothetical	  protein/453	  downstream	  conserved	  hypothetical	  proteinHypothetical,	  u classified,	  unknown/Hypothetical,	  unclassified,	  unknown1
listI N208N Silent PA1588 sucC succinyl-­‐CoA	  synthetase	  beta	  chain Energy	  metabolism 1
listI D184N Missense PA1775 cmpX Membrane	  proteins 2
listJ D18G Missense PA0762 algU sigma	  factor	  AlgU Transcriptional	  regulators 5
listKA R504C Missense PA4418 ftsI penicillin-­‐binding	  protein	  3 Cell	  division;	  Cell	  wall	  /	  LPS	  /	  capsule 2
listKB G344G Silent PA4900 1
listKB T122T Silent PA4089 probable	  short-­‐chain	  dehydrogenase Putative	  enzymes 1
listKB 235 Silent PA1094 fliD flagellar	  capping	  protein	  FliD 1
listKB V193M Missense PA2329 Transport	  of	  small	  molecules 1
listKB V849G Missense PA3168 gyrA DNA	  gyrase	  subunit	  A 2
listKB G118S Missense PA4266 fusA1 elongation	  factor	  G 2
listKB G301R Missense PA4860 probable	  permease	  of	  ABC	  transporter 1
listKB A379V Missense PA0835 pta phosphate	  acetyltransferase Carbon	  compound	  catabolism 1
listKB H162R Missense PA4954 motA chemotaxis	  protein	  MotA Adaptation,	  Protection;	  Chemotaxis 1
listKB T213T Silent PA1818 ldcA Amino	  acid	  biosynthesis	  and	  metabolism 1
listKB E182K Missense PA1810 Transport	  of	  small	  molecules 1
listKB P230P Silent PA4811 fdnH Energy	  metabolism 1
listKB R243C Missense PA4843 probable	  two-­‐component	  response	  regulator 1
listKC A8T Missense PA3951 conserved	  hypothetical	  protein Hypothetical,	  unclassified,	  unknown 1
listKC H261L Missense PA3878 narX two-­‐component	  sensor	  NarX 1
listKC D292A Missense PA5320 coaC 2
listKC L39L Silent PA0761 nadB L-­‐aspartate	  oxidase 1
listKC L32L Silent PA1121 yfiR YfiR Cell	  wall	  /	  LPS	  /	  capsule 1
listKC Y196_ Nonsense PALES_43561oprD Transport	  of	  small	  molecules 1
listKC F190F Silent PA2069 probable	  carbamoyl	  transferase Putative	  enzymes 1
listKC P36L Missense PA2674 probable	  type	  II	  secretion	  system	  protein Protein	  secretion/export	  apparatus 1
listKD 124819 Intergenic PA2138/PA2139/ 16	  downstream	  probable	  ATP-­‐dependent	  DNA	  ligase/60	  upstream	  hypothetical	  protein/Hypothetical,	  unclassifi d,	  unknow 1
listKE P353L Missense PA3162 rpsA 30S	  ribosomal	  protein	  S1 1
listKE 8641 Intergenic PA1563/PA1564/ 38	  downstream	  conserved	  hypothetical	  protein/47	  upstream	  conserved	  hypothetical	  proteinHy o hetical,	  unclassified,	  unknown/Hypothetical,	  unclassified,	  unknown1
listKF R160R Silent PA2156 conserved	  hypothetical	  protein Hypothetical,	  unclassified,	  unknown 1
listKG 4965 Not	  annotated 0
listKG 20159 Intergenic PA0915/PA0916/ 59	  upstream	  conserved	  hypothetical	  protein/3	  downstream	  conserved	  hypothetical	  proteinHypothetical,	  unclassified,	  unknown/Hypothetical,	  unclassified,	  unknown1
listKH T84P Missense PA4310 pctB chemotactic	  transducer	  PctB Adaptation,	  Protection;	  Chemotaxis 1
listKH 7743 Intergenic PA4610/PA4611/ 45	  downstream	  hypothetical	  protein/17	  downstream	  hypothetical	  proteinHypothe ical,	  unclassif ed,	  unknown/Hypothetical,	  unclassified,	  unknown1
listKH L666L Silent PA1181 conserved	  hypothetical	  protein Membrane	  proteins 1
listKH V255V Silent PA0687 probable	  type	  II	  secretion	  system	  protein Protein	  secretion/export	  apparatus 1
listL E572K Missense PA14_03220 Hypothetical	  protein Hypothetical,	  unclassified,	  unknown 2
listL R40C Missense PA4499 probable	  transcriptional	  regulator Transcriptional	  regulators 1
listM R21P Missense PA2537 probable	  acyltransferase Fatty	  acid	  and	  phospholipid	  metabolism 1
listM G107R Missense PA1923 hypothetical	  protein 1
listM S190S Silent PA4809 fdhE FdhE	  protein Energy	  metabolism 1
listM T345P Missense PA3464 hypothetical	  protein Hypothetical,	  unclassified,	  unknown 1
listM N545K Missense PA1992 ercS ErcS Two-­‐component	  regulatory	  systems 1
listN G641G Silent PA4021 probable	  transcriptional	  regulator Transcriptional	  regulators 1
listN Y258Y Silent PA0091 vgrG1 VgrG1 Hypothetical,	  unclassified,	  unknown 1
listO A431T Missense PA5338 spoT 1
listO Y59_ Nonsense PA0762 algU sigma	  factor	  AlgU Transcriptional	  regulators 5
listO G72G Silent PA0136 Transport	  of	  small	  molecules 1
listPA P113L Missense PA2687 pfeS two-­‐component	  sensor	  PfeS Two-­‐component	  regulatory	  systems 1
listPA A3021A Silent PA2424 pvdL PvdL Adaptation,	  Protection 2
listPA S173L Missense PA0762 algU sigma	  factor	  AlgU Transcriptional	  regulators 5
listPA R40Q Missense PA3304 conserved	  hypothetical	  protein Hypothetical,	  unclassified,	  unknown 1
listPB A1060A Silent PA14_36730 putative	  trehalose	  synthase Carbon	  compound	  catabolism 1
listPB L49L Silent PA4815 hypothetical	  protein Membrane	  proteins 1
listPC L273L Silent PA2776 conserved	  hypothetical	  protein Hypothetical,	  unclassified,	  unknown 1
listPC A115A Silent PA2925 hisM histidine	  transport	  system	  permease	  HisM 1
listPD G345D Missense PA2597 hypothetical	  protein Putative	  enzymes 1
listPE G308S Missense PA0368 conserved	  hypothetical	  protein Hypothetical,	  unclassified,	  unknown 1
listPF 1786 Intergenic PA4109/PA4110ampR/ampC104	  upstream	  transcriptional	  regulator	  AmpR/45	  upstream	  beta-­‐lactamase	  precursorTranscription l	  regulators/Adaptation,	  Protection 1
listPF A55V Missense PA0607 rpe ribulose-­‐phosphate	  3-­‐epimerase Energy	  metabolism 1
listPF A775A Silent PA0903 alaS alanyl-­‐tRNA	  synthetase 1
listPF 29218 Intergenic PA2330/PA2331/ 7	  upstream	  hypothetical	  protein/43	  downstream	  hypothetical	  proteinHypothetical,	  unclassified,	  unknown/Membrane	  proteins 1
listPF I208I Silent PA5320 coaC 2
listPG A289V Missense PA2998 nqrB Energy	  metabolism 1
listPG D277N Missense PA3547 algL poly(beta-­‐d-­‐mannuronate)	  lyase	  precursor	  AlgL 1
Gene	  name
listPG V278M Missense PA4102 bfmS BfmS 1
listPG 11767 Intergenic PA1499/PA1500/ 256	  upstream	  conserved	  hypothetical	  protein/41	  downstream	  probable	  oxidoreductasePutative	  enzymes/Putative	  enzymes 1
listPG Q185_ Nonsense PA4410 ddlB D-­‐alanine-­‐-­‐D-­‐alanine	  ligase Cell	  wall	  /	  LPS	  /	  capsule 1
listPG G257R Missense PA4418 ftsI penicillin-­‐binding	  protein	  3 Cell	  division;	  Cell	  wall	  /	  LPS	  /	  capsule 2
listPG G75S Missense PA3168 gyrA DNA	  gyrase	  subunit	  A 2
listPG 17777 Intergenic PA3168/PA3169gyrA/ 228	  upstream	  DNA	  gyrase	  subunit	  A/9	  downstream	  5-­‐methylthioribose-­‐1-­‐phosphate	  isomerase	  MtnA/ 1
listPG K95N Missense PA4248 rplF 50S	  ribosomal	  protein	  L6 1
listPG D467G Missense PA4266 fusA1 elongation	  factor	  G 2
listPG G132G Silent PA5103 hypothetical	  protein Hypothetical,	  unclassified,	  unknown 1
listPG F779S Missense PA0004 gyrB DNA	  gyrase	  subunit	  B 2
listPG 85377 Not	  annotated 0
listPG H104Y Missense PA1167 hypothetical	  protein Hypothetical,	  unclassified,	  unknown 1
listPG Q402_ Nonsense PA0411 pilJ twitching	  motility	  protein	  PilJ Chemotaxis;	  Motility	  &	  Attachment 1
listPG P221P Silent PA1459 probable	  methyltransferase Chemotaxis 1
listPG N141D Missense PA1775 cmpX Membrane	  proteins 2
listPG T1282I Missense PA2424 pvdL PvdL Adaptation,	  Protection 2
listPG S59L Missense PA2426 pvdS sigma	  factor	  PvdS Transcriptional	  regulators 1
listPG S280L Missense PA3267 hypothetical	  protein Membrane	  proteins 1
listPG P71L Missense PA3385 amrZ alginate	  and	  motility	  regulator	  Z 1
listPG P358P Silent PA3339 PlpD 	  patatin-­‐like	  protein,	  PlpD	   1
listPG A28A Silent PA5039 aroK shikimate	  kinase Amino	  acid	  biosynthesis	  and	  metabolism 1
listPG P149L Missense PA5034 hemE uroporphyrinogen	  decarboxylase 1
listPG G543E Missense PA3141 wbpM nucleotide	  sugar	  epimerase/dehydratase	  WbpM 1
listPG 4892 Not	  annotated 0
listPG R61H Missense PA0337 ptsP Transport	  of	  small	  molecules 2
listPG A72T Missense PA0204 probable	  permease	  of	  ABC	  transporter 1
listPG A419A Silent PA2652 probable	  chemotaxis	  transducer Adaptation,	  Protection;	  Chemotaxis 1
listPG V135M Missense PA2620 clpA ATP-­‐binding	  protease	  component	  ClpA 1
listPG R84H Missense PA2837 probable	  outer	  membrane	  protein	  precursor Transport	  of	  small	  molecules 1
listPG E267K Missense PA5241 ppx exopolyphosphatase 1
listPG R19R Silent PA4785 probable	  acyl-­‐CoA	  thiolase Putative	  enzymes 1
listPG P330P Silent PA1255 hypothetical	  protein Hypothetical,	  unclassified,	  unknown 1
listPH T296T Silent PA5013 ilvE branched-­‐chain	  amino	  acid	  transferase Amino	  acid	  biosynthesis	  and	  metabolism 1
listPH S466A Missense PA0004 gyrB DNA	  gyrase	  subunit	  B 2
listPH L345L Silent PA2059 probable	  permease	  of	  ABC	  transporter 1
listPI D18G Missense PA0762 algU sigma	  factor	  AlgU Transcriptional	  regulators 5
listQ 25053 Not	  annotated 0
listR E258Q Missense PA4670 prs ribose-­‐phosphate	  pyrophosphokinase 1
listS M332I Missense PA5035 gltD glutamate	  synthase	  small	  chain Amino	  acid	  biosynthesis	  and	  metabolism 1
listXB A112T Missense PA5133 conserved	  hypothetical	  protein Membrane	  proteins 1
listXB 22058 Intergenic PA1578/PA1579/ 10	  downstream	  hypothetical	  protein/482	  upstream	  hypothetical	  proteinHypothetical,	  unclassified,	  unknown/Hypothetical,	  unclassified,	  unknown1
listXB V163G Missense PA1833 probable	  oxidoreductase Putative	  enzymes 1
listXB S36_ Nonsense PA4661 pagL Lipid	  A	  3-­‐O-­‐deacylase Hypothetical,	  unclassified,	  unknown 1
listXB H269Q Missense PA4666 hemA glutamyl-­‐tRNA	  reductase 1
listXB D106N Missense PA0705 migA alpha-­‐1,6-­‐rhamnosyltransferase	  MigA Putative	  enzymes;	  Cell	  wall	  /	  LPS	  /	  capsule 1
listXB 72043 Intergenic PA2894/PA2895/ 40	  upstream	  hypothetical	  protein/306	  downstream	  hypothetical	  proteinHypothetical,	  unclassified,	  unknown/Hypothetical,	  unclassified,	  unknown2
listXC H215Y Missense PA4110 ampC beta-­‐lactamase	  precursor Adaptation,	  Protection 1
listXC P534S Missense PA3545 algG alginate-­‐c5-­‐mannuronan-­‐epimerase	  AlgG 2
listXC H353H Silent PA1331 conserved	  hypothetical	  protein Hypothetical,	  unclassified,	  unknown 1
listXC Q37Q Silent PA3103 xcpR general	  secretion	  pathway	  protein	  E Protein	  secretion/export	  apparatus 1
listXC A461V Missense PA4228 pchD pyochelin	  biosynthesis	  protein	  PchD 1
listXC 19417 Intergenic PA4709/PA4710/phuR 128	  upstream	  probable	  hemin	  degrading	  factor/53	  upstream	  P tative	  enzymes/Transport	  of	  small	  molecules 1
listXC 11844 Intergenic PA5136/PA5137/ 12	  downstream	  hypothetical	  protein/25	  downstream	  hypothetical	  proteinHypothe ical,	  unclassif ed,	  unknown/Hypothetical,	  unclassified,	  unknown1
listXC V452V Silent PA5554 atpD ATP	  synthase	  beta	  chain Energy	  metabolism 1
listXC R25H Missense PA2109 hypothetical	  protein Hypothetical,	  unclassified,	  unknown 1
listXC R808H Missense PA3297 probable	  ATP-­‐dependent	  helicase Transcription,	  RNA	  processing	  and	  degradation 1
listXC G94D Missense PA3432 hypothetical	  protein Membrane	  proteins 1
listXC I16I Silent PA4827 arylamine	  N-­‐acetyltransferase Adaptation,	  Protection;	  Putative	  enzymes 1
listXC T250M Missense PA3593 probable	  acyl-­‐CoA	  dehydrogenase Putative	  enzymes 1
listZZ A71A Silent PA1095 hypothetical	  protein Hypothetical,	  unclassified,	  unknown 1
listZZ P31P Silent PA14_58740 hypothetical	  protein Hypothetical,	  unclassified,	  unknown 1
listZZ I61I Silent PA2185 katN non-­‐heme	  catalase	  KatN Adaptation,	  Protection 1
listZZ T74I Missense PA1583 sdhA succinate	  dehydrogenase	  (A	  subunit) Energy	  metabolism 1
listZZ S372S Silent PA0172 hypothetical	  protein Hypothetical,	  unclassified,	  unknown 1
listZW A182A Silent PA3541 alg8 alginate	  biosynthesis	  protein	  Alg8 1
listZW Q10_ Nonsense PA0789 probable	  amino	  acid	  permease 1
listZW H102Q Missense PA4726 cbrB two-­‐component	  response	  regulator	  CbrB 1
listZW V79V Silent PA0749 hypothetical	  protein Hypothetical,	  unclassified,	  unknown 1
listZW A192V Missense PA3232 probable	  nuclease Putative	  enzymes 1
listZW T149P Missense PA1696 pscO translocation	  protein	  in	  type	  III	  secretion Protein	  secretion/export	  apparatus 1
listZW L42L Silent PA0337 ptsP Transport	  of	  small	  molecules 2
listZW 56672 Intergenic PA2634/PA2635aceA/ 178	  downstream	  isocitrate	  lyase	  AceA/1	  upstream	  hypothetical	  proteinPutative	  enzymes/Hypothetical,	  unclassified,	  unknown 1
listZW 72043 Intergenic PA2894/PA2895/ 40	  upstream	  hypothetical	  protein/306	  downstream	  hypothetical	  proteinHypothetical,	  unclassified,	  unknown/Hypothetical,	  unclassified,	  unknown2
Branch	  names	  are	  denoted	  in	  the	  phylogenetic	  tree	  in	  Figure	  2.
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Abstract	  14	  
The	   phenotype	   of	   infecting	   environmental	   P.	   aeruginosa	   has	   been	   shown	   to	   change	   significantly	   during	  15	  
chronic	  infection.	  Loss	  or	  reduction	  of	  several	  virulence	  factors	  important	  for	  initiation	  of	  acute	  infections	  is	  16	  
selected	  for	  during	  long-­‐term	  evolution	  to	  the	  CF	  airways.	  Mutations	  in	  the	  virulence	  factor	  regulator	  (vfr)	  17	  
gene	  have	  been	  consistently	  identified	  in	  clinical	  isolates	  from	  CF	  patients,	  indicating	  that	  vfr	  is	  a	  common	  18	  
mutational	  target	  in	  the	  adaptation	  of	  P.	  aeruginosa	  to	  the	  CF	  airways.	  	  19	  
The	  adaptation	  and	  evolutionary	  dynamics	  of	  the	  dominant	  and	  highly	  successful	  P.	  aeruginosa	  DK1	  clone	  20	  
has	  been	  investigated	  recently	  revealing	  early	  fixation	  of	  a	  mutation	  in	  the	  global	  transcriptional	  regulator	  21	  
Vfr	  (substitution).	  	  22	  
Here	  we	  investigate	  the	  dominant	  vfr	  mutation	  that	  emerged	  in	  the	  DK1	  clone	  during	  chronic	  infection	  by	  23	  
moving	   the	   mutation	   to	   the	   genome	   of	   the	   reference	   strain	   PAO1	   and	   examine	   the	   phenotypic	  24	  
consequences.	   Our	   findings	   showed	   that	   a	   single	   naturally	   occurring	   mutation	   resulted	   in	   altered	  25	  
phenotypic	  expression	  of	   several	  virulence	   factors	   including	  protease	  secretion,	  production	  of	  pyocyanin,	  26	  
and	   twitching	   and	   swimming	   motility.	   It	   was	   demonstrated	   that	   the	   substitution	   did	   not	   result	   in	   a	  27	  
knockout	  Vfr	  but	  caused	  a	  functional	  modification	  in	  the	  Vfr	  protein	  that	  resulted	  in	  alternative	  regulation.	  28	  
We	   show	   evidence	   of	   bacterial	   rewiring	   of	   the	   regulatory	   network	   by	   mutation	   in	   Vfr	   resulting	   in	   a	  29	  
phenotype	   resembling	   late	   chronic	   isolates,	   indicating	   that	   the	   role	   of	   Vfr	   in	   the	   regulation	   of	   virulence	  30	  
factors	  are	  quite	  complex	  and	  that	  mutations	  in	  vfr	  may	  confer	  selective	  advantages	  of	  P.	  aeruginosa	  in	  the	  31	  
CF	  environment	  during	  adaptation	  by	  fine-­‐tuning	  of	  regulatory	  networks.	  32	  
	   	  33	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Introduction	  34	  
Pseudomonas	  aeruginosa	  cause	  chronic	  airway	  infections	  in	  patients	  with	  cystic	  fibrosis	  (CF)	  and	  is	  the	  main	  35	  
cause	  of	  morbidity	   and	  mortality	   in	   these	  patients.	   	  P.	   aeruginosa	   acquires	  mutations	   and	  other	   genetic	  36	  
changes	  during	  the	  course	  of	  chronic	  infection	  in	  response	  to	  the	  selective	  forces	  in	  the	  CF	  airways.	  Hence	  37	  
the	  phenotypic	  characteristics	  of	  a	  chronic	  isolate	  sampled	  after	  long-­‐term	  infection	  is	  significantly	  different	  38	  
from	  the	  initially	  infecting	  strain.	  While	  initially	  infecting	  strains	  often	  resemble	  environmental	  phenotypes	  39	  
e.g.	   fast	   growing,	   non-­‐mucoid,	   and	   susceptible	   to	   antibiotics	   [1],	   chronic	   isolates	   display	   slow	   growth,	  40	  
mucoidy,	   antibiotic	   resistance,	   loss	   or	   reduction	   of	   multiple	   virulence	   factors,	   lack	   of	   motility,	   loss	   of	  41	  
quorum	  sensing	  and	  changed	  nutrition	  utilization	  [2-­‐5].	  	  	  42	  
It	  remains	  a	  central	  interest	  to	  understand	  the	  effects	  of	  such	  mutations	  on	  the	  physiology	  and	  behaviour	  43	  
of	  infecting	  bacterial	  isolates.	  It	  has	  been	  proposed	  that	  regulatory	  genes	  rather	  than	  structural	  genes	  play	  44	  
important	  roles	  during	  adaptation	  [6],	  as	  mutations	  in	  transcription	  regulation	  can	  shape	  entirely	  new	  traits	  45	  
by	   altering	   the	   function	   or	   activity	   of	   one	   central	   protein	   involved	   in	   a	   complex	   regulatory	   network	   and	  46	  
therefore	  have	  widespread	  pleiotropic	  effects.	  	  47	  
We	   observed	   previously,	   that	   early	   regulatory	   mutations	   and	   their	   epistatic	   interactions	   indeed	   were	  48	  
important	   for	   the	   adaptation	   of	   the	   dominant	   P.	   aeruginosa	   DK2	   clone	   contributing	   to	   the	   major	  49	  
phenotypic	   changes	   [7].	   Experimental	   evolution	   studies	   have	   likewise	   documented	   that	   transcriptional	  50	  
regulators	  often	  are	  targets	  for	  adaptive	  mutations	  [8,	  9].	  	  51	  
Recent	  investigation	  detected	  an	  early	  and	  persistent	  mutation	  in	  the	  virulence	  factor	  regulator	  (vfr)	  gene	  52	  
observed	  in	  all	  DK1	  isolates	  after	  1973	  [10].	  Here	  we	  investigate	  this	  first	  regulatory	  mutation	  observed	  in	  53	  
the	  DK1	  lineage.	  54	  
The	   transcriptional	   regulator	  Vfr	   is	  a	  homolog	  of	   the	  cyclic	  AMP	   (cAMP)	   receptor	  protein	   (CRP)	   in	  E.	   coli,	  55	  
being	   67	   %	   identical	   and	   91%	   similar	   to	   CRP	   [11].	   The	   cloned	   vfr	   gene	   was	   able	   to	   complement	   a	   crp	  56	  
deficient	  E.	   coli	  mutant	   [11],	   suggesting	   functional	   similarities	  between	   these	   two	  proteins.	  Furthermore,	  57	  
amino	  acids	  important	  for	  CRP	  cAMP	  binding,	  DNA	  binding	  and	  bending,	  and	  RNA	  polymerase	  interaction	  58	  
were	  identical	  or	  conserved	  in	  Vfr	  [11].	  Depending	  on	  the	  protein-­‐protein	  interaction	  with	  RNA	  polymerase,	  59	  
CRP	   promoters	   can	   be	   divided	   into	   two	   classes	   [12].	   At	   class	   I	   CRP-­‐dependent	   promoters	   CRP	   bind	  60	  
upstream	   of	   the	   RNA	   polymerase	   and	   interact	   with	   α-­‐CTD	   domain	   involving	   Activating	   Region	   1	   (AR1),	  61	  
which	  is	  a	  surface-­‐exposed	  loop	  comprising	  residues	  156	  to	  164	  [13,	  14].	  At	  class	  II	  promoters	  CRP	  binds	  to	  62	  
a	   site	   overlapping	   the	   RNA	   polymerase	   binding	   site.	   The	   interaction	   involves	   both	   AR1	   and	   α-­‐CTD	  63	  
interaction	  but	  also	  AR2	  (residues	  19,	  21,	  96,	  and	  101)	  interaction	  with	  the	  α	  subunit	  of	  the	  N-­‐terminal	  of	  64	  
RNA	   polymerase	   [15].	   In	   addition	   to	   these	   two	   classes	   there	   exists	   a	   third	   class	   of	   CRP	   promoters	   that	  65	  
require	  multiple	  CRP	  dimers	  and/or	  other	  activator	  molecules	  [12].	  	  	  66	  
	   4	  
Vfr	  has	  been	  shown	  to	  control	  expression	  of	  over	  200	  genes	  [16,	  17].	  Vfr	  positively	  regulate	  the	  production	  67	  
of	  several	  virulence	  factors	  important	  for	  acute	  infection	  mainly	  through	  the	  regulation	  of	  the	  las	  quorum	  68	  
sensing	  (QS)	  system,	  as	  it	  binds	  directly	  to	  a	  DNA	  sequence	  within	  the	  promoter	  of	  lasR	  [18].	  	  In	  most	  cases	  69	  
Vfr	  requires	  the	  binding	  of	  cAMP	  to	  be	  activated	  like	  the	  E.	  coli	  CRP	  protein,	  however,	  cAMP	  is	  not	  required	  70	  
for	  Vfr	  binding	  to	  the	  lasR	  promoter	  [19].	  Vfr	  has	  also	  been	  found	  to	  bind	  directly	  within	  promoter	  regions	  71	  
of	  toxA	  (encoding	  exotoxin	  A),	  regA,	  ptxR	  (encoding	  toxA	  regulators),	  fleQ	  (encoding	  flagellar	  transcriptional	  72	  
regulator	   FleQ),	   and	   cpdA	   (encoding	   a	   cAMP	   phosphodiesterase)	   [20-­‐23]	   and	   positively	   or	   negatively	  73	  
regulating	  the	  transcription	  of	  these	  genes.	  Furthermore,	  Vfr	  has	  been	  suggested	  to	  negatively	  regulate	  the	  74	  
PQS	  quorum	  sensing	  systems	  [24].	  A	  recent	  study	  showed	  that	  Vfr	  regulates	  rhlR	  transcription	  by	  binding	  to	  75	  
several	  Vfr-­‐binding	  sites	  present	   in	  the	  rhlR	  promoter	  region,	  one	  of	  which	  negatively	  regulates	  rhlR	   [25].	  76	  
These	  findings	  suggest	  that	  Vfr	   is	   implicated	   in	  the	  complex	  network	  of	  regulating	  acute	  virulence	  factors	  77	  
and	  the	  quorum	  sensing	  system.	  The	  mutation	  in	  vfr	  may	  therefore	  be	  important	  for	  the	  adaptation	  of	  P.	  78	  
aeruginosa	  to	  the	  CF	  airways.	  We	  consequently	  hypothesized	  that	  this	  regulatory	  mutation	  in	  vfr	  was	  the	  79	  
first	  step	  of	  becoming	  a	  successful	  colonizer.	  80	  
Here	  we	  investigated	  the	  point	  mutation	  in	  vfr	  and	  characterized	  regulatory	  consequences	  and	  pleiotropic	  81	  
effects	  caused	  by	  the	  mutation	  compared	  to	  wild	  type	  and	  a	  knockout	  mutant.	  82	  
It	  was	  observed	  that	  the	  point	  mutation	  modified	  several	  phenotypes	  including	  transcriptional	  profile	  and	  83	  
catabolic	   performance	   towards	   a	   phenotype	   associated	   with	   chronic	   infection,	   indicating	   that	   a	   single	  84	  
mutation	   may	   cause	   completely	   alterations	   of	   multiple	   phenotypes	   reflecting	   the	   transition	   from	   an	  85	  
environmental	  strain	  to	  a	  host	  specific	  pathogen	  for	  CF	  patients.	  86	  
Understanding	  the	  evolutionary	  paths	  by	  which	  P.	  aeruginosa	  adapts	  to	  the	  CF	  airways	  may	  provide	  useful	  87	  







	   5	  
Results	  95	  
Computational	  investigation	  of	  the	  vfr	  mutation	  96	  
We	  have	  recently	  determined	   the	  sequence	  of	  genetic	  and	  phenotypic	  changes	   in	   the	  P.	  aeruginosa	  DK1	  97	  
lineage	  that	  resulted	   in	   its	  successful	  establishment	   in	   the	  CF	  airways	  of	  a	   large	  number	  of	  patients	   from	  98	  
1973	   to	  2012	   [10].	   The	   first	  mutation	  within	  a	   gene	  with	   regulatory	   function	  was	  an	  A-­‐to-­‐C	   transition	  at	  99	  
position	  487	  in	  the	  vfr	  gene.	  This	  mutation	  was	  found	  in	  DK1	  isolates	  from	  1973	  and	  was	  immediately	  fixed	  100	  
in	  the	  lineage	  (i.e.	  found	  in	  all	  descending	  isolates	  including	  contemporary	  isolates).	  	  101	  
The	  A487C	  mutation	   in	  vfr	   results	   in	  substitution	  of	   threonine-­‐163	  to	  a	  proline	  residue.	  SIFT	  analysis	   [26]	  102	  
predicted	  that	  this	  amino	  acid	  substitution	  had	  an	  effect	  of	  the	  function	  of	  the	  protein.	  103	  
Based	  on	  the	  crystal	  structure	  of	  Vfr	  proposed	  by	  Cordes	  and	  colleagues	  [27]	  amino	  acids	  163	  and	  164	  have	  104	  
solvent-­‐exposed	   side	   chains,	   and	   could	   therefore	   potentially	   participate	   in	   direct	   side-­‐chain	   interactions	  105	  
required	   for	   transcriptional	   activation	   or	   DNA	   binding.	   Comparison	   of	   Vfr	   with	   its	   E.	   coli	   homolog	   CRP	  106	  
showed	   that	   the	  mutation	   occurred	   in	   the	   AR1	   region	   (Figure	   1).	   It	   has	   been	   reported	   that	   this	   region	  107	  
(AMTHPDG)	  is	  involved	  in	  CRP-­‐RNA	  polymerase	  interaction	  in	  E.	  coli	  but	  not	  DNA	  binding	  and	  DNA	  bending	  108	  
[11,	   14],	   indicating	   that	   the	   substitution	   of	   threonine-­‐163	   to	   proline	   could	   interfere	   with	   Vfr-­‐RNA	  109	  
polymerase	   interaction	   and	   modify	   the	   function	   of	   Vfr.	   To	   verify	   this	   hypothesis,	   mutants	   of	   vfr	   was	  110	  
constructed	   and	   the	   phenotypic	   impact	   of	   the	   vfrT163P	   mutant	   was	   examined	   and	   compared	   to	   a	   vfr	  111	  
knockout	  mutant.	  112	  
	  113	  
Transcriptional	  profiles	  of	  vfrT163P	  and	  Δvfr	  mutants	  114	  
We	   next	   sought	   to	   study	   the	   impact	   of	   the	   vfrT163P	  mutation	   on	   gene	   expression.	   It	   has	   previously	   been	  115	  
reported	   that	   Vfr	   levels	   peak	   during	   late-­‐exponential/early	   stationary	   phase	   [28,	   29].	   For	   this	   reason,	  116	  
transcriptome	  analysis	  was	  performed	  on	  PAO1,	  vfrT163P	  and	  Δvfr	  mutants	  grown	  to	  both	  exponential	  phase	  117	  
and	  late-­‐exponential/early	  stationary	  phase	  in	  order	  to	  investigate	  the	  effect	  of	  Vfr	  on	  gene	  expression.	  The	  118	  
analysis	  was	  done	  using	  Affymetrix	  GeneChip	  (see	  Materials	  and	  methods).	  It	  was	  observed	  that	  under	  the	  119	  
experimental	   conditions,	   Vfr	   affected	   most	   genes	   during	   exponential	   phase.	   Of	   the	   5883	   genes	   and	  120	  
intergenic	  regions	  present	  on	  the	  microarray,	  898	  genes	  (15.3%)	  showed	  significantly	  altered	  expression	  in	  121	  
the	  vfrT163P	  mutant	  compared	  to	  PAO1,	  and	  1415	  genes	  (24.1%)	  in	  the	  Δvfr	  mutant	  compared	  to	  PAO1	  (P	  <	  122	  
0.05)	   at	   exponential	   phase	   (Table	   S1).	   In	   stationary	   phase,	   only	   66	   genes	   showed	   significantly	   altered	  123	  
expression	   in	  vfrT163P	  mutant	  compared	  to	  PAO1,	  and	  52	  genes	  were	  differently	  expressed	   in	  Δvfr	  mutant	  124	  
compared	  to	  PAO1	  (Table	  S2),	  indicating	  that	  in	  stationary	  phase	  both	  mutants	  resembled	  wild	  type	  PAO1	  125	  
compared	   with	   exponential	   phase	   data.	   Here,	   we	   therefore	   mainly	   focused	   on	   gene	   expression	   in	  126	  
exponential	  phase.	  127	  
	   6	  
Venn	  diagrams	  were	  constructed	  to	  visualize	  the	  overlap	  and	  difference	  of	  gene	  expression	  in	  exponential	  128	  
phase	  between	  the	  mutants	   (Figure	  2).	  From	  this	   it	  was	  observed	   that	   the	   two	  mutants	  overlapped	  with	  129	  
589	   differently	   expressed	   genes	   compared	   to	   PAO1.	   The	  Δvfr	   mutant	   expressed	   826	   genes	   significantly	  130	  
different	  from	  the	  vfrT163P	  mutant,	  while	  309	  genes	  were	  found	  to	  be	  differential	  expressed	  specific	  for	  the	  131	  
vfrT163P	  mutant.	  From	  this	  it	  was	  clear	  that	  the	  two	  mutants	  were	  significantly	  different	  from	  PAO1	  and	  that	  132	  
the	  vfrT163P	  mutation	  indeed	  had	  functional	  effects.	  Importantly,	  the	  expression	  data	  showed	  that	  the	  two	  133	  
mutants	  were	  distinct	  which	   suggested	   that	   the	  vfrT163P	  mutation	  modified	  Vfr	  and	   its	   regulon	  differently	  134	  
than	  a	  loss-­‐of-­‐function,	  knockout	  strain.	  	  135	  
	  136	  
Mutations	  in	  vfr	  result	  in	  CF	  associated	  phenotypes	  137	  
To	  experimentally	  address	  functional	  consequences	  of	  the	  observed	  transcriptome	  changes,	  we	  focused	  on	  138	  
differentially	  expressed	  genes	  with	  minimal	  twofold	  expression	  changes	  (Table	  1).	  	  139	  
Vfr	  has	  been	  described	  to	  be	  required	  for	  twitching	  motility	  [30].	  Likewise,	  we	  observed	  that	  pilJ	  involved	  in	  140	  
twitching	  motility	   was	   downregulated	   in	   both	  mutants	   (Table	   1).	   The	  Δvfr	   mutant	   furthermore	   showed	  141	  
downregulation	   of	   the	   type	   4	   fimbrial	   precurser	   pilA.	   Measuring	   twitching	   zones	   in	   1%	   agar	   plates	  142	  
confirmed	  this	  (Figure	  3A).	  Whereas	  the	  vfr	  mutant	  significantly	  twitched	  less	  than	  PAO1,	  the	  Δvfr	  mutant	  143	  
significantly	  twitched	  less	  than	  vfrT163P	  (Student’s	  t-­‐test,	  P	  <	  0.05),	  probably	  as	  a	  result	  of	  downregulation	  of	  144	  
pilA.	   In	   addition	   to	   its	   effect	   on	   twitching,	   Vfr	   has	   previously	   been	   described	   to	   negatively	   regulate	   the	  145	  
expression	  of	   flagellar	  genes	  by	   repressing	   the	   flagellar	   transcriptional	   regulator	  FleQ	   [20].	  Dasgupta	  and	  146	  
colleagues	  found	  FleQ	  production	  to	  be	  downregulated	  following	  Vfr	  overproduction,	  but	  was	  unchanged	  147	  
in	  a	  Vfr	  knockout	  mutant	  [20].	  Likewise,	  we	  did	  not	  observed	  difference	  in	  fleQ	  transcription	  in	  the	  vfrT163P	  148	  
and	  the	  Δvfr	  mutant.	  However,	  we	  did	  see	  a	  small	  but	  significant	  increase	  in	  swimming	  motility	  compared	  149	  
to	  PAO1	  (Figure	  3B),	  suggesting	  that	  even	  a	  small	  change	   in	  FleQ	  transcription	  may	  have	  an	   influence	  on	  150	  
swimming	  motility	  or	  that	  swimming	  motility	  may	  be	  regulated	  via	  a	  mechanism	  independent	  of	  FleQ.	  Both	  151	  
twitching	  and	  swimming	  motility	  was	  restored	  to	  wild-­‐type	  levels	  in	  the	  complementary	  strain	  vfr-­‐com.	  	  152	  
Another	  group	  of	  genes	  was	   found	  to	  have	  differential	  expression	   in	  the	  vfr	  mutants	  compared	  to	  PAO1.	  153	  
The	  expression	  of	  genes	  involved	  in	  iron	  acquisition	  was	  increased	  in	  the	  vfrT163P	  mutant	  including	  pch	  genes	  154	  
(required	   for	   production	   of	   the	   pyochelin	   sideophore)	   and	   fptA	   encoding	   the	   ferric-­‐pyochelin	   receptor	  155	  
(Tabel	   1).	   Furthermore,	   ampP	   (also	   known	   as	   fptX,	   involved	   in	   ferripyochelin	   transport),	   which	   has	  156	  
previously	  been	  described	  to	  be	  upregulated	  in	  iron-­‐limited	  conditions,	  was	  found	  to	  be	  upregulated	  in	  the	  157	  
vfrT163P	  mutant.	  This	  suggested	  that	  the	  vfrT163P	  mutant	  had	  increased	  ability	  to	  utilize	  pyochelin	  and	  grow	  in	  158	  
iron-­‐limited	  media.	   Indeed,	   when	   the	   vfrT163P	  mutant	   and	   PAO1	  were	   grown	   on	   iron-­‐depleted	   VB	   plates	  159	  
supplemented	  with	  Fe3+	  or	  Fe2+	  ,	  the	  vfrT163P	  mutant	  grew	  significantly	  better	  than	  PAO1	  (Student’s	  t-­‐test,	  P	  160	  
	   7	  
<	  0.05)	   (Figure	  4A).	   Interestingly,	   the	   same	  effect	  was	  observed	   for	   the	  Δvfr	  mutant	  although	  only	   slight	  161	  
upregulation	  of	  genes	  involved	  in	  pyochelin	  production	  and	  reception	  was	  observed	  in	  this	  mutant	  (Table	  162	  
1).	  	  	  163	  
To	  verify	  that	  the	  growth	  under	  iron-­‐limited	  condition	  was	  due	  to	  upregulation	  of	  pyochelin,	  we	  measured	  164	  
the	  pyoverdin	  production.	  No	  difference	  was	  observed	   in	  pyoverdin	  production	  between	  the	  vfr	  mutants	  165	  
and	  PAO1	  (Figure	  4B),	  suggesting	  that	  the	  ability	  to	  grow	  under	  iron	  limited	  condition	  was	  due	  to	  changed	  166	  
pyochelin	  expression.	  167	  
Vfr	   has	   previously	   been	   shown	   to	   directly	   bind	   and	   activate	   transcription	   of	   lasR	   [18].	   LasR	   is	   the	  major	  168	  
regulator	   of	   quorum	   sensing	   control	   in	  P.	   aeruginosa	   that	   positively	   regulates	   the	   expression	   of	   a	   large	  169	  
number	  of	  genes	   including	   those	   for	  elastase	   (lasB)	  and	  the	  type	   II	   secretion	  apparatus.	  Therefore	   it	  was	  170	  
not	  surprising	  that	  microarray	  data	  showed	  downreguation	  of	  lasR	  in	  both	  mutants	  (see	  below)	  and	  genes	  171	  
belonging	  to	  type	   II	   secretion	  (Table	  S1).	   In	  agreement	  with	  this,	  protease	  secretion	  was	  reduced	   in	  both	  172	  
mutants	  compared	  with	  PAO1	  (Figure	  5A).	  Another	  virulence	  factor	  described	  to	  be	  QS	  dependent	  was	  the	  173	  
production	  of	  pyocyanin.	  The	  vfr	  mutants	  showed	  increased	  pyocyanin	  production	  compared	  to	  PAO1	  after	  174	  
16	   hours	   of	   incubation	   (Figure	   5B),	   indicating	   negative	   regulation	   of	   pyocyanin	   production	   probably	  175	  
through	  lasR.	  This	  was	  supported	  by	  previous	  observations	  that	  a	  lasR	  mutant	  was	  found	  to	  have	  elevated	  176	  
pyocyanin	  production	  compared	  to	  wild	  type	  after	  14	  hours	  [31].	  	  	  177	  
	  178	  
Mutations	  in	  vfr	  change	  catabolic	  performance	  179	  
The	   nutritional	   composition	   of	   the	   environment	   has	   an	   impact	   on	   evolution	   and	   adaptation	   of	   P.	  180	  
aeruginosa.	  We	   therefore	   sought	   to	   examine	   the	   ability	   of	   the	  vfr	  mutants	   to	  utilize	   various	   carbon	  and	  181	  
nitrogen	  sources	  using	   the	  Biolog	  Phenotype	  MicroArray	   (Materials	  and	  Methods).	  Significant	  differential	  182	  
growth	  was	   observed	   on	   38	   substrates	   of	   both	   carbon	   and	   nitrogen	   sources	   (P	  >	   0.05).	   The	   Biolog	   data	  183	  
confirmed	   the	  observed	  difference	  between	   the	  vfrT163P	   and	   the	  vfr::Gm	  mutant	   and	   further	   showed	   the	  184	  
growth	  difference	  compared	  to	  PAO1	  (Figure	  6).	  185	  
The	  vfr	  mutants	  were	  found	  to	  grow	  significantly	  better	  on	  several	  sugars	  including	  xylose,	  fucose,	  ribose,	  186	  
and	   arabinose.	   Interestingly,	   both	   mutants	   showed	   significantly	   increased	   respiration	   of	   several	   amino	  187	  
acids	   including	   proline,	   alanine	   and	   valine	   compared	   to	   PAO1.	   The	   differences	   in	   catabolic	   performance	  188	  
between	   PAO1	   and	   the	   vfr	   mutants	   on	   proline	   were	   supported	   by	   gene	   expression	   analysis	   showing	  189	  
upregulation	  of	  the	  proC	  gene	  involved	  in	  proline	  metabolism	  (Table	  S1).	  In	  contrast,	  both	  mutants	  showed	  190	  
significantly	   reduced	   respiration	   on	   nitrogen	   sources	   compared	   to	   PAO1.	   These	   data	   showed	   that	   Vfr	  191	  
directly	   or	   indirectly	   regulated	   genes	   involved	   in	   metabolism	   and	   that	   mutations	   in	   Vfr	   changed	   the	  192	  
catabolic	  performance	  of	  the	  strain.	  	  	  193	  
	   8	  
Differences	  between	  vfrT163	  and	  the	  knockout	  mutants	  194	  
From	   the	  presented	  data	   it	  was	   clear	   that	   the	   two	  vfr	  mutants	  were	   significantly	  different	   from	  PAO1	   in	  195	  
expression	  of	  motility,	   iron	  acquisition,	  QS	  dependent	  phenotypes,	  and	   respiration	  of	   certain	  carbon	  and	  196	  
nitrogen	  substrates.	  In	  contrast	  to	  this,	  we	  also	  observed	  differences	  between	  the	  vfrT163P	  and	  the	  knockout	  197	  
mutants.	   The	   vfrT163P	   mutant	   utilized	   several	   nitrogen	   sources	   better	   than	   the	   vfr::Gm	  mutant	   including	  198	  
alanine	   and	   serine,	   implying	   that	   under	   certain	   growth	   conditions	   vfrT163P	   would	   grow	   better	   than	   the	  199	  
vfr::Gm	  mutant.	  	  200	  
Furthermore,	  microarray	   analysis	   revealed	   differences	   in	   gene	   expression	   between	   the	   two	  mutants	   not	  201	  
only	   in	   exponential	   phase	   but	   also	   in	   stationary	   phase	   (Table	   1),	   indicating	   that	   there	   were	   regulatory	  202	  
difference	  between	  the	  vfrT163P	  and	  the	  Δvfr	  mutant.	  These	  differences	  were	  among	  others	  observed	  in	  the	  203	  
expression	  of	   the	  pqsA-­‐E	   operon,	   involved	   in	   the	   conversion	  of	   anthranilate	   to	  HHQ.	   The	  pqsA-­‐E	   operon	  204	  
was	   upregulated	   in	   Δvfr	   compared	   to	   the	   vfrT163P	   mutant	   (Table	   1	   and	   Table	   S1),	   suggesting	   that	   Vfr	  205	  
negatively	   regulated	   the	   PQS	   system,	   however,	   this	   was	   not	   the	   case	   for	   vfrT163P	   showing	   the	   same	  206	  
transcriptional	   levels	  of	   the	  pqs	  operon	  as	  PAO1.	  This	   indicated	   that	   the	  modified	  Vfr	   from	  vfrT163P	   is	   still	  207	  
able	   to	   directly	   or	   indirectly	   regulate	   the	  pqs	   operon	   as	   in	   PAO1.	   In	   addition,	   both	  mutants	   showed	   the	  208	  
metallic,	  iridescent	  sheen	  when	  grown	  on	  agar	  (Figure	  7).	  This	  metallic	  sheen	  has	  been	  associated	  with	  the	  209	  
accumulation	  of	  HHQ	  seen	   in	   lasR	  mutants	   [3].	  However	   the	  vfrT163P	  mutant	  exhibited	  a	  higher	  degree	  of	  210	  
metallic	   sheen	   than	   the	   Δvfr	   mutant	   (Figure	   7).	   While	   both	   mutants	   downregulated	   lasR	   shown	   to	  211	  
positively	   regulate	  pqsH,	   converting	  HHQ	  to	  PQS,	  Δvfr	   showed	  1.2	   fold	  upregulation	  of	   lasR	   compared	  to	  212	  
the	   vfrT163P	   mutant.	   The	   difference	   could	   furthermore	   be	   seen	   in	   the	   expression	   of	   pqsH,	   which	   was	  213	  
expressed	  1.2	  fold	  less	  in	  the	  vfrT163P	  mutant	  compared	  to	  Δvfr.	  This	  suggests	  that	  the	  observed	  difference	  214	  
in	  metallic	  sheen	  may	  be	  caused	  by	  distinct	  rates	  of	  converting	  HHQ	  to	  PQS.	  	  215	  
	  216	  
Discussion	  217	  
Mutations	  in	  transcriptional	  regulators	  have	  important	  implications	  for	  P.	  aeruginosa	  when	  adapting	  to	  the	  218	  
highly	   complex	   environment	   of	   CF	   patients.	   One	   mutation	   can	   have	   major	   phenotypic	   effects,	   as	  219	  
transcriptional	   regulators	   often	   are	   central	   proteins	   in	   a	   complex	   regulatory	   network.	   Here	   we	   have	  220	  
characterized	   the	   regulatory	   consequences	   and	   pleiotropic	   effects	   caused	   by	   a	   consistent	   vfr	   mutation	  221	  
acquired	  during	  adaptation	  of	  the	  P.	  aeruginosa	  DK1	  clone.	  The	  mutation	  (Thr163Pro)	  was	  within	  the	  RNA	  222	  
polymerase	  interacting	  binding	  region	  AR1	  (Figure	  1).	  Single	  amino	  acid	  substitutions	  within	  AR1	  of	  E.	  coli	  223	  
CRP	  protein	  (Vfr	  homolog)	  have	  been	  demonstrated	  to	  reduce	  transcription	  activation	  but	  not	  affect	  DNA	  224	  
binding	  and	  DNA	  bending	   [14].	   In	   fact,	  Thr158	   in	  CRP	   (Thr163	   in	  Vfr)	  has	  been	  shown	  to	  be	  essential	   for	  225	  
transcription	   activation	   and	   the	  most	   important	   side-­‐chain	   for	   function	  of	  AR1	   [32].	   Furthermore,	   it	  was	  226	  
	   9	  
proposed	  that	  Thr-­‐158	  made	  direct	  contact	  with	  RNA	  polymerase	  [32]	  and	  was	  therefore	  a	  very	  important	  227	  
site	  for	  interaction	  with	  RNA	  polymerase.	  We	  therefore	  argue	  that	  the	  observed	  mutation	  in	  vfr	  of	  clinical	  228	  
DK1	   isolates	   modified	   the	   interaction	   with	   RNA	   polymerase	   resulting	   in	   re-­‐directed	   regulatory	   capacity	  229	  
rather	  than	  loss-­‐of-­‐function.	  This	  hypothesis	  was	  supported	  by	  the	  presented	  data	  that	  showed	  differences	  230	  
in	   gene	   expression	   profiles,	   catabolic	   performance	   and	   colony	  morphology	   (i.e.	  metallic	   sheen)	   between	  231	  
vfrT163P	  and	  knockout	  mutants.	  	  The	  single	  vfr	  mutation	  seemed	  to	  change	  the	  phenotype	  to	  a	  more	  chronic	  232	  
stage	   of	   phenotype	   represented	   by	   reduced	   protease	   secretion	   and	   twitching	   motility	   through	  233	  
downregulation	  of	   lasR,	   type	   II	   secretion	  genes,	   and	  pili	   genes.	   It	   has	  previously	  been	   reported	   that	   a	  P.	  234	  
aeruginosa	  PAK	  deficient	  in	  Vfr,	  did	  not	  have	  an	  effect	  on	  pilA	  transcription.	  However	  this	  seemed	  to	  be	  the	  235	  
case	  in	  a	  PAO1	  background,	  indicating	  that	  there	  exist	  differences	  between	  the	  regulons	  of	  Vfr	  depending	  236	  
on	  the	  strain	  background	  237	  
The	   vfrT163P	   mutant	   was	   found	   to	   grow	   better	   on	   several	   amino	   acids	   including	   those	   found	   in	   high	  238	  
concentrations	   in	   sputum	   samples.	   The	   CF	   sputum	   has	   previously	   been	   reported	   to	   have	   increased	  239	  
availability	  of	  amino	  acid	  compared	  to	  healthy	  individuals	  [2],	  and	  clinical	  isolates	  have	  been	  shown	  to	  use	  240	  
these	   amino	   acids	   as	   preferred	   carbon	   sources	   in	   sputum	   [33],	   indicating	   that	   vfr	  mutants	  may	   have	   an	  241	  
selective	  advantage	  in	  the	  CF	  airways.	  The	  vfrT163P	  mutant	  utilized	  several	  nitrogen	  sources	  better	  than	  the	  242	  
Δvfr	   mutant	   including	   alanine	   and	   serine,	   implying	   that	   the	   point	   mutation	   would	   provide	   a	   selective	  243	  
advantage	  in	  the	  CF	  habitat.	  In	  addition,	  we	  observed	  that	  the	  vfr	  mutants	  grew	  significantly	  better	  under	  244	  
iron	  limited	  condition	  compared	  to	  wild	  type	  PAO1.	  The	  transcriptional	  regulator	  PchR	  regulates	  expression	  245	  
of	   the	   pchABCDE	   and	   fptA	   genes,	   however	   pchR	   was	   not	   found	   to	   be	   upregulated,	   indicating	   that	   the	  246	  
modified	  Vfr	  produced	  by	  the	  vfrT163P	  mutant	  may	  function	  as	  an	  alternate	  regulator	  of	  the	  pch	  operon	  or	  247	  
that	   the	   increase	   in	  expression	   level	  of	   the	  pch	  operon	  was	  due	   to	  change	   in	  mRNA	  stability	   rather	   than	  248	  
transcription	  rate.	  	  249	  
Even	  though	  there	  was	  a	  difference	  in	  upregulation	  of	  pch	  genes	  between	  vfrT163P	  and	  ∆vfr,	  this	  difference	  250	  
was	  not	  detected	  in	  the	  iron	  depletion	  assay.	  It	  should	  be	  kept	  in	  mind	  that	  the	  conditions	  in	  which	  gene	  251	  
expression	  and	  iron	  depletion	  were	  measured	  were	  completely	  different.	  Therefore	  it	  is	  possible	  that	  under	  252	  
the	  iron	  depletion	  condition	  both	  vfr	  mutants	  show	  increased	  expression	  of	  pyochelin	  compared	  to	  PAO1.	  	  253	  
Previously,	   it	   has	   been	   documented	   that	  P.	   aeruginosa	   grows	   under	   iron-­‐restricted	   conditions	   in	   the	   CF	  254	  
airways	   [34],	   supporting	   the	   hypothesis	   that	  mutations	   in	   vfr	  would	   confer	   a	   selective	   advantage	   when	  255	  
adapting	   to	   the	   CF	   environment.	   This	   was	   further	   supported	   by	   previous	   observations	   by	   Fox	   and	  256	  
colleagues	  showing	  that	  under	  certain	  growth	  conditions	  there	  was	  a	  positive	  selection	  of	  vfr	  mutants	  and	  257	  
demonstrated	  that	  vfr	  mutants	  had	  a	  selective	  advantage	  over	  wild	  type	  after	  growth	  in	  static	  cultures	  [35].	  258	  
These	  results	  are	  quite	  intriguing	  as	  vfr	  mutants	  of	  P.	  aeruginosa	  naturally	  and	  frequently	  arise	  in	  the	  cystic	  259	  
	   10	  
fibrosis	   environment	   during	   long-­‐term	   colonization	   [36].	   We	   therefore	   propose	   that	   this	   single	   point	  260	  
mutation	  in	  vfr	  was	  the	  first	  step	  of	  becoming	  a	  successful	  colonizer	  of	  the	  CF	  airways,	  giving	  P.	  aeruginosa	  261	  
multiple	  selective	  advantages.	  	  262	  
The	  expression	  of	  other	  known	  Vfr	   targets	   such	  as	   regA,	   fleQ,	  ptxR	   and	   toxA	  were	  not	  altered	   in	   the	  Vfr	  263	  
mutants	   indicating	   that	   under	   the	   investigated	   conditions	   numerous	   other	   regulators	   may	   control	  264	  
transcription	  of	  these	  genes.	  265	  
Experimental	   evolution	   studies	   conducted	   in	   laboratory	   conditions	   have	   frequently	   documented	   that	  266	  
transcriptional	   regulators	   are	   targets	   for	   adaptive	   mutations	   [8,	   9].	   Recently,	   this	   was	   confirmed	   for	   a	  267	  
number	  of	  regulatory	  mutations	  observed	  to	  arise	  in	  the	  DK2	  clone	  These	  mutations	  helped	  the	  DK2	  clone	  268	  
to	   adapt	  by	   continuous	  optimization	  of	   existing	   regulatory	  networks	   [7].	   Likewise,	  we	   identified	   an	  early	  269	  
appearing	   mutation	   in	   the	   global	   transcriptional	   regulator	   Vfr	   in	   the	   DK1	   lineage.	   This	   mutation	   was	  270	  
observed	   in	   all	   DK1	   isolates	   from	   1973	   and	   onward	   with	   the	   exception	   of	   one	   historical	   isolate,	   that	  271	  
surprisingly	  enough	  had	  a	  mutation	   in	   lasR	   instead,	   indicating	   that	   the	   two	  mutations	  might	  compensate	  272	  
for	  each	  other.	  This	  was	  supported	  by	  the	  observation	  that	  vfr	  mutants	  shared	  many	  of	  the	  phenotypes	  of	  a	  273	  
lasR	  mutant,	  indicating	  that	  the	  same	  phenotypic	  outcome	  is	  possible	  by	  different	  evolutionary	  paths.	  274	  
Based	  on	  the	  presented	  data,	  we	  therefore	  propose	  that	  this	  single	  point	  mutation	  in	  vfr	  was	  the	  first	  step	  275	  
of	  becoming	  a	  successful	  colonizer	  of	  the	  CF	  airways,	  giving	  P.	  aeruginosa	  multiple	  selective	  advantages.	  276	  
In	  conclusion,	  vfrT163P	  was	  shown	  to	  be	  a	  mutant	  of	  PAO1	  distinct	  from	  a	  knockout	  mutant	  and	  was	  found	  to	  277	  
have	  great	  pleiotropic	  effects	  on	  gene	  expression	  and	  catabolic	  performance.	  	  	   	  278	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Method	  279	  
Bacterial	  strains	  and	  plasmids	  280	  
The	   bacterial	   strains	   used	   in	   this	   study	   are	   described	   in	   Table	   2.	   E.	   coli	   and	   P.	   aeruginosa	   strains	   were	  281	  
routinely	  grown	  in	  Luria-­‐Bertani	  (LB)	  broth	  or	  on	  LB	  agar	  at	  37	  °C.	  When	  needed	  appropriate	  antibiotic	  was	  282	  
added.	  	  283	  
	  284	  
Construction	  of	  vfr	  mutants	  	  285	  
The	  vfrT163P	  mutant	  and	  the	  vfr	  deletion	  mutant	  (Δvfr)	  was	  constructed	  by	  allelic	  replacement.	  The	  vfr	  gene	  286	  
containing	   the	   mutation	   vfr(A487T)	   was	   amplified	   from	   a	   DK1	   isolate	   using	   the	   primers	   vfr-­‐fw-­‐SacI	  287	  
(GAGAGAGCTCCAGACTCCCGCCGGCAAAGG)	  and	  vfr-­‐rev-­‐XbaI	  (ACATTCTAGAGGACACGCCGTTGATGGGCA)	  or	  288	  
vfr-­‐rev-­‐PstI	  (ACATCTGCAGGGACACGCCGTTGATGGGCA).	  The	  fragment	  was	  digested	  with	  SacI	  and	  XbaI/PstI	  289	  
and	  ligated	  onto	  the	  plasmid	  pNJ1	  and	  transformed	  into	  E.	  coli	  CC118λpir	  by	  standard	  protocols	  [37].	  290	  
The	  deletion	  mutant	  Vfr-­‐null	  was	  constructed	  by	  cutting	  out	  two	  base	  pair	  at	  position	  108	  in	  the	  vfr	  gene	  on	  291	  
pTM1	  creating	  a	  frame	  shift.	  The	  insertion	  mutant	  TM4	  was	  constructed	  by	  inserting	  a	  gentamycin	  cassette	  292	  
at	  position	  233.	  293	  
The	  mutants	  were	  constructed	  by	  triparental	  matings	  in	  which	  the	  recipient	  received	  pTM1	  or	  pTN2.	  E.	  coli	  294	  
HB101	  (pRK600)	  was	  used	  as	  helper	  strain	  and	  E.	  coli	  CC118λpir	  as	  donor.	  295	  
A	  complement	  strain	  of	  vfrT163P	  was	  constructed	  by	  introducing	  plasmid	  pME6031	  harboring	  the	  wt	  vfr	  gene	  296	  
(pTN1)	  by	  electroporation.	  	  297	  
	  298	  
Affymetrix	  GeneChip	  299	  
Strains	  were	  grown	  aerobically	  at	  37°C	  in	  LB	  medium	  starting	  at	  OD600	  =	  0.01	  and	  harvested	  at	  OD600	  =	  0.5	  300	  
and	   OD600	   =	   0.8.	   Immediately	   after	   harvesting,	   cells	   were	   mixed	   with	   STOP	   solution	   (95%	   ethanol,	   5%	  301	  
phenol),	   pelleted	   by	   centrifugation	   and	   stored	   at	   -­‐80°C.	   Total	   RNA	   was	   extracted	   by	   RNeasy	   Mini	   Kit	  302	  
(Qiagen,	  Germany)	  and	  the	  RNase-­‐Free	  DNase	  Set	  was	  used	  for	  a	  more	  complete	  DNA	  removal.	  The	  total	  303	  
yield	  of	  RNA	  and	  A260/A280	  was	  measured	  using	  NanoDrop.	  Preparation	  of	  cDNA,	  labelling,	  hybridization	  and	  304	  
processing	  of	   the	  P.	  aeruginosa	  GeneChip	  were	  performed	  at	   the	  RH	  Microarray	  Center,	  Department	   for	  305	  
Genomic	   Medicine,	   Rigshospitalet,	   Copenhagen	   University.	   The	   raw	   CEL	   files	   were	   obtained	   using	   the	  306	  
Affymetrix	  GeneChip	  Operating	  System	  1.4	  and	  analyzed	  using	  BioConductor	  for	  the	  statistical	  software	  R.	  307	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Biolog	  Phenotype	  MicroArrayTM	  	  312	  
The	  catabolic	  performance	  of	  the	  vfr	  mutants	  and	  reference	  strain	  PAO1	  was	  tested	  on	  carbon	  and	  nitrogen	  313	  
sources	   by	   the	   Biolog	   Phenotype	  MicroArrays	   (Biolog,	   Hayward,	   CA).	   The	   Biolog	   Phenotype	  Microarrays	  314	  
were	  performed	  in	  duplicates	  according	  to	  manufacturer	  instructions	  [38,	  39].	  Briefly,	  strains	  were	  streaked	  315	  
on	  LB	  agar	  plates	  and	  incubated	  at	  37°C	  for	  24	  h.	  Cells	  were	  swabbed	  from	  the	  plates	  and	  suspended	  in	  IF-­‐0	  316	  
GN	  Base	  (inoculation	  fluid)	  at	  a	  density	  corresponding	  to	  42%	  transmittance	  in	  the	  Biolog	  turbidimeter.	  The	  317	  
cell	   suspensions	   were	   diluted	   1:6	   in	   IF-­‐0	   minimal	   medium	   containing	   Biolog	   redox	   dye	   mixture	   D	  318	  
(tetrazolium),	  and	  100	  µL	  aliquots	  were	  added	  to	  carbon	  source	  plates	  (PM1).	  Nitrogen	  plates	  (PM3)	  were	  319	  
prepared	  with	  ferric	  citrate	  and	  glucose	  supplemented	  to	  the	  inoculation	  mixture.	   In	  total	  190	  substrates	  320	  
were	  available	  on	  the	  two	  plates.	  Of	  these	  126	  were	  found	  to	  be	  informative	  by	  showing	  consistent	  growth	  321	  
between	  replicates	  and	  not	  autoinducing	  the	  color	  change	  (49	  carbon	  substrates	  and	  77	  nitrogen	  sources).	  322	  
OmniLog	  OL_FM/Kin	  1.20.02	  software	   (Biolog)	  was	  used	   to	  export	  of	   the	  OmniLog	  data	  and	   the	  average	  323	  
area	  beneath	  each	  kinetic	  curve	  was	  used	  for	  analysis.	  Further	  data	  and	  statistical	  analysis	  was	  performed	  324	  
using	  R	  version	  2.10.1	  (R	  Development	  Core	  Team	  2009).	  325	  
	  326	  
Motility	  assay	  327	  
The	  swimming	  and	  twitching	  ability	  of	  each	  mutant	  was	  measured	  on	  ABT	  plates	   (AB	  medium	  containing	  328	  
2.5	   mg/L	   thiamine)	   supplemented	   with	   0.5%	   casamino	   acids	   and	   0.5%	   glucose.	   For	   swimming	   motility,	  329	  
colonies	  grown	  overnight	  (ON)	  on	  LB	  agar	  were	  stabbed	  in	  the	  middle	  of	  the	  0.3%	  (wt/vol)	  ABT	  agar	  using	  a	  330	  
sterile	   toothpick	   and	   incubated	   24	   hours	   at	   30°C.	   For	   twitching	   motility,	   a	   colony	   of	   each	   isolate	   was	  331	  
stabbed	  though	  1.5%	  (wt/vol)	  ABT	  agar	  and	  placed	  on	  the	  bottom.	  Twitching	  motility	  was	  determined	  by	  332	  
measuring	  the	  diameters	  of	  the	  twitching	  zone	  after	  48	  hours	  of	  incubation	  at	  37°C.	  	  333	  
The	  determination	  of	  swimming	  and	  twitching	  motility	  was	  performed	  in	  triplicates	  and	  the	  motility	  zones	  334	  
were	  calculated	  relative	  to	  the	  reference	  strain	  PAO1.	  	  335	  
	  336	  
Determination	  of	  pyocyanin	  production	  	  337	  
The	  pyocyanin	  concentration	  produced	  by	  PAO1,	  TM1	  and	  vfr-­‐null	  was	  determined	  as	  previously	  described	  338	  
[40].	  Briefly,	   culture	   supernatant	  was	  mixed	  with	  0.3	   vol	  of	   chloroform.	  The	  organic	  phase	  was	   removed	  339	  
and	  acidified	  by	  addition	  of	  0.1	   vol	  0.2	  M	  HCl.	   	   The	  pink	   top	   layer	  was	   removed	  and	   its	   absorbance	  was	  340	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Skim	  milk	  protease	  assay	  345	  
The	  production	  of	  protease	  was	  determined	  by	  applying	  one	  colony	  of	  the	  isolate	  grown	  on	  LB	  ON	  to	  skim	  346	  
milk	  plates	  (LB	  agar	  with	  10%	  skim	  milk).	  The	  plates	  were	  incubated	  for	  24	  h	  at	  37°C	  and	  the	  clearing	  zones	  347	  
were	  measured.	  	  348	  
	  349	  
Iron	  depletion	  assay	  350	  
Bacteria	  grown	  ON	  in	  LB	  broth	  were	  repeatedly	  washed	  with	  0.9%	  (wt/vol)	  NaCl,	  and	  100	  μL	  of	  OD600	  were	  351	  
plated	   on	   iron-­‐depleted	   Vogel-­‐Bonner	   minimal	   medium	   agar	   (200	   mg/L	   MgSO4•7H2O,	   2	   g/L	   citric	   acid	  352	  
monohydrate,	  10	  g/L	  K2HPO4,	  3.5	  g/L	  NaNH4PO4,	  2%	  glucose)	  supplemented	  with	  2	  mM	  iron	  chelator	  2,2-­‐353	  
dipyridyl.	  Sterile	  filter	  disks	  were	  placed	  on	  top	  of	  the	  agar	  and	  8	  µL	  Fe2+	  (200	  mM	  ferrous	  sulfate)	  or	  Fe3+	  354	  
(100	  mM	  ferric	  citrate)	  and	  incubated	  at	  37°C	  for	  24h.	  	  355	  
	  356	  
Pyoverdin	  measurements	  	  357	  
Pyoverdin	   concentration	   was	   determined	   as	   previously	   described	   [41].	   Briefly,	   strains	   were	   grown	  358	  
overnight	   in	  ABT	  minimal	  medium	  containing	  0.01	  FeCl3	  plus	  0.5%	  casamino	  acids	  supplemented	  with	  50	  359	  
μM	  2,2-­‐dipyridyl	  to	  induce	  pyoverdine	  production.	  The	  supernatant	  was	  diluted	  10X	  in	  1	  M	  of	  Tris-­‐HCl	  (pH	  360	  
8)	  and	  the	  pyoverdin	  concentration	  was	  determined	  as	  OD405	  normalized	  with	  OD600.	  	  361	  
	  362	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  Figures:	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  485	  
	  486	  
Figure	  1.	  Schematic	  overview	  of	  sequence	  annotation	  of	  the	  Vfr	  protein.	  RNA	  polymerase	  interaction	  sites	  487	  
AR1	  and	  AR2	  are	   represented	   in	   red,	   cAMP	  binding	   sites	   are	   shown	   in	   green,	   and	  DNA	  binding	   sites	   are	  488	  
shown	  in	  blue.	  The	  location	  of	  the	  observed	  vfr	  mutation	  is	  marked	  in	  the	  AR1	  region	  and	  aligned	  with	  the	  489	  
E.	  coli	  CRP	  protein.	  	  490	  
	  491	  
	  492	  
Figure	  2.	  Venn	  diagram	  showing	  significantly	  (P	  <	  0.05)	  upregulated	  genes	  of	  Δvfr	  and	  the	  vfrT163P	  mutants	  493	  
compared	  to	  PAO1	  (A),	  and	  downregulated	  genes	  of	  Δvfr	  and	  the	  vfrT163P	  mutants	  compared	  to	  PAO1	  (B).	  	  494	  
	  495	  
	   18	  
	  496	  
Figure	  3.	  Motility	  diameters	  of	  PAO1	  and	  vfr	  mutants.	  A)	  Twitching	  motility.	  Significant	  reduction	  was	  497	  
observed	  between	  PAO1	  and	  all	  of	  the	  Vfr	  mutants.	  B)	  Swimming	  motility.	  All	  mutants	  showed	  significantly	  498	  
increased	  swimming	  compared	  with	  PAO1.	  	  499	  
	  500	  
	  501	  
Figure	  4.	  Iron	  acquisition	  of	  mutants.	  A)	  Growth	  zones	  of	  PAO1,	  vfr-­‐com,	  vfrT163P,	  Δvfr	  under	  iron	  limited	  502	  
conditions.	  Bacteria	  were	  spread	  on	  iron	  depleted	  VB	  plates	  and	  repleated	  with	  Fe2+	  (200	  mM)	  on	  applied	  503	  
filter	  disks.	  The	  same	  result	  was	  observed	  when	  applying	  Fe3+	  (data	  not	  shown).	  B)	  Pyoverdin	  concentration	  504	  
of	  PAO1,	  vfr-­‐com,	  the	  vfrT163P	  mutant,	  and	  Δvfr.	  Knockout	  mutant	  ΔpvdS	  of	  PAO1	  was	  used	  as	  negative	  505	  
control.	  506	  
	  507	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  508	  
Figure	  5.	  Pyocyanin	  production	  in	  mutant	  strains.	  The	  vfrT163P,	  vfr::Gm,	  and	  Δvfr	  mutants	  were	  significant	  509	  
different	  from	  PAO1,	  while	  no	  significant	  difference	  was	  observed	  between	  the	  isolates	  (Student’s	  t-­‐test,	  P	  510	  
<	  0.05).	  	  511	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  512	  
	  513	  
Figure	  6.	  Analysis	  of	  catabolic	  performance	  of	  PAO1,	  the	  vfrT163P	  mutant,	  and	  vfr::Gm	  represented	  as	  a	  514	  
heatmap.	  Significant	  differences	  in	  catabolic	  performance	  among	  PAO1,	  the	  vfrT163P	  mutant	  and	  Δvfr	  were	  515	  
observed	  for	  38	  substrates	  (student’s	  t-­‐test,	  P	  <	  0.05).	  	  516	  
	  517	  
	  518	  
Figure	  7.	  Vfr	  mutants	  show	  variant	  degree	  of	  metallic	  sheen.	  Growth	  on	  LB	  agar,	  photographed	  after	  519	  
incubation	  overnight	  at	  37°C.	  520	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TABLES:	  522	  





Gene_product_name	   Exponential	  phase	   Stationary	  phase	  
PAO1/	  	  vfrT163P	  
a	  




PAO1/Δvfr	   vfrT163P	  /Δvfr	  
PA4218	   ampP	   AmpP	   2,26	   1,16	   -­‐	   -­‐	   -­‐	   -­‐	  
PA4220	   fptB	   hypothetical	  protein	   4,56	   1,38	   -­‐3,30	   -­‐	   -­‐	   -­‐	  
PA4221	   fptA	   Fe(III)-­‐pyochelin	  outer	  membrane	  
receptor	  precursor	  
3,76	   1,23	   -­‐3,05	   -­‐	   -­‐	   -­‐	  
PA4224	   pchG	   pyochelin	  biosynthetic	  protein	  PchG	   2,03	   1,20	   -­‐1,70	   -­‐	   -­‐	   -­‐	  
PA4226	   pchE	   dihydroaeruginoic	  acid	  synthetase	   2,77	   1,20	   -­‐2,31	   -­‐	   -­‐	   -­‐	  
PA4228	   pchD	   pyochelin	  biosynthesis	  protein	  PchD	   2,20	   1,11	   -­‐1,98	   -­‐	   -­‐	   -­‐	  
PA4229	   pchC	   pyochelin	  biosynthetic	  protein	  PchC	   2,62	   1,25	   -­‐2,11	   -­‐	   -­‐	   -­‐	  
PA4230	   pchB	   salicylate	  biosynthesis	  protein	  PchB	   2,59	   -­‐	   -­‐2,14	   -­‐	   -­‐	   -­‐	  
PA3397	   fpr	   ferredoxin-­‐-­‐NADP+	  reductase	   -­‐2,10	   -­‐1,88	   -­‐	   -­‐	   -­‐	   -­‐	  
PA3476	   rhlI	   autoinducer	  synthesis	  protein	  RhlI	   -­‐2,35	   -­‐1,56	   1,51	   -­‐	   -­‐	   -­‐	  
PA3904	   	   hypothetical	  protein	   -­‐3,64	   -­‐1,75	   2,07	   -­‐	   -­‐	   -­‐	  
PA3905	   	   hypothetical	  protein	   -­‐2,01	   -­‐	   1,47	   -­‐	   -­‐	   -­‐	  
PA3907	   	   hypothetical	  protein	   -­‐2,20	   -­‐	   1,48	   -­‐	   -­‐	   -­‐	  
PA3908	   	   hypothetical	  protein	   -­‐2,04	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	  
PA4778	   cueR	   CueR	   -­‐2,02	   -­‐1,49	   1,35	   -­‐	   -­‐	   -­‐	  
PA0997	   pqsB	   PqsB	   -­‐	   2,04	   2,92	   -­‐	   -­‐	   -­‐	  
PA0411	   pilJ	   twitching	  motility	  protein	  PilJ	   -­‐1,95	   -­‐2,19	   -­‐	   -­‐	   -­‐	   -­‐	  
PA0652	   vfr	   transcriptional	  regulator	  Vfr	   -­‐1,73	   -­‐2,69	   -­‐1,55	   -­‐	   -­‐	   -­‐	  
PA3266	   capB	   cold	  acclimation	  protein	  B	   -­‐1,82	   -­‐2,13	   -­‐	   -­‐	   -­‐	   -­‐	  
PA4525	   pilA	   type	  4	  fimbrial	  precursor	  PilA	   -­‐	   -­‐2,28	   -­‐	   -­‐	   -­‐	   -­‐	  
PA5240	   trxA	   thioredoxin	   -­‐1,83	   -­‐2,20	   -­‐	   -­‐	   -­‐	   -­‐	  
PA0026	   plcB	   phospholipase	  C,	  PlcB	   -­‐2,07	   -­‐2,58	   -­‐	   -­‐	   -­‐	   -­‐	  
PA0563	   	   conserved	  hypothetical	  protein	   -­‐2,11	   -­‐2,21	   -­‐	   -­‐	   -­‐	   -­‐	  
PA2761	   	   hypothetical	  protein	   -­‐2,24	   -­‐2,36	   -­‐	   -­‐	   -­‐	   -­‐	  
PA3031	   	   hypothetical	  protein	   -­‐2,01	   -­‐2,23	   -­‐	   -­‐	   -­‐	   -­‐	  
PA3713	   spdH	   spermidine	  dehydrogenase,	  SpdH	   -­‐2,67	   -­‐2,82	   -­‐	   -­‐	   -­‐	   -­‐	  
PA4616	   	   probable	  c4-­‐dicarboxylate-­‐binding	  
protein	  
-­‐2,63	   -­‐2,83	   -­‐	   -­‐	   -­‐	   -­‐	  
PA4747	   secG	   secretion	  protein	  SecG	   -­‐2,53	   -­‐2,27	   -­‐	   -­‐	   -­‐	   -­‐	  
PA5049	   rpmE	   50S	  ribosomal	  protein	  L31	   -­‐2,25	   -­‐2,42	   -­‐	   -­‐	   -­‐	   -­‐	  
PA0996	   pqsA	   probable	  coenzyme	  A	  ligase	   -­‐	   -­‐	   2,04	   -­‐	   -­‐	   -­‐	  
PA0998	   pqsC	   PqsC	   -­‐	   -­‐	   2,92	   -­‐	   -­‐	   -­‐	  
PA0999	   pqsD	   3-­‐oxoacyl-­‐[acyl-­‐carrier-­‐protein]	  
synthase	  III	  
-­‐	   -­‐	   2,65	   -­‐	   -­‐	   -­‐	  
PA0266	   gabT	   4-­‐aminobutyrate	  aminotransferase	   -­‐	   -­‐	   -­‐	   2,60	   2,04	   -­‐1,28	  
PA0446	   	   conserved	  hypothetical	  protein	   -­‐	   -­‐	   -­‐	   3,01	   -­‐	   -­‐	  
PA3569	   mmsB	   3-­‐hydroxyisobutyrate	  dehydrogenase	   -­‐	   -­‐	   -­‐	   4,03	   -­‐	   -­‐	  
PA3570	   mmsA	   methylmalonate-­‐semialdehyde	  
dehydrogenase	  
-­‐	   -­‐	   -­‐	   4,30	   -­‐	   -­‐	  
PA1342	   	   probable	  binding	  protein	  component	  
of	  ABC	  transporter	  
-­‐	   -­‐	   -­‐	   -­‐2,44	   -­‐	   -­‐	  
PA5507	   	   hypothetical	  protein	   -­‐	   -­‐	   -­‐	   -­‐5,55	   -­‐	   -­‐	  
PA0887	   acsA	   acetyl-­‐coenzyme	  A	  synthetase	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐9,61	   -­‐	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PA5083	   	   conserved	  hypothetical	  protein	   -­‐	   -­‐	   -­‐	   -­‐	   4,88	   -­‐	  
PA5082	   	   probable	  binding	  protein	  component	  
of	  ABC	  transporter	  
-­‐	   -­‐	   -­‐	   -­‐	   5,65	   -­‐	  
(a)	   Positive	   values	   represent	   upregulation	   of	  mutant	   gene	   expression	   compared	   to	   PAO1,	  while	   negative	  524	  
values	  represent	  downregulation	  of	  mutant	  gene	  expression	  compared	  to	  PAO1.	  	  525	  
(b)	   Positive	   values	   represent	   upregulation	   in	   the	   Δvfr	   mutant	   compared	   to	   the	   vfrT163P	   mutant,	   while	  526	  
negative	  values	  represent	  downregulation	  in	  Δvfr	  compared	  to	  the	  vfrT163P	  mutant.	  The	  list	  does	  not	  include	  527	  
tRNA	  genes	  or	  intergenic	  regions.	  For	  full	  list	  see	  Table	  S1	  and	  S2.	  528	  
	  529	  
	  530	  
Table	  2:	  Bacterial	  strains	  and	  plasmids	  used	  in	  this	  study.	  531	  
Strains,	  plasmids	  or	  primers	   Relevant	  genotype	  or	  phenotype	   Source	  of	  reference	  
Strains	   	   	  
E.	  coli	   	   	  
CC118λpir	   E.coli	  CC18	  lysogenized	  with	  lambda	  pir	  phage	   [42]	  
HB101	   recA,	  thi,	  pro,	  leu,	  hsd	  RM+;	  SmR	   [43]	  
P.	  aeruginosa	   	   	  
PAO1	   Wild-­‐type	   [44]	  
vfrT163P	   PAO1	  vfr(A487T)	   This	  study	  
vfr::Gm	   PAO1	  Δvfr	  ,	  Gmr	   This	  study	  
Δvfr	   PAO1	  Δvfr	   This	  study	  
vfr-­‐com	   vfrT163P	  complemented	  in	  trans	  by	  electroporation	  with	  pTN1	   This	  study	  
ΔpvdS	   PAO1	  ΔpvdS	   [45]	  
Plasmids	   	   	  
pNJ1	   TcR,	  sacB+	  R6K	  ori,	  mobRp4,	  allelic	  replacement	  vector	  derived	  
from	  pDS132	  
[46]	  
pME6031	   TcR	   [47]	  
pTM1	   ,	  pNJ1	  with	  SacI-­‐XbaI	  fragment	  containing	  PAO1	  vfr	  (A487T)	   This	  study	  
pTN1	   ,	  pME6031	  with	  SacI-­‐XbaI	  fragment	  containing	  PAO1	  wt	  vfr	   This	  study	  
pTM4	   ,	  pNJ1	  with	  SacI-­‐XbaI	  fragment	  containing	  PAO1	  vfr	  deleted	  by	  
GmR	  cassette	  
This	  study	  
pTN2	   ,	   pNJ1	   with	   SacI-­‐PstI	   fragment	   containing	   PAO1	   vfr	   with	  
deletion	  of	  two	  base	  pairs	  resulting	  in	  a	  frame	  shift.	  
This	  study	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Supplementary	  information	  534	  
Table	  S1.	  	  535	  
https://www.dropbox.com/sh/m59pwhg91edn80z/JgZnkeRDqO	  	  536	  
	  537	  
Table	  S2.	  Gene	  expression	  changes	  in	  vfr-­‐point	  and	  vfr-­‐del	  compared	  to	  PAO1	  in	  stationary	  phase.	  538	  
Gene	   Gene_name	   Gene_product_name	   PAO1/vfrT163P	   PAO1/Δvfr	   vfrT163P/Δvfr	  
PA5507	   	   hypothetical	  protein	   -­‐5,55	   -­‐	   -­‐	  
PA1342	   	   probable	  binding	  protein	  component	  of	  ABC	  transporter	   -­‐2,44	   -­‐	   -­‐	  
PA4211	   phzB1	   probable	  phenazine	  biosynthesis	  protein	   -­‐1,80	   -­‐	   2,17	  
PA4141	   	   hypothetical	  protein	   -­‐1,70	   -­‐	   -­‐	  
PA5555	   atpG	   ATP	  synthase	  gamma	  chain	   -­‐1,70	   -­‐	   -­‐	  
PA4130	   	   probable	  sulfite	  or	  nitrite	  reductase	   -­‐1,60	   -­‐	   -­‐	  
PA4762	   grpE	   heat	  shock	  protein	  GrpE	   -­‐1,49	   -­‐	   -­‐	  
PA1902	   phzD2	   phenazine	  biosynthesis	  protein	  PhzD	   -­‐1,35	   -­‐	   -­‐	  
PA1999	   dhcA	   DhcA,	  dehydrocarnitine	  CoA	  transferase,	  subunit	  A	   -­‐1,28	   -­‐	   -­‐	  
PA3660	   yjcE	   probable	  sodium/hydrogen	  antiporter	   -­‐1,23	   -­‐	   -­‐	  
PA5295	   	   hypothetical	  protein	   -­‐1,18	   -­‐	   -­‐	  
PA4547	   pilR	   two-­‐component	  response	  regulator	  PilR	   -­‐1,17	   -­‐	   -­‐	  
PA4013	   yohK	   conserved	  hypothetical	  protein	   -­‐1,17	   -­‐1,24	   -­‐	  
PA3759	   	   probable	  aminotransferase	   -­‐1,16	   -­‐	   -­‐	  
PA0076	   tagF1	   TagF1	   -­‐1,15	   -­‐	   -­‐	  
PA3284	   	   hypothetical	  protein	   -­‐1,15	   -­‐	   -­‐	  
PA0230	   pcaB	   3-­‐carboxy-­‐cis,cis-­‐muconate	  cycloisomerase	   -­‐1,13	   -­‐	   -­‐	  
PA1209	   	   hypothetical	  protein	   -­‐1,13	   -­‐1,10	   -­‐	  
PA5486	   yhgN	   conserved	  hypothetical	  protein	   -­‐1,12	   -­‐	   -­‐	  
PA3850	   	   hypothetical	  protein	   -­‐1,12	   -­‐	   -­‐	  
PA1491	   	   probable	  transporter	   -­‐1,12	   -­‐	   -­‐	  
PA1693	   pscR	   translocation	  protein	  in	  type	  III	  secretion	   -­‐1,11	   -­‐	   -­‐	  
PA0360	   	   hypothetical	  protein	   -­‐1,11	   -­‐	   -­‐	  
PA3670	   	   hypothetical	  protein	   -­‐1,09	   -­‐	   -­‐	  
PA4953	   motB	   chemotaxis	  protein	  MotB	   -­‐1,08	   -­‐	   -­‐	  
PA1067	   	   probable	  transcriptional	  regulator	   -­‐1,08	   -­‐1,03	   -­‐	  
PA0981	   	   hypothetical	  protein	   -­‐1,07	   -­‐	   -­‐	  
PA4369	   	   hypothetical	  protein	   -­‐1,07	   -­‐	   -­‐	  
PA0415	   chpC	   probableChemotaxis	  protein	   -­‐1,06	   -­‐	   -­‐	  
PA0568	   	   hypothetical	  protein	   1,01	   -­‐	   -­‐	  
PA4533	   	   hypothetical	  protein	   1,04	   -­‐1,10	   -­‐1,14	  
PA4378	   inaA	   InaA	  protein	   1,04	   -­‐	   -­‐	  
PA1595	   	   hypothetical	  protein	   1,06	   -­‐	   -­‐	  
PA5369	   pstS	   phosphate	  ABC	  transporter,	  periplasmic	  phosphate-­‐
binding	  protein,	  PstS	  
1,06	   -­‐	   -­‐	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PA1565	   	   probable	  oxidoreductase	   1,06	   -­‐	   -­‐	  
PA2404	   	   hypothetical	  protein	   1,07	   -­‐	   -­‐	  
PA0534	   	   conserved	  hypothetical	  protein	   1,07	   -­‐	   -­‐	  
PA1182	   	   probable	  transcriptional	  regulator	   1,08	   -­‐	   -­‐	  
PA5309	   	   probable	  oxidoreductase	   1,10	   -­‐	   -­‐	  
PA1433	   	   conserved	  hypothetical	  protein	   1,10	   -­‐	   -­‐	  
PA2525	   opmB	   probable	  outer	  membrane	  protein	  precursor	   1,11	   -­‐	   -­‐	  
PA1568	   	   conserved	  hypothetical	  protein	   1,12	   -­‐	   -­‐	  
PA2584	   pgsA	   CDP-­‐diacylglycerol-­‐-­‐glycerol-­‐3-­‐phosphate	  3-­‐
phosphatidyltransferase	  
1,12	   -­‐	   -­‐1,06	  
PA1191	   	   hypothetical	  protein	   1,13	   -­‐	   -­‐	  
PA1107	   	   conserved	  hypothetical	  protein	   1,16	   -­‐	   -­‐1,16	  
PA1788	   	   hypothetical	  protein	   1,16	   -­‐	   -­‐	  
PA1919	   nrdG	   class	  III	  (anaerobic)	  ribonucleoside-­‐triphosphate	  
reductase	  activating	  protein,	  'activase',	  NrdG	  	  
1,17	   -­‐	   -­‐	  
ig_3265210_
3265847	  
NA	   NA	   1,20	   -­‐	   -­‐	  
PA3622	   rpoS	   sigma	  factor	  RpoS	   1,20	   -­‐	   -­‐	  
PA1471	   	   hypothetical	  protein	   1,26	   -­‐	   -­‐1,15	  
PA5377	   	   probable	  permease	  of	  ABC	  transporter	   1,27	   -­‐	   -­‐1,22	  
PA4015	   	   conserved	  hypothetical	  protein	   1,30	   -­‐	   -­‐	  
PA0588	   yeaG	   conserved	  hypothetical	  protein	   1,31	   -­‐	   -­‐	  
PA2562	   	   hypothetical	  protein	   1,37	   -­‐	   -­‐	  
PA5546	   	   conserved	  hypothetical	  protein	   1,37	   -­‐	   -­‐	  
PA0900	   	   hypothetical	  protein	   1,38	   -­‐	   -­‐	  
PA0129	   gabP	   gamma-­‐aminobutyrate	  permease	   1,46	   -­‐	   -­‐	  
PA5313	   paaT	   probable	  pyridoxal-­‐dependent	  aminotransferase	   1,46	   -­‐	   -­‐	  
PA4501	   opdD	   Glycine-­‐glutamate	  dipeptide	  porin	  OpdP	   1,65	   -­‐	   -­‐	  
PA0299	   spuC	   putrescine	  aminotransferase	   1,69	   -­‐	   -­‐	  
PA5178	   	   conserved	  hypothetical	  protein	   1,69	   -­‐	   -­‐	  
PA5373	   betB	   betaine	  aldehyde	  dehydrogenase	   1,72	   -­‐	   -­‐	  
PA0266	   gabT	   4-­‐aminobutyrate	  aminotransferase	   2,60	   2,04	   -­‐1,28	  
PA0446	   	   conserved	  hypothetical	  protein	   3,01	   -­‐	   -­‐	  
PA3569	   mmsB	   3-­‐hydroxyisobutyrate	  dehydrogenase	   4,03	   -­‐	   -­‐	  
PA3570	   mmsA	   methylmalonate-­‐semialdehyde	  dehydrogenase	   4,30	   -­‐	   -­‐	  
PA0887	   acsA	   acetyl-­‐coenzyme	  A	  synthetase	   -­‐	   -­‐9,61	   -­‐	  
PA5365	   phoU	   phosphate	  uptake	  regulatory	  protein	  PhoU	   -­‐	   -­‐1,20	   -­‐	  
PA5562	   spoOJ	   chromosome	  partitioning	  protein	  Spo0J	   -­‐	   -­‐1,19	   -­‐	  
PA2107	   	   hypothetical	  protein	   -­‐	   -­‐1,18	   -­‐	  
PA3267	   	   hypothetical	  protein	   -­‐	   -­‐1,16	   -­‐	  
PA0117	   	   probable	  short	  chain	  dehydrogenase	   -­‐	   -­‐1,15	   -­‐	  
PA4851	   	   hypothetical	  protein	   -­‐	   -­‐1,15	   -­‐	  
PA3841	   exoS	   exoenzyme	  S	   -­‐	   -­‐1,14	   -­‐	  
PA0629	   	   conserved	  hypothetical	  protein	   -­‐	   -­‐1,13	   -­‐	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PA3881	   	   hypothetical	  protein	   -­‐	   -­‐1,13	   -­‐	  
PA4771	   lldD	   L-­‐lactate	  dehydrogenase	   -­‐	   -­‐1,12	   -­‐	  
PA2064	   pcoB	   copper	  resistance	  protein	  B	  precursor	   -­‐	   -­‐1,12	   -­‐	  
PA3486	   	   conserved	  hypothetical	  protein	   -­‐	   -­‐1,11	   -­‐	  
PA4548	   dadA	   probable	  D-­‐amino	  acid	  oxidase	   -­‐	   -­‐1,11	   -­‐	  
PA4609	   radA	   DNA	  repair	  protein	  RadA	   -­‐	   -­‐1,11	   -­‐	  
PA3705	   wspD	   hypothetical	  protein	   -­‐	   -­‐1,10	   -­‐	  
PA1524	   xdhA	   xanthine	  dehydrogenase	   -­‐	   -­‐1,09	   -­‐	  
PA4955	   	   hypothetical	  protein	   -­‐	   -­‐1,08	   -­‐	  
PA2154	   ybhN	   conserved	  hypothetical	  protein	   -­‐	   -­‐1,08	   -­‐	  
PA4183	   	   hypothetical	  protein	   -­‐	   -­‐1,08	   -­‐	  
PA3599	   	   probable	  transcriptional	  regulator	   -­‐	   -­‐1,07	   -­‐1,07	  
PA1184	   	   probable	  transcriptional	  regulator	   -­‐	   -­‐1,07	   -­‐	  
PA3603	   dgkA	   diacylglycerol	  kinase	   -­‐	   -­‐1,06	   -­‐	  
PA1992	   ercS	   ErcS	   -­‐	   -­‐1,05	   -­‐	  
PA4581	   rtcR	   transcriptional	  regulator	  RtcR	   -­‐	   -­‐1,05	   -­‐	  
PA3067	   	   probable	  transcriptional	  regulator	   -­‐	   -­‐1,05	   -­‐	  
PA2806	   yqcD	   conserved	  hypothetical	  protein	   -­‐	   -­‐1,04	   -­‐	  
PA0951	   rbn	   probable	  ribonuclease	   -­‐	   -­‐1,04	   -­‐	  
PA4720	   trmA	   tRNA	  (uracil-­‐5-­‐)-­‐methyltransferase	   -­‐	   -­‐1,02	   -­‐	  
PA5135	   yibQ	   conserved	  hypothetical	  protein	   -­‐	   -­‐1,02	   -­‐	  
PA3217	   cyaB	   CyaB	   -­‐	   -­‐1,02	   -­‐	  
PA0385	   	   hypothetical	  protein	   -­‐	   1,02	   -­‐	  
PA3474	   yigM	   conserved	  hypothetical	  protein	   -­‐	   1,03	   -­‐	  
PA2527	   yegN	   probable	  Resistance-­‐Nodulation-­‐Cell	  Division	  (RND)	  
efflux	  transporter	  
-­‐	   1,05	   -­‐	  
PA3363	   amiR	   aliphatic	  amidase	  regulator	   -­‐	   1,06	   -­‐	  
PA2432	   bexR	   bistable	  expression	  regulator,	  BexR	   -­‐	   1,07	   -­‐	  
PA1290	   	   probable	  transcriptional	  regulator	   -­‐	   1,07	   -­‐	  
PA0916	   yliG	   conserved	  hypothetical	  protein	   -­‐	   1,07	   -­‐	  
PA0566	   	   hypothetical	  protein	   -­‐	   1,09	   -­‐	  
PA1762	   	   hypothetical	  protein	   -­‐	   1,12	   -­‐	  
PA4574	   yqhA	   conserved	  hypothetical	  protein	   -­‐	   1,13	   -­‐	  
PA0132	   oapT	   beta-­‐alanine-­‐-­‐pyruvate	  transaminase	   -­‐	   1,14	   -­‐	  
PA2550	   	   probable	  acyl-­‐CoA	  dehydrogenase	   -­‐	   1,18	   -­‐	  
PA3501	   	   hypothetical	  protein	   -­‐	   1,36	   -­‐	  
PA0745	   	   probable	  enoyl-­‐CoA	  hydratase/isomerase	   -­‐	   1,97	   -­‐	  
PA5083	   	   conserved	  hypothetical	  protein	   -­‐	   4,88	   -­‐	  
PA5082	   	   probable	  binding	  protein	  component	  of	  ABC	  transporter	   -­‐	   5,65	   -­‐	  
PA0603	   	   probable	  ATP-­‐binding	  component	  of	  ABC	  transporter	   -­‐	   -­‐	   -­‐1,40	  
PA5528	   	   hypothetical	  protein	   -­‐	   -­‐	   -­‐1,35	  
PA2014	   liuB	   methylcrotonyl-­‐CoA	  carboxylase,	  beta-­‐subunit	   -­‐	   -­‐	   -­‐1,26	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PA4500	   	   probable	  binding	  protein	  component	  of	  ABC	  transporter	   -­‐	   -­‐	   -­‐1,26	  
PA4913	   	   probable	  binding	  protein	  component	  of	  ABC	  transporter	   -­‐	   -­‐	   -­‐1,20	  
PA3919	   ylaK	   conserved	  hypothetical	  protein	   -­‐	   -­‐	   -­‐1,20	  
PA0315	   	   hypothetical	  protein	   -­‐	   -­‐	   -­‐1,20	  
PA2229	   yiiM	   conserved	  hypothetical	  protein	   -­‐	   -­‐	   -­‐1,19	  
PA3615	   	   hypothetical	  protein	   -­‐	   -­‐	   -­‐1,19	  
PA0973	   oprL	   Peptidoglycan	  associated	  lipoprotein	  OprL	  precursor	   -­‐	   -­‐	   -­‐1,19	  
PA5153	   	   amino	  acid	  
(lysine/arginine/ornithine/histidine/octopine)	  ABC	  
transporter	  periplasmic	  binding	  protein	  
-­‐	   -­‐	   -­‐1,19	  
PA4198	   	   probable	  AMP-­‐binding	  enzyme	   -­‐	   -­‐	   -­‐1,18	  
PA3264	   yocS	   probable	  transporter	   -­‐	   -­‐	   -­‐1,18	  
PA4524	   nadC	   nicotinate-­‐nucleotide	  pyrophosphorylase	   -­‐	   -­‐	   -­‐1,17	  
PA2907	   cobL	   precorrin-­‐6y-­‐dependent	  methyltransferase	  CobL	   -­‐	   -­‐	   -­‐1,17	  
PA1235	   	   probable	  transcriptional	  regulator	   -­‐	   -­‐	   -­‐1,16	  
PA5148	   yggX	   conserved	  hypothetical	  protein	   -­‐	   -­‐	   -­‐1,16	  
PA3177	   	   hypothetical	  protein	   -­‐	   -­‐	   -­‐1,15	  
PA4724	   yadB	   probable	  aminoacyl-­‐transfer	  RNA	  synthetase	  (class	  I)	   -­‐	   -­‐	   -­‐1,15	  
ig_3265210_
3265847	  
NA	   NA	   -­‐	   -­‐	   -­‐1,15	  
PA1326	   ilvA2	   threonine	  dehydratase,	  biosynthetic	   -­‐	   -­‐	   -­‐1,14	  
PA2363	   	   hypothetical	  protein	   -­‐	   -­‐	   -­‐1,14	  
PA4937	   rnr	   exoribonuclease	  RNase	  R	   -­‐	   -­‐	   -­‐1,14	  
PA2131	   cupA4	   fimbrial	  subunit	  CupA4	   -­‐	   -­‐	   -­‐1,13	  
PA2430	   	   conserved	  hypothetical	  protein	   -­‐	   -­‐	   -­‐1,12	  
PA2251	   	   hypothetical	  protein	   -­‐	   -­‐	   -­‐1,12	  
PA3208	   ydjA	   conserved	  hypothetical	  protein	   -­‐	   -­‐	   -­‐1,11	  
PA4419	   ftsL	   cell	  division	  protein	  FtsL	   -­‐	   -­‐	   -­‐1,11	  
PA4361	   	   probable	  oxidoreductase	   -­‐	   -­‐	   -­‐1,11	  
PA1934	   	   hypothetical	  protein	   -­‐	   -­‐	   -­‐1,10	  
PA3854	   	   hypothetical	  protein	   -­‐	   -­‐	   -­‐1,10	  
PA5279	   	   conserved	  hypothetical	  protein	   -­‐	   -­‐	   -­‐1,10	  
PA2661	   	   hypothetical	  protein	   -­‐	   -­‐	   -­‐1,09	  
PA2495	   oprN	   Multidrug	  efflux	  outer	  membrane	  protein	  OprN	  
precursor	  
-­‐	   -­‐	   -­‐1,09	  
PA2447	   	   probable	  transcriptional	  regulator	   -­‐	   -­‐	   -­‐1,08	  
PA3795	   	   probable	  oxidoreductase	   -­‐	   -­‐	   -­‐1,07	  
PA3239	   	   conserved	  hypothetical	  protein	   -­‐	   -­‐	   -­‐1,07	  
PA2260	   kguE	   hypothetical	  protein	   -­‐	   -­‐	   -­‐1,07	  
PA2440	   	   hypothetical	  protein	   -­‐	   -­‐	   -­‐1,07	  
PA2024	   	   probable	  ring-­‐cleaving	  dioxygenase	   -­‐	   -­‐	   -­‐1,04	  
PA1714	   exsD	   ExsD	   -­‐	   -­‐	   -­‐1,04	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PA0992	   cupC1	   fimbrial	  subunit	  CupC1	   -­‐	   -­‐	   -­‐1,03	  
PA1275	   cobD	   cobalamin	  biosynthetic	  protein	  CobD	   -­‐	   -­‐	   -­‐1,03	  
PA1563	   ygdE	   conserved	  hypothetical	  protein	   -­‐	   -­‐	   1,02	  
PA1612	   	   hypothetical	  protein	   -­‐	   -­‐	   1,03	  
PA2912	   	   probable	  ATP-­‐binding	  component	  of	  ABC	  transporter	   -­‐	   -­‐	   1,03	  
PA1669	   	   hypothetical	  protein	   -­‐	   -­‐	   1,03	  
PA1650	   	   probable	  transporter	   -­‐	   -­‐	   1,04	  
PA2065	   pcoA	   copper	  resistance	  protein	  A	  precursor	   -­‐	   -­‐	   1,05	  
ig_1554415_
1553675	  
NA	   NA	   -­‐	   -­‐	   1,06	  
PA5366	   pstB	   ATP-­‐binding	  component	  of	  ABC	  phosphate	  transporter	   -­‐	   -­‐	   1,08	  
PA5487	   	   hypothetical	  protein	   -­‐	   -­‐	   1,08	  
PA0022	   	   conserved	  hypothetical	  protein	   -­‐	   -­‐	   1,08	  
ig_2451707_
2450765	  
NA	   NA	   -­‐	   -­‐	   1,09	  
PA4782	   	   hypothetical	  protein	   -­‐	   -­‐	   1,09	  
PA4319	   	   conserved	  hypothetical	  protein	   -­‐	   -­‐	   1,09	  
PA3254	   	   probable	  ATP-­‐binding	  component	  of	  ABC	  transporter	   -­‐	   -­‐	   1,09	  
PA4368	   	   hypothetical	  protein	   -­‐	   -­‐	   1,09	  
PA1170	   	   conserved	  hypothetical	  protein	   -­‐	   -­‐	   1,10	  
PA4064	   	   probable	  ATP-­‐binding	  component	  of	  ABC	  transporter	   -­‐	   -­‐	   1,10	  
PA5072	   	   probableChemotaxis	  transducer	   -­‐	   -­‐	   1,10	  
PA4571	   	   probable	  cytochrome	  c	   -­‐	   -­‐	   1,11	  
PA5189	   	   probable	  transcriptional	  regulator	   -­‐	   -­‐	   1,12	  
PA1300	   	   probable	  sigma-­‐70	  factor,	  ECF	  subfamily	   -­‐	   -­‐	   1,13	  
PA0907	   	   hypothetical	  protein	   -­‐	   -­‐	   1,13	  
PA3381	   phnF	   probable	  transcriptional	  regulator	   -­‐	   -­‐	   1,13	  
PA3565	   	   probable	  transcriptional	  regulator	   -­‐	   -­‐	   1,14	  
PA0743	   	   probable	  3-­‐hydroxyisobutyrate	  dehydrogenase	   -­‐	   -­‐	   1,14	  
PA0365	   	   hypothetical	  protein	   -­‐	   -­‐	   1,14	  
PA3906	   	   hypothetical	  protein	   -­‐	   -­‐	   1,18	  
ig_4559649_
4560294	  
NA	   NA	   -­‐	   -­‐	   1,18	  
PA2021	   	   hypothetical	  protein	   -­‐	   -­‐	   1,22	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Abstract	  13	  
Pseudomonas	  aeruginosa	  is	  the	  leading	  course	  of	  morbidity	  and	  mortality	  of	  patients	  suffering	  from	  cystic	  14	  
fibrosis.	  During	  chronic	  infection	  bacterial	  populations	  are	  subject	  to	  complex	  processes	  of	  diversification.	  15	  
Although	   P.	   aeruginosa	   population	   diversity	   within	   infected	   individuals	   has	   been	   observed,	   our	  16	  
understanding	   on	   how	   this	   diversity	   is	   generated	   is	   very	   poor.	   Knowledge	   about	   population	   dynamics	   is	  17	  
crucial	  for	  optimal	  therapeutic	  interventions.	  	  18	  
Horizontal	  gene	  transfer	  (HGT)	  is	  an	  important	  evolutionary	  process	  by	  which	  bacteria	  rapidly	  can	  acquire	  19	  
new	  traits	  and	  adapt	  to	  very	  hostile	  environments.	  The	  evolutionary	  role	  and	  relevance	  of	  HGT	  in	  bacterial	  20	  
evolution	  within	  natural	  chronic	  infections	  remains	  poorly	  understood	  despite	  the	  huge	  interest.	  	  21	  
To	  gain	  new	   insight	   into	  the	  evolutionary	  roles	  of	  HGT	  during	  chronic	  polyclonal	   infections,	  we	  examined	  22	  
the	  population	  structure	  and	  dynamics	  of	  a	  CF	  patient	  polyclonally	   infected	  with	   two	   transmissible	  clone	  23	  
types	  of	  P.	  aeruginosa.	  	  24	  
We	  showed	  a	  complex	  population	  structure	  of	  the	  infecting	  clones	  represented	  by	  multiple	  co-­‐existing	  sub-­‐25	  
populations	  each	  with	  distinct	  phenotypic	  and	  genotypic	  signatures	  and	  identified	  an	  in	  vivo	  HGT	  of	  217	  kb	  26	  
between	  the	  two	  clones	  of	  P.	  aeruginosa	  using	  whole	  genome	  sequencing.	  The	  HGT	  was	  demonstrated	  to	  27	  
contribute	  to	  the	  observed	  diversity	  by	  generating	  novel	  strains	  with	  mosaic	  genomes	  that	  were	  found	  to	  28	  
persist	  in	  the	  CF	  airways.	  	  29	  
We	  further	  showed	  that	  the	  HGT	  resulted	  in	  altered	  intraclonal	  interactions	  by	  increasing	  the	  resistance	  to	  30	  
R5	   pyocin	   giving	   the	   recipient	   cell	   a	   selective	   advantage	   in	   bacterial	   warfare.	   The	   results	   of	   this	   study	  31	  
highlight	   the	   importance	   of	   HGT	   in	   shaping	   both	   individual	   clones	   and	   the	   population	   dynamics	   during	  32	  
chronic	  infection.	  	  33	  
	  34	  
	   	  35	  
	   3	  
Introduction	  36	  
Bacteria	  are	  able	  to	  react	  to	  environmental	  changes	  and	  rapidly	  evolve	  not	  only	  by	  acquisition	  of	  mutations	  37	  
but	   also	   by	   exchange	  of	  DNA.	  Horizontal	   gene	   transfer	   (HGT)	   has	   an	   important	   role	   in	   the	   fast	   bacterial	  38	  
evolution	   as	   HGT	  may	   give	   the	   recipient	   cell	   the	   ability	   to	   survive	   in	   very	   specific	   hostile	   environments.	  39	  
While	   fixation	   of	   beneficial	   point	  mutations	   can	   be	   considered	   a	   slow	   evolutionary	   process,	   HGT	   rapidly	  40	  
provides	   the	   recipient	   cell	   with	   new	   traits.	   However,	   not	   all	   HGT	   events	   are	   beneficial.	   In	   a	   bacterial	  41	  
population	  HGT	  might	  cause	  deleterious	  effects	  and	  thus	  these	  bacteria	  will	  be	  lost	  over	  time.	  In	  addition,	  42	  
HGT	  may	   be	   neutral	   and	   survival	  will	   depend	   on	   other	   changes.	   Some	   transfer	   events	  might	   confer	   the	  43	  
recipient	   cell	   a	   selective	   advantage	   and	   when	   this	   is	   the	   case,	   the	   cell	   lineage	   may	   be	   spread	   and	  44	  
maintained	  in	  the	  population	  [1].	  Furthermore,	  HGT	  can	  lead	  to	  intraclonal	  diversification	  by	  incorporation	  45	  
of	  new	  genes	  or	  identical	  genes	  containing	  single	  nucleotide	  polymorphisms	  (SNPs)	  and/or	  indels	  [2].	  In	  this	  46	  
way,	   HGT	   contributes	   to	   genetic	   diversity	   and	   sub-­‐speciation	   in	   bacteria	   by	   blurring	   the	   boundaries	  47	  
between	  species	  and	  generating	  novel	  strains	  with	  mosaic	  genomes	  [2,	  3].	  	  48	  
It	  is	  known	  that	  bacterial	  diversity	  provides	  the	  populations	  with	  the	  ability	  to	  survive	  and	  persist	  by	  impair	  49	  
the	  adaptive	   immune	  response	  [4].	  Furthermore,	  HGT	  has	  been	  highly	  associated	  with	  the	  widespread	  of	  50	  
antibiotic	  resistance	  and	  virulence	  genes	  [5].	  This	  rapid	  acquisition	  of	  antibiotic	  resistance	  through	  HGT	  is	  a	  51	  
huge	  challenge	  in	  clinical	  settings.	  Consequently,	  HGT	  is	  exceedingly	  relevant	  for	  the	  population	  dynamics	  52	  
in	  natural	  populations	  including	  chronic	  infections.	  Despite	  of	  the	  huge	  interest,	  very	  little	  is	  known	  about	  53	  
the	  impact	  of	  HGT	  processes	  during	  chronic	  infections	  [6]	  and	  only	  a	  few	  studies	  have	  addressed	  this	  topic	  54	  
directly	   [3,	   7].	   It	   therefore	   remains	   of	   high	   interest	   to	   understand	   the	   evolutionary	   role	   of	   HGT	   during	  55	  
chronic	  polyclonal	  infection.	  Here	  we	  sought	  to	  investigate	  the	  role	  of	  HGT	  in	  a	  chronic	  cystic	  fibrosis	  (CF)	  56	  
infection.	  	  	  57	  
The	   main	   reason	   for	   morbidity	   and	   mortality	   of	   patients	   suffering	   from	   CF	   is	   chronic	   infections	   with	  58	  
Pseudomonas	  aeruginosa.	  The	  opportunistic	  pathogen	  P.	  aeruginosa	   is	   ideal	  for	  studying	  evolution	  within	  59	  
natural	   chronic	   infections.	  Multiple	   selective	  pressures	  such	  as	  antibiotic	   treatment,	   the	   immune	  system,	  60	  
interactions	  between	  the	  infecting	  microbes,	  and	  the	  heterogeneous	  distribution	  of	  nutrients	  and	  chemical	  61	  
components	  in	  the	  spatially	  different	  CF	  environment	  shape	  the	  evolution	  and	  adaptation	  of	  P.	  aeruginosa	  62	  
[8].	  Synergistic	  interactions	  between	  the	  infecting	  microbes	  as	  well	  as	  hostile	  interactions	  such	  as	  bacterial	  63	  
warfare	  through	  production	  and	  release	  of	  strain	  specific	  pyocins	  furthermore	  contribute	  to	  the	  evolution.	  64	  
These	  different	  interactions	  may	  provide	  the	  driving	  force	  for	  acquisition	  of	  HGT.	  	  65	  
Two	  dominant	  and	  highly	  transmissible	  clones,	  DK1	  and	  DK2,	  have	  been	  found	  to	  successfully	  persist	  and	  66	  
spread	  among	  Danish	  CF	  patients.	  Recently	  55	  longitudinal	  isolates	  of	  the	  DK2	  clone	  have	  been	  sequenced	  67	  
in	  order	  to	  describe	  in	  detail	  the	  evolution	  dynamics	  of	  a	  bacterial	  pathogen	  within	  its	  human	  host	  [9].	   In	  68	  
	   4	  
this	  investigation	  a	  DK2	  isolate	  sampled	  in	  2002	  from	  patient	  P24M2	  (DK2-­‐P24M2-­‐2002)	  was	  found	  to	  have	  69	  
accumulated	   a	   high	  number	  of	   SNPs	   changes	  without	   being	   a	   hypermutators	   i.e.	   a	   strain	  with	   increased	  70	  
mutation	  rate.	  Previously	  it	  has	  been	  demonstrated	  that	  several	  hundred	  kilo-­‐bases	  can	  be	  transferred	  and	  71	  
incorporated	   by	   homologous	   recombination	   under	   laboratory	   conditions	   [2].	   However,	   to	   date	   few	  72	  
observations	  have	  been	  made	  on	  in	  vivo	  detection	  of	  HGT	  between	  chronic	  bacterial	  pathogens.	  Our	  main	  73	  
focus	  has	   therefore	  been	   to	  analyze	   the	  population	  dynamics	  of	   isolates	   from	  patient	  P24M2	   in	  order	   to	  74	  
identify	   if	   the	   observed	   changes	   were	   a	   result	   of	   acquisition	   of	   foreign	   DNA	   and	   to	   understand	   the	  75	  
evolutionary	  role	  of	  HGT	  in	  polyclonal	  infections.	  76	  
By	   locating	   the	  SNPs	  changes	  between	  DK2	   reference	  genome	  and	   the	  genome	  of	  DK2-­‐P24M2-­‐2002	  and	  77	  
mapping	  the	  epidemiology	  of	  the	  patient,	  we	  demonstrated	  that	  a	  large	  DNA	  fragment	  of	  217	  kb	  from	  the	  78	  
DK1	   clone	   was	   transferred	   to	   DK2	   creating	   a	   novel	   strain	   (referred	   to	   as	   DK1/2).	   The	   transferred	   DNA	  79	  
seemed	   to	   give	   the	   recipient	   cell	   a	   selective	   advantage	   showing	   increased	   resistance	   against	   R-­‐type	  80	  
pyocins.	   Furthermore,	   we	   demonstrated	   that	   the	   novel	   strain	   DK1/2	   persisted	   over	   time	   and	   identified	  81	  
among	  the	   transferred	  genes	  a	  potential	  contributor	   to	   low-­‐level	   tobramycin	  resistance,	  which	  may	  have	  82	  
caused	  graduated	  increase	  of	  resistance.	  	  83	  
Studying	  this	  HGT	  example	  can	  provide	  information	  about	  the	  bacterial	  responses	  to	  the	  different	  types	  of	  84	  
interactions	  acting	  on	  the	   infecting	  population,	  as	  well	  as	  providing	  the	  foundation	  for	  the	  role	  of	  HGT	   in	  85	  
shaping	  bacterial	  pathogen	  survival	  and	  adaptation	  to	  the	  human	  environment.	  	  86	  
	  87	  
Results	  88	  
Detection	  of	  recombined	  genomic	  regions	  in	  the	  DK2	  lineage	  89	  
Whole	  genome	  sequencing	  of	  isolate	  DK2-­‐P24M2-­‐2002	  revealed	  a	  high	  number	  of	  accumulated	  SNPs	  when	  90	  
comparing	   to	   the	   reference	   genome	   of	   DK2	   (CF333-­‐07a;	   Genbank	   accession	   no.	   CP003149)	   [9].	   No	  91	  
mutations	  in	  DNA	  repair	  associated	  genes	  were	  detected	  indicating	  that	  the	  high	  number	  of	  SNPs	  was	  not	  a	  92	  
result	   of	   increased	  mutation	   rate.	  Mapping	   of	   the	   SNP	   changes	   in	   isolate	   DK2-­‐P24M2-­‐2002	   to	   the	   DK2	  93	  
reference	  genome	  showed	  that	  265	  out	  of	  the	  273	  SNPs	  detected	  clustered	  in	  two	  regions,	  region	  1	  (251	  94	  
SNPs;	   81	   non-­‐synonymous	   and	   170	   synonymous)	   and	   region	   2	   (14	   SNPs;	   2	   non-­‐synonymous	   and	   12	  95	  
synonymous)	  and	  were	  therefore	  non-­‐randomly	  distributed	  in	  the	  genome	  (Figure	  1A).	  This	  indicated	  that	  96	  
the	   two	   regions	  were	   acquired	   through	  HGT	   and	   recombination.	   Region	   1	   covered	   217	   kb	   including	   the	  97	  




	   5	  
Recombined	  DNA	  originates	  from	  co-­‐existing	  clone	  types	  in	  the	  patient	  102	  
To	  identify	  a	  possible	  donor	  of	  the	  recombined	  DNA,	  we	  examined	  the	  infection	  history	  of	  patient	  P24M2	  103	  
and	  identified	  a	  total	  of	  30	  isolates	  that	  were	  sampled	  and	  stored	  from	  this	   individual	  between	  1987	  and	  104	  
2003.	   In	   this	   period	   the	   patient	  was	   attending	   the	   CF	   Centre	   at	   regular	   basis	   and	  P.	   aeruginosa	   isolates	  105	  
were	  sampled	  routinely.	  However,	  after	  2003	  samples	  were	  not	  available	  as	  the	  patient	  was	  relocated.	  	  106	  
Using	  a	  low-­‐resolution	  genotyping	  method	  (see	  Materials	  and	  methods)	  we	  determined	  that	  all	  30	  isolates	  107	  
were	   either	   DK1	   or	   DK2	   clone	   type	   (Figure	   1B).	   The	   patient	   had	   been	   chronically	   infected	  with	   the	  DK2	  108	  
clone	  type	  since	  1987,	  and	  from	  1992	  and	  onward	  co-­‐infected	  with	  the	  DK1	  clone	  type	  (Figure	  1B).	  We	  have	  109	  
previously	  observed	  polyclonal	  infections	  in	  which	  DK1	  and	  DK2	  co-­‐exist	  in	  infected	  airways	  [10].	  Since	  the	  110	  
patient	  relocated	  we	  were	  not	  able	  to	  investigate	  further	  microbial	  developments	  in	  the	  patient.	  	  111	  
To	  explore	  the	  possibility	  that	  the	  co-­‐existing	  DK1	  clone	  type	  was	  the	  source	  of	  the	  recombined	  DNA,	  we	  112	  
sequenced	  the	  genomes	  of	  two	  DK1	  isolates	  sampled	  from	  the	  patient	  in	  1992	  and	  in	  2003	  (isolates	  DK1-­‐113	  
P24M2-­‐1992a	  and	  DK1-­‐P24M2-­‐2003a)	  as	  well	  as	  a	  DK1	  isolate	  sampled	  in	  1973	  from	  an	  unrelated	  patient	  114	  
(isolate	  DK1-­‐P33F0-­‐1973).	  We	  constructed	  a	  phylogenetic	  tree	  to	  investigate	  the	  relationship	  between	  DK2-­‐115	  
P24M2-­‐2002,	  the	  reference	  DK2	  genome,	  and	  the	  three	  DK1	  isolates	  in	  relation	  to	  region	  1	  (Figure	  1C).	  We	  116	  
observed	   that	   in	   region	   1,	   DK2-­‐P24M2-­‐2002	   diverged	   from	   the	   reference	   DK2	   clone	   with	   251	   SNPs	   as	  117	  
described	   above.	   In	   contrast,	   the	   cluster	   of	   DK1	   isolates	   only	   diverged	   with	   6	   SNPs	   (Figure	   1C).	   The	  118	  
observation	  that	  the	  vast	  majority	  of	  accumulated	  SNPs	  in	  isolate	  DK2-­‐P24M2-­‐2002	  were	  highly	  related	  to	  119	  
DK1	  clone	  DNA,	  strongly	  suggest	  that	  a	  DK2	  isolate	  had	  horizontally	  acquired	  DNA	  from	  DK1	  resulting	  in	  a	  120	  
“hybrid”	  isolate,	  referred	  to	  as	  DK1/2-­‐P24M2-­‐2002.	  	  	  121	  
In	   the	   case	   of	   region	   2,	  we	   observed	   that	   DK1/2-­‐P24M2-­‐2002	   shared	   all	   14	   SNPs	  with	   the	  DK1	   isolates.	  122	  
However,	   DK1	   isolates	   possessed	   additional	   19	   different	   SNPs	   (Figure	   1D),	   suggesting	   that	   region	   2	   had	  123	  
been	  derived	  from	  a	  P.	  aeruginosa	  clone	  type	  different	  from	  DK1.	  It	  therefore	  appears	  that	  DK1/2-­‐P24M2-­‐124	  
2002	   had	   acquired	   DNA	   from	   two	   independent	   HGT	   events;	   region	   1	   was	   acquired	   from	   DK1	   and	   the	  125	  
divergent	  region	  2	  was	  derived	  from	  an	  unsampled	  and	  unknown	  clone	  type.	  In	  this	  study,	  we	  only	  focused	  126	  
on	  region	  1.	  	  127	  
With	  this	  knowledge	  we	  constructed	  a	  PCR	  strategy	  for	  detecting	  the	  transferred	  regions	  in	  other	  isolates	  128	  
from	   this	   patient	   (see	  Materials	   and	  methods).	  One	  other	  hybrid	  DK2	   strain	  with	   incorporated	  DK1	  DNA	  129	  
was	  detected	  at	   time	  point	  1997	   (DK1/2-­‐P24M2-­‐1997)	   (Figure	  1B),	   indicating	   that	   the	  horizontal	   transfer	  130	  
happened	   before	   this	   time	   point,	   and	   that	   the	   sub-­‐lineage	   has	   been	   surviving	   in	   the	   airways	   of	   the	   CF	  131	  
patient	  while	  co-­‐existing	  with	  both	  DK1	  and	  DK2	  clones.	  132	  
	  133	  
	  134	  
	   6	  
Population	  structure	  and	  dynamics	  of	  patient	  P24M2	  135	  
To	   further	   understand	   the	   population	   dynamics	   in	   P24M2	   we	  measured	   CF-­‐relevant	   phenotypes	   of	   the	  136	  
isolates	  from	  P24M2	  (Table	  S1).	  The	  phenotype	  profiling	  of	  DK2	  and	  DK1	  isolates	  showed	  that	  several	  sub-­‐137	  
populations	   existed,	   each	   with	   distinct	   functional	   signatures;	   while	   DK1	   isolates	   co-­‐existed	   as	   two	   sub-­‐138	  
populations	   (mucoid	   and	   non-­‐mucoid),	   distinct	   phenotypes	  were	   observed	   among	  DK2	   isolates	   (mucoid,	  139	  
non-­‐mucoid,	  hypermutators,	  and	  non-­‐hypermutators)	  (Table	  S1).	  Sequencing	  of	  selected	  isolates	  from	  DK2	  140	  
confirmed	  the	  co-­‐existence	  of	  distinct	  sub-­‐populations	  (Figure	  2A).	  These	  data	  combined	  revealed	  a	  highly	  141	  
diverse	   population	   structure	   of	   infecting	  P.	   aeruginosa	   in	   patient	   P24M2	   represented	   as	   co-­‐existence	   of	  142	  
different	   sub-­‐populations,	   and	   that	   this	   diversity	   was	   further	   increased	   by	   HGT	   and	   the	   emergence	   of	  143	  
DK1/2	  (Figure	  2B).	  	  144	  
	  145	  
Recombination	  does	  not	  change	  the	  gene	  inventory	  and	  results	  in	  limited	  recombinatorial	  repair	  	  146	  
Uptake	   and	   recombination	   of	   large	   regions	   of	   DNA	   could	   potentially	   introduce	   new	   genes.	   However,	  147	  
examination	  of	  the	  recombined	  region	  revealed	  that	  the	  gene	  inventory	  remained	  unchanged	  in	  region	  1.	  148	  
In	  contrast,	  we	  found	  8	  indels	  in	  region	  1	  in	  addition	  to	  the	  251	  SNP	  changes	  identified	  (Table	  S2).	  	  149	  
We	  next	  inspected	  region	  1	  for	  evidence	  of	  recombinatorial	  repair	  of	  genes	  inactivated	  by	  mutation	  in	  the	  150	  
DK2	   lineage.	   We	   therefore	   sought	   to	   identify	   SNPs	   or	   indels	   in	   DK2	   reference	   genome	   that	   were	  151	  
complemented	  by	  the	  transfer	  and	  recombination	  of	  DK1	  DNA.	  We	  found	  only	  a	  total	  of	  six	  SNPs	  (but	  no	  152	  
indels)	   in	   the	   corresponding	   region	   in	   the	   DK2	   reference	   genome	   that	   were	   complemented	   in	   DK1/2-­‐153	  
P24M2-­‐2002:	   one	   missense	   and	   three	   silent	   mutations	   in	   trkA	   (encoding	   a	   potassium	   transporter	  154	  
peripheral	   membrane	   component),	   one	   silent	   mutation	   in	   PADK2_28735	   (PA5400	   in	   PAO1),	   and	   one	  155	  
intergenic	   mutation	   between	   soxG	   and	   purU2	   (encoding	   a	   sarcosine	   oxidase	   gamma	   subunit	   and	  156	  
formyltetrahydrofolate	   deformylase,	   respectively)	   (Table	   2).	   Since	   the	   DK2	   lineages	   that	   successfully	   co-­‐157	  
existed	  in	  parallel	  with	  DK1/2	  and	  DK1	  in	  the	  patient	  (Figure	  2)	  all	  carried	  the	  mutated	  trkA	  allele	  it	  appears	  158	  
that	  ecological	  success	  of	  DK1/2	  was	  not	  dependent	  on	  repair	  by	  recombination	  of	  this	  missense	  mutation.	  	  159	  
	  160	  
The	  HGT	  changes	  the	  pyocin	  profile	  in	  DK1/2	  	  161	  
With	  the	  detection	  of	  the	  exchange	  of	  genetic	  material	  between	  DK1	  and	  DK2,	  we	  reasoned	  that	  both	  clone	  162	  
types	  colonized	  the	  same	  niche	  in	  the	  infected	  airways.	  Since	  niche	  establishment	  and	  protection	  in	  mixed	  163	  
populations	   is	  presumed	   to	  be	   influenced	  by	   strain-­‐specific	  production	  of	  bacteriocins	   such	  as	  R-­‐pyocins,	  164	  
we	  examined	  pyocin	  production	  in	  the	  isolates	  as	  well	  as	  their	  ability	  to	  grow	  in	  the	  presence	  of	  different	  R-­‐165	  
type	  pyocins.	  R-­‐pyocins	  kills	  rapidly	  and	  specifically	  closely	  related	  bacteria	  by	  binding	  to	  sugar	  residues	  of	  166	  
the	  LPS	  core	  [11-­‐13]	  resulting	  in	  cell	  death	  through	  depolarization	  of	  the	  cytoplasmic	  membrane	  [14].	  Five	  167	  
	   7	  
different	  R-­‐pyocins	  (R1-­‐R5)	  has	  been	  described	  based	  on	  their	  killing	  abilities	  and	  the	  amino	  acid	  sequence	  168	  
of	  the	  tail	  fiber	  protein	  Prf15	  (PA0621)	  [15]. 169	  
R-­‐pyocins	  were	   isolated	   from	  DK1,	  DK2,	   and	  DK1/2	   strains	  and	   tested	  on	  a	   sensitive	   control	   strain	   (DK2-­‐170	  
CF510-­‐2006)	  to	  determine	  if	  the	  clinical	  strains	  were	  producing	  R-­‐pyocins	  (Figure	  S1).	  While	  R1-­‐R5	  pyocins	  171	  
type	  killed	  WTB,	  it	  was	  observed	  that	  neither	  DK1,	  DK2,	  nor	  DK1/2	  produced	  pyocins	  that	  were	  able	  to	  kill	  172	  
WTB.	  In	  support	  of	  this	  observation,	  we	  could	  not	  detect	  the	  tail	  fiber	  protein	  gene	  prf15	  of	  R1-­‐R5	  pyocins	  173	  
in	  the	  genomes	  of	  either	  of	  the	  isolates.	  	  	  174	  
Next,	   the	   susceptibility	  of	   the	   clinical	   isolates	  was	  examined	  against	   the	   five	  R-­‐type	  pyocins	   (Figure	  3).	   It	  175	  
was	  observed	  that	  all	  DK1	  clones	  were	  resistant	  to	  R3	  and	  R5	  where	  all	  DK2	  isolates	  were	  susceptible	  to	  R5.	  176	  
Remarkably,	   the	   DK1/2	   was	   significantly	   more	   resistant	   to	   R5-­‐type	   pyocins	   compared	   to	   DK2	   as	  177	  
approximately	  five	  fold	  more	  of	  DK1/2	  was	  able	  to	  survive	  in	  the	  R5	  spot	  zone	  (Figure	  3).	  This	  suggests	  that	  178	  
the	  transferred	  DNA	  from	  DK1	  had	  changed	  the	  DK1/2	  pyocin	  profile	  making	   it	  more	  resistant	  to	  R5-­‐type	  179	  
pyocins.	  	  180	  
	  181	  
Mutation	  in	  wbpZ	  affects	  DK1	  LPS	  production.	  182	  
It	  has	  been	  demonstrated	  that	  LPS	  has	  an	  important	  role	  as	  both	  a	  protective	  shield	  and	  receptor	  site	  for	  R-­‐183	  
pyocins	   [11,	   13].	  We	   therefore	   theorized	   that	   the	   increased	   resistance	   in	  DK1/2	  was	   due	   to	   distinct	   LPS	  184	  
profiles	  and	  reduced	  availability	  of	  R-­‐pyocin	  receptors.	  Hence	  we	  sought	  to	  identify	  transferred	  mutations	  185	  
in	  genes	  involved	  in	  LPS	  synthesis	  in	  order	  to	  suggest	  a	  molecular	  mechanism	  for	  the	  observed	  phenotype.	  186	  
Only	   one	   candidate	   gene	   (wbpZ)	   with	   a	   known	   role	   in	   LPS	   synthesis	   could	   be	   identified	   among	   the	  187	  
transferred	  alleles.	  The	  wbpZ	  gene	  encodes	  a	  glycosyltransferase	  involved	  in	  A-­‐band	  LPS	  biosynthesis	  [16].	  188	  
To	  test	  if	  the	  mutation	  in	  wbpZ	  caused	  increased	  pyocin	  resistance,	  the	  specific	  wbpZ	  allele	  was	  introduced	  189	  
in	   wild	   type	   PAO1,	   isolate	   DK1-­‐P24M2-­‐2003a,	   and	   DK2-­‐P24M2-­‐2003a	   isolate	   by	   allelic	   replacement.	  190	  
Furthermore,	  the	  point	  mutation	  was	  restored	  to	  wild	  type	  in	  the	  DK1/2	  isolates.	  The	  isogenic	  wbpZ	  strains	  191	  
were	   then	  evaluated	   for	   altered	  pyocin	   resistance.	   Surprisingly,	  we	  observed	   that	   the	  mutants	  displayed	  192	  
unchanged	  sensitivity	  compared	  to	  their	  parental	  strain	  (data	  not	  shown),	  rejecting	  the	  hypothesis	  that	  the	  193	  
mutation	   in	  wbpZ	   caused	  an	   increase	   in	  pyocin	  resistance.	  Consequently,	  we	  examined	  the	  LPS	  profile	  of	  194	  
DK1,	  DK2,	  and	  DK1/2	   in	  order	  to	  determine	   if	  the	  resistance	  was	  caused	  by	  distinct	  LPS	  profiles.	  Western	  195	  
immunoblotting	  using	  the	  A-­‐band	  specific	  MAb	  (N1F10)	  showed	  a	  clear	  difference	  between	  DK1	  and	  DK2	  196	  
isolates.	   It	  was	  observed	   that	  DK1	   isolates	   expressed	  A-­‐band	   LPS,	  while	  DK2	   seemed	   to	  have	   lost	   the	  A-­‐197	  
band	  as	  no	  binding	  was	  observed	   (Figure	  4B).	   Introducing	   the	  wbpZ	   point	  mutation	   in	  a	  DK1	   isolate	  and	  198	  
reference	   strain	   PAO1	   caused	   loss	   of	   A-­‐band	   as	   was	   observed	   for	   the	   isolate	   DK1-­‐P24M2-­‐2003awbpZ	  199	  
(isogenic	   mutant	   of	   DK1-­‐P24M2-­‐2003a)	   and	   PAO1wbpZ	   mutant.	   This	   demonstrated	   that	   wbpZ	   point	  200	  
	   8	  
mutation	   caused	   loss	   of	   A-­‐band	   LPS	   in	   PAO1	   and	   DK1.	   The	   production	   of	   A-­‐band	   was	   restored	   by	  201	  
complementation	  in	  trans	  using	  plasmid	  pHERD-­‐wbpZ	  in	  wbpZ	  mutant	  strains	  (Figure	  3C).	  In	  addition,	  it	  was	  202	  
observed	   that	   A-­‐band	   production	   could	   not	   be	   restored	   by	   insertion	   of	   wild	   type	  wbpZ	   in	   DK2	   isolates,	  203	  
indicating	  that	  DK2	  may	  have	  other	  mutations	  causing	  loss	  of	  A-­‐band.	  Both	  DK1	  and	  DK2	  isolates	  had	  lost	  B-­‐204	  
bands	  (data	  not	  shown).	  Based	  on	  this	  it	  could	  be	  reasoned	  that	  DK1	  isolates	  produced	  A-­‐band	  LPS,	  while	  205	  
DK2	  and	  DK1/2	  had	   lost	  A-­‐band	  production.	  Subsequently,	   the	  wbpZ	  mutation	  only	  had	  an	  effect	   in	  DK1	  206	  
clones	  and	  was	  not	  the	  cause	  of	  increased	  pyocin	  resistance.	  Interestingly,	  the	  resistance	  phenotype	  must	  207	  
be	  caused	  by	  a	  genetic	  determinant	  unrelated	  to	  wbpZ.	  In	  relation	  to	  this,	  it	  was	  observed	  that	  12%	  of	  the	  208	  
transferred	  alleles	  (31	  SNPs	  and	  indels)	  were	  encoding	  membrane	  protein	  (Table	  S2).	  Of	  the	  31	  SNPs	  and	  209	  
indels,	   12	   candidates	   besides	   wbpZ	   were	   non-­‐synonymous	   and	   may	   therefore	   represent	   possible	  210	  
candidates.	  211	  
	  212	  
Low-­‐level	  resistance.	  	  213	  
Besides	  functioning	  as	  receptors	  for	  pyocins,	  LPS	  also	  mediates	  direct	   interaction	  with	  antibiotics.	  Several	  214	  
studies	   have	   shown	   that	   alteration	   of	   LPS	   structure	   confers	   increased	   permeability	   resistance	   to	  215	  
aminoglycosides	   [17-­‐19].	   A	   knockout	   mutant	   of	   wbpZ	   has	   previously	   been	   described	   to	   affect	   the	  216	  
tobramycin	  resistance	  against	  tobramycin	  making	  it	  more	  resistant	  [19].	  Tobramycin	  competitively	  binds	  to	  217	  
LPS	   causing	   increased	   membrane	   permeability	   by	   disrupting	   the	   integrity	   of	   the	   outer	   membrane	   [19].	  218	  
Therefore	  we	  performed	  tobramycin	  killing	  curves	  mimicking	  MIC	  conditions	  (Figure	  5)	  in	  order	  to	  examine	  219	  
if	  the	  mutation	  in	  wbpZ	  gave	  rise	  to	  low	  level	  resistance.	  	  220	  
Interestingly,	  the	  PAO1wbpZ	  mutant	  showed	  significant	  reduction	  of	  killing	  during	  60	  minutes	  by	  1	  µg/mL	  221	  
tobramycin	   compared	   to	   the	   wild	   type	   (P	   <	   0.05),	   demonstrating	   that	   the	   mutation	   gave	   low-­‐level	  222	  
resistance	   (Figure	  5).	   This	   suggests	   that	   the	   transfer	  between	  DK1	  and	  DK2	  not	  only	   changed	   the	  pyocin	  223	  
sensitivity,	  but	  may	  also	  have	  an	   impact	  on	  antibiotic	  resistance.	  However,	  this	   low	  level	  resistance	  could	  224	  
not	  be	  confirmed	  when	  the	  wbpZ	  mutation	  was	  inserted	  in	  a	  DK1	  or	  DK2	  background	  as	  the	  clinical	  isolates	  225	  
already	  had	  increased	  resistance	  against	  tobramycin	  (Table	  S3).	  226	  
	  227	  
Discussion	  228	  
Our	   analysis	   of	   genome	   sequences	   from	   several	   DK1	   and	   DK2	   isolates	   provided	   evidence	   for	   two	  229	  
independent	   events	   of	   uptake	   and	   recombination	   of	   P.	   aeruginosa	   DNA	   into	   the	   chromosome	   of	   a	   DK2	  230	  
isolate.	  One	  of	  the	  recombined	  regions	  (region	  1)	  was	  217	  kb	  in	  size	  and	  contained	  251	  polymorphisms	  of	  231	  
which	  245	  were	  also	  found	  in	  DK1	  DNA.	  Since	  DK1	  and	  DK2	  isolates	  co-­‐existed	  in	  the	  patient,	  we	  conclude	  232	  
that	   region	   1	   was	   transferred	   from	   DK1	   to	   DK2	   generating	   a	   hybrid	   strain	   called	   DK1/2.	   The	   six	   SNPs	  233	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difference	  between	  region	  1	  of	  DK1/2	  and	  the	  analysed	  DK1	  isolates	  suggested	  that	  the	  specific	  DK1	  donor	  234	  
isolate	  was	  not	  among	  the	  sequenced	  DK1	  isolates.	  We	  were	  unable	  to	  identify	  the	  original	  DK1	  donor	  by	  235	  
PCR	  screening	  of	  the	  remaining	  DK1	  from	  P24M2,	  indicating	  that	  the	  original	  DK1	  donor	  may	  not	  have	  been	  236	  
sampled	   and	   stored.	   Alternatively,	   6	   SNPs	   accumulated	   in	   the	   region	   in	   DK1/2	   after	   the	   recombination	  237	  
event.	  The	  imported	  DNA	  in	  relation	  to	  the	  smaller	  region	  2	  was	  not	  related	  to	  DK1,	  and	  we	  suggest	  that	  238	  
this	  region	  was	  acquired	  independently	  from	  a	  donor	  clonally	  unrelated	  to	  DK1.	  	  239	  
This	   is	   a	   remarkable	   observation	   given	   the	   low	   frequency	  of	   previously	   detected	  HGT	   in	   clinical	   isolates,	  240	  
indicating	  either	  that	  specific	  environment	  conditions	  existed	  in	  this	  patients	  which	  promoted	  interactions	  241	  
and	  consequently	   transfer	  of	  genetic	  material	  between	   isolates,	  or	   that	   the	   increasing	  numbers	  of	  whole	  242	  
genome	  sequencing	  now	  makes	  it	  possible	  to	  detect	  such	  events.	  	  243	  
Different	   processes	   exist	   to	   transfer	  DNA	   from	  one	  organism	   to	   another.	   These	   includes	   transformation,	  244	  
where	  naked	  DNA	   is	   taken	  up	  and	   incorporated	   into	  the	  chromosome;	  conjugation	  that	   is	  mediated	  by	  a	  245	  
cell-­‐to-­‐cell	  contact	  and	  a	  pore	  where	  DNA	  can	  pass;	  and	  transduction,	  where	  a	  bacteriophage	  acts	  as	  the	  246	  
vector	  for	  injection	  of	  DNA	  into	  the	  recipient	  cell	  [1].	  It	  has	  been	  well	  documented	  that	  P.	  aeruginosa	  uses	  247	  
both	   transduction	   and	   conjugation	   for	   acquiring	   DNA.	   However,	   we	   did	   not	   find	   genes	   related	   to	  248	  
mobilization	  and	  transfer	  of	  DNA	  or	  phage	  related	  genes	  within	  a	  10	  kb	  range	  of	  the	  predicted	  boundaries	  249	  
of	  the	  horizontally	  transferred	  regions.	  In	  contrast,	  P.	  aeruginosa	  are	  not	  known	  to	  be	  naturally	  competent	  250	  
and	   no	   published	   reports	   of	  P.	   aeruginosa	   natural	   transformation	   is	   to	   data	   available.	  Nevertheless,	   the	  251	  
data	   presented	   here	   indicate	   that	   transformation	   was	   the	   most	   likely	   mechanism	   to	   account	   for	   the	  252	  
detected	   transfer	   of	   DNA.	   Furthermore,	   a	   number	   of	   studies	   have	   demonstrated	   examples	   of	  253	  
recombination	  between	  different	  P.	   aeruginosa	   genotypes	   in	   environmental	   and	   clinical	   isolates	   [20-­‐22].	  254	  
This	  indicates	  that	  under	  certain	  conditions	  could	  promote	  natural	  competence	  and	  DNA	  transfer	  through	  255	  
transformation.	  256	  
Bacterial	  infection	  in	  CF	  is	  often	  associated	  with	  biofilm	  growth	  mode,	  where	  multiple	  species	  may	  coexist	  257	  
and	   interact	   within	   the	   biofilm	   [23,	   24].	   Biofilm	   cells	   are	   embedded	   in	   a	   matrix	   and	   one	   of	   the	   major	  258	  
components	   of	   the	  biofilm	  matrix	   is	   extracellular	  DNA	   released	  by	   the	  bacteria	   [25].	   Transformation	  has	  259	  
furthermore	   been	   demonstrated	   to	   be	   104-­‐fold	   higher	   in	   biofilms	   than	   in	   planktonic	   cells	   [26].	   It	   is	  260	  
therefore	   likely	   that	   the	   transfer	   of	  DNA	   in	   CF	   infections	   occurred	   in	   a	   biofilm	  where	   the	   two	  dominant	  261	  
clones	   DK1	   and	   DK2	   were	   coexisting.	   Another	   possible	   mechanism	   involves	   the	   release	   and	   uptake	   of	  262	  
membrane	   vesicles.	   During	   growth	   P.	   aeruginosa	   as	   many	   gram-­‐negative	   bacteria	   release	   membrane	  263	  
vesicles	   into	   the	   environment.	   These	   vesicles	   have	   been	   described	   to	   contain	   virulence	   factors	   from	   the	  264	  
periplasm	   [27].	   Furthermore,	   it	   has	   been	   reported	   that	   these	   vesicles	   also	   contain	   large	   fragments	   of	  265	  
chromosomal	  DNA	  [28,	  29].	  Hence,	  it	  has	  been	  indicated	  that	  the	  vesicles	  may	  be	  involved	  in	  the	  transfer	  of	  266	  
	   10	  
genetic	  material	  among	  similar	  bacterial	  species	  [30].	  Transfer	  mediated	  by	  vesicles	  allows	  protection	  from	  267	  
DNases	   [30]	   and	   enhance	   the	   efficiency	   of	   DNA	   delivery	   to	   a	   recipient	   cell	   as	   they	   fuse	   directly	   to	   the	  268	  
membrane	  and	  unload	  the	  content.	  	  269	  
The	   DK1/2	   clone	  was	   found	   to	   be	  maintained	   during	   chronic	   CF	   infection	   (i.e.	   the	   horizontally	   acquired	  270	  
region	  could	  be	  traced	  back	  to	  an	   isolate	  sampled	  from	  1997,	  and	  detected	  again	   in	  2002).	  This	  suggests	  271	  
that	  the	  recipient	  cell	  may	  have	  acquired	  genes	  or	  mutations	  that	  conferred	  a	  selective	  advantage	  or	  are	  272	  
neutral	  depending	  on	  the	  conditions.	  	  273	  
HGT	  is	  associated	  with	  the	  widespread	  distribution	  of	  antibiotic	  resistance	  genes,	  biodegradative	  pathways	  274	  
gene	   cluster,	   and	   pathogenicity	   determinants	   [5].	   Likewise	   we	   observed	   that	   the	   hybrid	   strain	   had	   an	  275	  
increase	   resistance	  against	   the	  bacteriocin	  R5	  pyocin.	   To	  our	   knowledge,	  pyocin	   resistance	  has	  not	  been	  276	  
described	  to	  be	  acquired	   through	  HGT.	  The	   increase	   in	  R5	  resistance	  most	   likely	  would	  be	  due	  to	   loss	  or	  277	  
modification	  of	  surface	  receptors	  that	  would	  reduce	  R5	  binding	  and	  killing	  of	  the	  cell.	  	  278	  
It	  has	  been	  demonstrated	  that	  sugar	  residues	  of	  the	  LPS	  core	  function	  as	  receptors	  for	  R-­‐pyocins	  [11,	  31]	  279	  
although	  alternative	  receptor	  sites	  might	  also	  exist.	  Köhler	  and	  colleagues	  identified	  two	  sugar	  residues	  in	  280	  
the	  outer	  core	  that	  appeared	  to	  be	   involved	   in	  R5	  pyocin	  recognition	  [11].	  Furthermore,	  an	  algC	  mutant,	  281	  
deficient	   in	   synthesizing	  D-­‐Glc	   of	   the	  outer	  membrane	  was	   found	   to	  be	   resistant	   to	  R5	  pyocin	   [11].	   This	  282	  
indicates	  that	  also	  mutations	  in	  genes	  involved	  in	  synthesis	  of	  the	  sugar	  residues	  of	  the	  outer	  core	  of	  LPS	  283	  
may	   change	   the	   sensitivity	   to	   pyocins.	   However,	   none	   of	   the	   enzymes	   involved	   in	   D-­‐Glc	   synthesis	   were	  284	  
found	  to	  be	  mutated	  in	  the	  DK1/2	  isolates.	  Instead,	  we	  identified	  wbpZ,	  encoding	  a	  glycosyltransferase	  as	  285	  
the	  only	  gene	  involved	  in	  LPS	  synthesis	  that	  was	  changed,	  which	  made	  it	  a	  possible	  candidate	  for	  R5	  pyocin	  286	  
resistance.	  	  	  	  287	  
The	  mutation	  did	  indeed	  cause	  loss	  of	  A-­‐band	  LPS	  in	  a	  PAO1	  and	  DK1	  background,	  however,	  it	  did	  not	  seem	  288	  
to	  have	  an	  effect	  in	  DK2	  as	  DK2	  clones	  had	  lost	  A-­‐band	  before	  introduction	  of	  the	  mutation.	  Furthermore,	  289	  
wbpZ	  mutants	  showed	  identical	  pyocin	  sensitivity	  profiles	  as	  parent	  strains,	  indicating	  that	  the	  increase	  in	  290	  
pyocin	   resistance	  was	   not	   a	   result	   of	   the	  mutation	   in	  wbpZ.	   Interestingly,	   this	   observation	   suggests	   that	  291	  
other	   genetic	  determinants	   caused	   the	   increase	   in	  R5	  pyocin	   resistance.	   From	   the	   identified	   SNPs	   in	   the	  292	  
transferred	   region	   we	   observed	   that	   several	   membrane	   proteins	   were	   mutated.	   It	   is	   possible	   that	   the	  293	  
observed	  change	  in	  resistance	  may	  be	  a	  result	  of	  modified	  cell	  surface	  components	  working	  as	  alternative	  294	  
R5	  pyocin	  receptors.	  Another	  possibility	  could	  be	  that	  the	  increased	  resistance	  in	  DK1/2	  isolates	  was	  due	  to	  295	  
the	   combination	   of	   several	   mutations.	   As	   DK2	   isolates	   had	   lost	   A-­‐band	   production,	   the	   combination	   of	  296	  
multiple	  mutations	  might	  account	  for	  the	  increase	  pyocin	  resistance.	  	  297	  
Although	  the	  mutation	  in	  wbpZ	  did	  not	  cause	  pyocin	  resistance	  in	  clinical	  isolates,	  we	  did	  observe	  an	  effect	  298	  
on	  LPS	  in	  DK1	  clones,	  suggesting	  that	  the	  mutation	  was	  disrupting	  protein	  function.	  Modifying	  cell	  surface	  299	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component	  in	  particular	  LPS,	  which	  plays	  an	  important	  role	  for	  directly	  interaction	  with	  host	  cell	  receptors	  300	  
and	   antibiotics	   [32],	   has	   also	   been	   illustrated	   to	   affect	   antibiotic	   resistance	   by	   decreasing	   the	  301	  
aminoglycosides	  passage	  across	  the	  outer	  membrane	  [18].	  Likewise,	  we	  confirmed	  that	  the	  mutation	  gave	  302	  
low-­‐level	  tobramycin	  resistance	  in	  a	  PAO1	  background	  but	  was	  not	  detectable	  in	  DK1	  and	  DK2	  backgrounds	  303	  
as	  the	  clinical	  isolates	  already	  showed	  increase	  in	  antibiotic	  resistance.	  	  304	  
It	  is	  not	  known	  if	  the	  observed	  HGT	  was	  a	  random	  event	  or	  if	  the	  selective	  pressures	  acting	  on	  the	  bacterial	  305	  
population	  during	  colonization	  and	  adaptation	  to	  the	  CF	  environment	  triggered	  the	  transfer.	  The	  presented	  306	  
data	  here	  suggested	  that	  the	  HGT	  might	  provide	  selective	  advantages	  relevant	  in	  the	  CF	  environment.	  The	  307	  
transfer	  and	  recombination	  delivered	  mutations	  to	  the	  hybrid	  DK1/2	  genotype	  that	  increased	  its	  resistance	  308	  
to	  strain-­‐specific	  antibiotics	  (R5	  pyocin)	  and	  protection	  against	  invading,	  R5	  producing	  P.	  aeruginosa	  strains.	  309	  
In	  addition,	   the	  recombination	  provided	  a	  mutation	  that	  potentially	   resulted	   in	   increased	  drug	  resistance	  310	  
(tobramycin).	   Interestingly,	  the	  patient	  was	  treated	  with	  tobramycin	  both	  by	  inhalation	  and	  intravenously	  311	  
at	  the	  time	  of	  the	  first	  detection	  of	  the	  hybrid	  strain	  DK1/2.	  	  	  312	  
The	   HGT	   may	   not	   only	   have	   an	   impact	   on	   the	   genome	   of	   the	   recipient	   cell,	   but	   also	   influence	   the	  313	  
population	   dynamics.	   As	   HGT	   blurs	   the	   boundaries	   of	   species	   by	   creating	   mixed	   genomes,	   it	   has	   been	  314	  
suggested	   that	  HGT	   is	  contributing	   to	  bacterial	  persistence	  by	  generating	  a	  more	  diverse	  population	   (the	  315	  
distributed	  genome	  hypothesis	  [33]).	  Likewise,	  we	  observed	  that	  the	  HGT	  contributed	  to	  genetic	  diversity	  316	  
and	  phenotypic	  variation	  in	  the	  infecting	  bacterial	  population	  as	  illustrated	  in	  the	  proposed	  model	  in	  Figure	  317	  
5.	  This	  complex	  and	  highly	  dynamic	  population	  structure	  may	  be	  a	  way	  to	  cope	  with	  the	  adaptive	  immunity	  318	  
and	  antibiotic	  therapy	  creating	  a	  population	  with	  high	  diversity	  that	  provides	  a	  genetic	  reservoir	  to	  acquire	  319	  
antibiotic	   resistance	  mutations,	   or	   other	   virulence	   trait.	   Therefore	  HGT	   and	   the	   generated	   diversity	  may	  320	  
have	  contributed	  to	  the	  persistence	  of	  P.	  aeruginosa	  in	  patient	  P24M2.	  	  321	  
In	  conclusion	  we	  observed	  a	  HGT	  between	  to	  dominant	  clones	  of	  P.	  aeruginosa	  infecting	  a	  CF	  patient.	  The	  322	  
HGT	   seemed	   to	   generate	  a	  more	  diverse	  population	  and	   changed	   the	  pyocin	  profile	  of	   the	   recipient	   cell	  323	  
giving	  the	  recipient	  cell	  a	  selective	  advantage.	  This	  study	  adds	  to	  the	  increasing	  realization	  of	  a	  complex	  and	  324	  
dynamic	  P.	  aeruginosa	  population	  structure	  in	  chronic	  CF	  airway	  infections.	  	  325	  
	  326	  
Material	  and	  methods	  327	  
Bacterial	  strains	  and	  plasmids	  	  328	  
The	  bacterial	  strains	  and	  plasmids	  used	  in	  this	  study	  are	  represented	  in	  Table	  2.	  All	  strains	  were	  grown	  in	  329	  
Luria	   Bertani	   (LB)	   broth	   unless	   otherwise	   stated.	   For	   plasmid	   maintenance	   in	   E.	   coli,	   the	   medium	   was	  330	  
supplemented	  with	  8	  μg/mL	  tetracycline	  (Tc).	  For	  marker	  selection	  in	  P.	  aeruginosa	  PAO1,	  50	  μg/mL	  Tc	  was	  331	  
used.	   332	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  333	  
Construction	  of	  mutants	  334	  
The	  wbpZ	  mutant	  was	  constructed	  by	  insertion	  of	  wbpZ(C896T)	  or	  wild	  type	  wbpZ	  by	  allelic	  replacement.	  335	  
Briefly,	  the	  wbpZ	  gene	  was	  amplified	  from	  DK1/2-­‐P24M2-­‐2002	  or	  PAO1	  using	  wbpZ-­‐fw-­‐SacI	  and	  wbpZ-­‐rev-­‐336	  
XbaI	  (See	  Table	  S4	  for	  primers).	  The	  fragment	  was	  digested	  with	  SacI	  and	  XbaI	  and	  ligated	  onto	  the	  plasmid	  337	  
pNJ1	  creating	  pTM2	  or	  pTM5	  and	  transformed	  into	  E.	  coli	  CC118λpir	  by	  standard	  protocols	  [34].	  338	  
The	  mutants	  were	  constructed	  by	  triparental	  matings	  in	  which	  the	  recipient	  received	  pTM2	  or	  pTM5.	  E.	  coli	  339	  
HB101	  (pRK600)	  was	  used	  as	  helper	  strain	  and	  E.	  coli	  CC118λpir	  as	  donor.	  340	  
PAO1wbpZ	  was	  complemented	  by	  electroporation	  with	  plasmid	  pHERD20T	  containing	  the	  wbpZ	  wild	  type	  341	  
gene	  (pYHJL31)	  by	  the	  method	  described	  by	  Choi	  et	  al.	  [35].	  The	  plasmid	  pYHJL31	  containing	  WT	  wbpZ	  was	  342	  
a	  kind	  gift	  from	  Hao	  et	  al.	  [36].	  343	  
	  344	  
CF	  patient	  and	  clinical	  isolates	  345	  
The	  focus	  of	  this	  study	  was	  on	  clinical	  isolates	  of	  P.	  aeruginosa	  from	  patient	  P24M2	  of	  genotype	  DK1	  and	  346	  
DK2.	  The	  patient	  was	  attending	  the	  Danish	  CF	  Centre	  at	  Rigshospitalet	   in	  Copenhagen	  from	  1987	  to	  2003	  347	  
from	  which	  30	  P.	  aeruginosa	  isolates	  were	  collected.	  Samples	  after	  2003	  were	  not	  available	  as	  the	  patient	  348	  
moved	  hospital.	  	  349	  
The	   clinical	   isolates	   and	   time	   of	   isolation	   used	   in	   this	   study	   can	   be	   observed	   in	   Table	   S2	   together	   with	  350	  
relevant	   phenotypes.	   All	   the	   clinical	   isolate	   were	   genotyped	   in	   order	   to	   determine	   which	   clones	   were	  351	  
present	   during	   the	   infection.	   Genotyping	   was	   done	   as	   previous	   described	   [10].	   Furthermore	   selected	  352	  
isolates	   (DK2-­‐P24M2-­‐1987,	   DK2-­‐P24M2-­‐1994,	   DK2-­‐P24M2-­‐2002a,	   DK2-­‐P24M2-­‐2003a,	   DK1-­‐P24M2-­‐1992a,	  353	  
DK1-­‐P24M2-­‐2003a,	  DK1/2-­‐P24M2-­‐1997,	  DK1/2-­‐P24M2-­‐2002,	  DK2-­‐P24M2-­‐2012)	  were	  genome	  sequenced	  354	  
in	  order	   to	  examine	  the	  evolutionary	  dynamic	  of	   this	  patient.	  The	  genome	  sequencing	  was	  performed	  as	  355	  
previously	   described	   [9].	   Mutation	   detection,	   analysis	   and	   construction	   of	   the	   phylogenetic	   tree	   were	  356	  
performed	  as	  previously	  described	  [37].	  357	  
	  358	  
Colony	  morphology	  and	  doubling	  time	  359	  
Isolates	  were	  plated	  on	  PIA	  agar	  and	  colony	  morphology	  was	  inspected	  after	  24	  h	  of	  growth	  at	  37°C	  using	  a	  360	  
Zeiss	  Axioplan	  2	  microscope	  with	  a	  2.5/0.075×	  neofluar	  plan	  objective.	  	  361	  
The	  doubling	  time	  was	  measured	   in	  LB	  broth.	  Briefly,	  50	  mL	  LB	   in	  250	  mL	  shaking	  flask	  with	  baffles	  were	  362	  
inoculating	  an	  OD600nm	  of	  0.01.	  The	  flask	  was	  incubated	  at	  37°C	  with	  shaking	  at	  240	  rpm	  in	  a	  New	  Brunswick	  363	  
Scientific	   incubator.	   Growth	   rates	   were	   measured	   by	   monitoring	   the	   OD600nm	   during	   growth.	   The	  364	  
	   13	  
measurements	  were	  done	  at	  least	  in	  duplicates.	  Growth	  rates	  were	  calculated	  from	  the	  exponential	  part	  of	  365	  
the	  growth	  curves	  and	  expressed	  as	  doubling	  times	  in	  minutes	  (ln(2)/minutes).	  	  366	  
	  367	  
PCR	  strategy	  for	  detecting	  HGT	  	  368	  
A	  PCR	  strategy	  was	  constructed	  for	  detecting	  if	  the	  DNA	  in	  region	  1	  could	  be	  classified	  as	  DK1	  or	  DK2	  DNA	  369	  
of	  isolates	  from	  patient	  P24M2.	  Primers	  were	  constructed	  for	  amplification	  of	  two	  independent	  fragments	  370	  
of	  region	  1.	  Primers	  are	  listed	  in	  Table	  3.	  After	  amplification,	  the	  PCR	  product	  was	  digested	  with	  either	  KpnI	  371	  
or	  EcoRI	  to	  detect	   if	  the	  fragment	  was	   identical	  to	  DK1	  or	  DK2	  DNA.	  An	  isolate	  with	  DK1	  DNA	  in	  region	  1	  372	  
would	  only	  be	  digested	  with	  KpnI,	  where	  a	  DNA	  fragment	  that	  originated	  from	  DK2	  only	  would	  be	  cut	  by	  373	  
EcoRI.	  In	  this	  way	  we	  could	  detect	  if	  a	  DK2	  clone	  had	  DK1	  DNA	  in	  region	  1.	  	  374	  
	  375	  
Pyocin	  susceptibility	  test	  	  376	  
The	  pyocin	  susceptibility	  of	  the	  clinical	  isolates	  was	  determined	  as	  previously	  described	  [11].	  Briefly,	  strains	  377	  
were	  grown	  overnight	   (ON)	  at	  37°C	   in	  LB	  broth.	  Cultures	  were	  spun	  down	  at	  11,000xg	   for	  5	  min	  and	  5%	  378	  
chloroform	  was	  added	  to	  the	  supernatant	  to	  kill	  the	  residual	  bacteria.	  This	  solution	  was	  used	  as	  a	  source	  of	  379	  
pyocins.	   The	   indicator	   strains	  were	   grown	  ON	  at	   diluted	   to	   an	  OD600	   =	   0.64	   in	   0.9%	  NaCl	   and	  3	  µL	  were	  380	  
added	  to	  3	  mL	  of	  top	  agar	  (0.4%	  LB	  agar)	  and	  poured	  onto	  a	  LB	  medium	  plate.	  4	  µL	  of	  the	  pyocin	  solution	  381	  
was	  spotted	  on	  the	  agar	  plate	  and	  incubated	  ON	  at	  30°C.	  Clear	  lysis	  zones	  were	  considered	  to	  be	  the	  result	  382	  
of	  pyocin	  activity.	  	  383	  
R-­‐pyocins	  were	   isolated	  from	  the	  following	  strains	  PAK	  (R1-­‐pyocin	  producer),	  PAO1	  (R2-­‐pyocin	  producer),	  384	  
NIH-­‐I	  (R3-­‐pyocin	  producer),	  NIH-­‐H	  (R4-­‐pyocin	  producer)	  and	  NIH-­‐1	  (R5-­‐pyocin).	  The	  clinical	  isolate	  WTB	  was	  385	  
used	  as	  control	  as	  it	  was	  sensitive	  to	  all	  R-­‐type	  pyocins.	  	  386	  
Fluorescence-­‐tagged	  strains	  were	  constructed	  as	  previously	  described	  with	  green	  fluorescent	  protein	  (GFP)	  387	  
or	   monomeric	   red	   fluorescent	   protein	   (mRFP1)	   using	   miniTn7	   constructs	   [38].	   The	   tagged	   strains	   were	  388	  
tested	  for	  their	  pyocin	  susceptibility	  as	  described	  above	  and	  the	  differences	  between	  DK1/2	  and	  DK2	  was	  389	  
visualized	  by	  inspecting	  the	  fluorescence	  of	  the	  strains	  in	  the	  R5	  undiluted	  spot	  zone	  with	  a	  Zeiss	  Axioplan	  2	  390	  
microscope	  using	  a	  2.5/0.075×	  neofluar	  plan	  objective.	  391	  
	  392	  
LPS	  purification	  and	  analysis	  393	  
LPS	  was	  prepared	  using	  the	  proteinase	  K	  digestion	  method	  described	  by	  Hitchcock	  and	  Brown	  [1].	  LPS	  was	  394	  
13nalysed	   by	   electrophoresis	   on	   12%	   SDS-­‐polyacrylamide	   gels.	   Banding	   patterns	   were	   visualized	   by	   the	  395	  
silver	   staining	  method	  of	  Fomsgaard	  et	  al.	   [30].	  Western	   immunoblot	  analysis	  was	  performed	  using	  Mab	  396	  
N1F10	   (specific	   for	   A-­‐band	   LPS	   [39])	   [40].	   The	   secondary	   antibody	   alkaline	   phosphatase-­‐conjugated	   goat	  397	  
	   14	  
anti-­‐mouse	   Fab2	   (Jackson	   ImmunoResearch)	   was	   used.	   Finally	   the	   blots	   were	   developed	   using	   nitroblue	  398	  
tetrazolium	  (NBT)	  and	  5-­‐bromo-­‐4-­‐chloro-­‐3-­‐indolylphosphate	  (BCIP)	  as	  described	  previously	  [40].	  In	  order	  to	  399	  
standardize	  the	  samples,	  the	  lower	  part	  of	  the	  LPS	  gel	  was	  silver	  stained,	  while	  the	  upper	  part	  was	  blotted	  400	  
with	  N1F10.	  	  	  	  401	  
	  402	  
Tobramycin	  killing	  curves	  	  403	  
The	   time	  kill	   curves	  of	  PAO1	  and	  mutant	  PAO1wbpZ	  were	  performed	   in	   triplicates	   in	  microtitre	  plates	  as	  404	  
described	  by	  Schurek	  et	  al.	  [19]	  with	  modifications.	  Briefly,	  isogenic	  mutants	  were	  grown	  in	  cation-­‐adjusted	  405	  
MHB	  (CAMHB)	  at	  37°C	  ON.	  Cultures	  were	  inoculated	  to	  an	  optical	  density	  at	  600	  nm	  of	  0.01	  and	  grown	  to	  406	  
OD600	   of	   0.5.	   Cultures	  were	   inoculated	   in	  microtitre	   plates	   containing	   2XMIC	  of	   tobramycin	   (1	  µg/mL	   for	  407	  
PAO1)	  at	  a	  final	  concentration	  of	  OD600	  0.005.	  Separate	  wells	  were	  inoculated	  for	  each	  time	  point.	  Aliquots	  408	  
were	  plated	  on	  LB	  plates	  at	  0,	  10,	  20,	  30,	  40,	  50,	  and	  60	  minutes	  and	  incubated	  ON	  at	  37°C	  for	  counting.	  409	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Figures:	  
	  
Figure	   1.	   Detection	   of	   horizontal	   gene	   transfer	   between	   DK2	   and	   DK1.	  A)	   SNPs	   of	   P24M2-­‐02	  mapped	  
against	   P.	   aeruginosa	   DK2	   chromosome.	   The	   SNPs	   cluster	   mainly	   in	   two	   regions;	   region	   1	   (position	  
6,205,709	  –	  19,887)	  and	  region	  2	  (position	  5,346,283	  –	  5,354,044).	  Black	  lines	  indicate	  the	  SNP	  difference	  
of	  DK2-­‐P24M2-­‐2002	  compared	  with	  CF333-­‐07.	  B)	  Overview	  of	  P.	  aeruginosa	   clones	   isolated	   from	  patient	  
P24M2.	   Sampling	   time	  and	   clone	   genotype	  are	   showed;	   red	  dots	   represent	  DK1	   isolates	  while	  blue	  dots	  
represent	  DK2.	  Blue	  dots	  with	  red	  circles	  represent	  DK1/2	   isolates.	  The	   isolates	  are	  named	  by	  their	  clone	  
type,	  and	  by	  the	  patient	  from	  whom	  they	  were	  isolated	  and	  their	  isolation	  year	  (e.g.	  DK2-­‐P24M2-­‐1987).	  	  C)	  
Phylogenetic	  tree	  of	  Region	  1.	  DK2-­‐P24M2-­‐2002	  and	  the	  DK1	  cluster	  are	  separated	  with	  6	  SNPs,	  while	  DK2-­‐
P24M2-­‐2002	  and	  DK2	  are	  separated	  with	  251	  SNPs.	  The	  6	  SNPs	  differences	  were	  4	  silent	  mutations	  and	  to	  
missense	  found	   in	  wbpZ	  and	  PADK2_28940.	  The	  phylogenetic	  tree	   is	  based	  on	  the	  251	   identified	  SNPs	  of	  
region	  1	   from	  whole-­‐genome	  sequencing	  and	   lengths	  of	  branches	  are	  proportional	   to	   the	  SNPs	  between	  
the	   isolates.	   D)	   Representation	   of	   differences	   between	  DK1,	  DK2,	   and	  DK1/2	   in	   region	   2.	   DK1/2-­‐P24M2-­‐
2002	   and	   DK2-­‐CF333-­‐2007	   are	   separated	   by	   14	   SNPs,	   while	   DK1/2-­‐P24M2-­‐2002	   and	   DK1-­‐CF33-­‐1973	   is	  
separated	  with	  19	  SNPs.	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Figure	  2.	  Population	   structure	  of	  P24M2.	  A)	  Phylogenetic	   three	  of	  DK2	  and	  DK1/2	   isolates	   from	  P24M2.	  
The	   three	   is	   based	   on	   SNPs	   identified	   by	   whole	   genome	   sequencing	   and	   lengths	   of	   branches	   are	  
proportional	  to	  the	  number	  of	  mutations.	   Isolate	  DK2-­‐CF66-­‐1973	  and	  DK2-­‐CF30-­‐1979	  (from	  [9])	  was	  used	  
as	  an	  outgroup	  to	  determine	  the	  root	  of	  the	  P24M2	  tree.	  B)	  Model	  of	  population	  structure	  and	  diversity	  of	  
five	  different	  sub-­‐populations	   (1-­‐5)	   from	  patient	  P24M2.	   (1)	  Sub-­‐population	  of	  DK2	   found	  to	  be	  mutator.	  
(2)	  Non-­‐mutators	   found	  to	  be	  closely	  related	  to	  DK1/2	  (4),	   that	  at	  a	  given	  time	  point	  before	  1997	  gained	  
horizontally	  transferred	  region	  (a)	  from	  DK1.	  (3)	  Sub-­‐population	  of	  DK2	  occurring	  in	  2002	  that	  was	  found	  to	  
be	  mucoid.	  DK1	  showed	  co-­‐existence	  of	  two	  sub-­‐populations:	  (5)	  was	  a	  non-­‐mucoid	  sub-­‐population	  and	  (6)	  
was	  found	  to	  be	  mucoid.	  The	  model	  is	  made	  based	  on	  both	  phenotypic	  and	  genotypic	  data.	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Figure	   3.	   Pyocin	   killing	   assay.	  A)	   The	   killing	   ability	   of	   R1-­‐R5	   pyocins	   isolated	   from	  P.	   aeruginosa	   strains	  
against	  DK1,	  DK2	  and	  DK1/2	  isolates	  were	  measured	  by	  spotting	  R1	  (PAK),	  R2	  (PAO1),	  R3,	  (NIH-­‐I),	  R4	  (NIH-­‐
H),	   and	   R5	   (NIH-­‐1)	   on	   top	   of	   the	   bacterial	   lawn	   in	   different	   concentrations.	   B)	   Spot	   zones	   of	   R5	   pyocin	  
(undiluted)	  on	  lawns	  of	  fluorescently	  tagged	  strains	  with	  either	  GFP	  (DK1/2-­‐P24M2-­‐2002	  and	  DK2-­‐P24M2-­‐
2003a)	  or	  mRFP1	  (DK1-­‐P24M2-­‐2003a).	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Figure	  4:	  SDS-­‐polyacrylamide	  gel	  and	  western	  immunoblot	  analysis	  of	  LPS	  from	  PAO1,	  wbpZ,	  and	  clinical	  
isolates	  from	  P24M2.	  A)	  (Top)	  Western	  immunoblot	  obtained	  with	  Mab	  N1F10	  (A-­‐band	  specific);	  (bottom)	  
silver	  stained	  SDS-­‐PAGE	  obtained	   from	  the	  same	  gel.	  B)	  Western	   immunoblot	  obtained	  with	  Mab	  N1F10.	  
Lanes	  1	  to	  20	  are	  identical	   in	  subfigure	  A	  and	  B.	  Colours	  indicate	  the	  genotype	  DK1	  (red),	  DK2	  (blue),	  and	  
DK1/2	   (green)	   of	   the	   clinical	   isolates.	   Note	   that	   the	   differences	   of	   reactivity	   of	   LPS	   observed	   between	  
samples	  are	  not	  due	  to	  loading	  variation.	  To	  ensure	  that	  the	  level	  of	  reactivity	  of	  LPS	  with	  Mab	  N1F10	  was	  
constant	  among	   the	  different	  clinical	   isolates	  and	  mutants,	   sample	   loads	  were	  simultaneously	  monitored	  
on	  silver	  stain	  (lower	  part	  of	  SDS-­‐PAGE)	  and	  Western	  blot	  by	  reacting	  the	  blots	  with	  Mab	  N1F10.	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Figure	  5.	  Tobramycin	  killing	  curves.	  A)	  Impact	  of	  wbpZ	  point	  mutation	  on	  tobramycin	  killing	  of	  strain	  PAO1.	  
Error	  bars	  represent	  the	  standard	  deviations	  calculated	  from	  at	  least	  triplicates.	  B)	  Percent	  survival	  of	  PAO1	  
and	   PAO1wbpZ	   point	   mutant	   after	   60	   minutes	   of	   exposure	   to	   tobramycin.	   Error	   bars	   represent	   the	  




Table	  1.	  Complementation	  of	  DK1/2	  by	  HGT	  from	  DK1.	  Nucleotides	  for	  PAO1,	  DK1,	  DK2	  and	  DK1/2	  is	  





Locus	  tag	   Gene	  name	   PAO1	   DK1	   DK2	   DK1/2	   PseudoCAP	  Function	  Class	  
18494	   Missense	   PADK2_00080	   trkA	   G	   G	   A	   G	   potassium	  transporter	  peripheral	  
membrane	  component	  
17391	   Silent	   PADK2_00080	   trkA	   A	   A	   C	   A	   potassium	  transporter	  peripheral	  
membrane	  component	  
17727	   Silent	   PADK2_00080	   trkA	   G	   G	   T	   G	   potassium	  transporter	  peripheral	  
membrane	  component	  
17751	   Silent	   PADK2_00080	   trkA	   A	   A	   G	   A	   potassium	  transporter	  peripheral	  
membrane	  component	  
6217415	   Silent	   PADK2_28735	   	   T	   T	   G	   T	   electron	  transfer	  flavoprotein,	  
alpha	  subunit	  
6237772	   Intergenic	   PADK2_28830//PADK2_28835	   G	   G	   A	   G	   27	  downstream	  sarcosine	  oxidase	  




Table	  2.	  Bacterial	  strains	  and	  plasmids	  used	  in	  this	  study.	  
Strains,	  plasmids	  or	  primers	   Relevant	  genotype	  or	  phenotype	   Source	  of	  reference	  
Strains	   	   	  
CC118λpir	   E.coli	  CC18	  lysogenized	  with	  λ-­‐pir	  phage	   [41]	  
HB101	   E.	  coli,	  recA,	  thi,	  pro,	  leu,	  hsd	  RM+;	  SmR	   [42]	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PAO1	   P.	  aeruginosa	  Wild-­‐type	   [43]	  
PAO1wbpZ	   PAO1	  wbpZ	  (C896T)	   This	  study	  
CF333-­‐07	   DK2	   isolate	   from	   patient	   CF333	   from	   2007,	   GenBank	   accession	   no.	  
CP003149)	  
[37]	  
DK1/2-­‐P24M2-­‐1997	   DK2	  isolate	  from	  patient	  P24M2	  sampled	  in	  1997	  containing	  the	  HGT.	   This	  study	  
DK1/2-­‐P24M2-­‐2002	   DK2	  isolate	  from	  patient	  P24M2	  sampled	  in	  2002	  containing	  the	  HGT.	   This	  study	  
DK1-­‐P24M2-­‐2003a	   DK1	  isolate	  from	  patient	  P24M2	  sampled	  in	  2003	   This	  study	  
DK2-­‐P24M2-­‐2003a	   DK2	  isolate	  from	  patient	  P24M2	  sampled	  in	  2003	   This	  study	  
DK1/2-­‐P24M2-­‐1997wbpZ(wt)	   DK1/2-­‐P24M2-­‐1997	  with	  wt	  wbpZ	   This	  study	  
DK1/2-­‐P24M2-­‐2002wbpZ(wt)	   DK1/2-­‐P24M2-­‐2002	  with	  wt	  wbpZ	   This	  study	  
DK2-­‐P24M2-­‐2003awbpZ	   DK2-­‐P24M2-­‐2003a	  with	  wbpZ(C896T)	   This	  study	  
DK1-­‐P24M2-­‐2003awbpZ	   DK1-­‐P24M2-­‐2003a	  with	  wbpZ(C896T)	   This	  study	  
PAO1pHERD-­‐wbpZ	   PAO1wbpZ	  complemented	  in	  trans	  with	  pYHJL31	   This	  study	  
DK1pHERD-­‐wbpZ	   DK1-­‐P24M2-­‐2003awbpZ	  complemented	  in	  trans	  with	  pYHJL31	   This	  study	  
Plasmids	   	   	  
pNJ1	   TcR,	   sacB+	   R6K	   ori,	   mobRP4,	   allelic	   replacement	   vector	   derived	   from	  
pDS132	  
[44]	  
pTM2	   ,	  pNJ1	  with	  SacI-­‐XbaI	  fragment	  containing	  PAO1	  wbpZ(C896T)	   This	  study	  
pTM5	   ,	  pNJ1	  with	  SacI-­‐XbaI	  fragment	  containing	  PAO1	  wt	  wpbZ	   This	  study	  
pYHJL31	   ,pHERD20T	  with	  SacI-­‐XbaI	  fragment	  containing	  PAO1	  wt	  wbpZ	   [36]	  
pTMM	   ,	  pNJ1	  with	  SacI-­‐XbaI	  fragment	  containing	  CF333-­‐07	  PADK2_24865	   This	  study	  
pTMI	   ,	   pNJ1	   with	   SacI-­‐XbaI	   fragment	   containing	   CF333-­‐07	  
PADK2_24875//PADK2_24880	  
This	  study	  
pRK600	   CmR,	  ori	  ColE1	  RK2-­‐Mob+	  RK2-­‐Tra+	  helper	  plasmid	  in	  triparental	  matings	   [42]	  
miniTn7	  GFP	   miniTn7(GM)PA1/04/03::gfp	  Gm
R	   [45]	  
miniTn7	  mRFP1	   miniTn7(GM)PA1/04/03::mRFP1	  Gm
R	   [46]	  
pUX-­‐BF13	   R6K	   replicon-­‐based	   helper	   plasmid,	   providing	   the	   Tn7	   transposition	  
function	  in	  trans.	  Amp+,	  mob+	  
[38]	  
	  
Table	  S2.	  List	  of	  Single	  Nucleotide	  Polymorphims	  and	  indels	  transferred	  from	  DK1	  to	  DK1/2	  in	  region	  1.	  
Table	  S2	  is	  available	  here:	  https://www.dropbox.com/sh/qqbt2ezwlhl6ahl/1EsaTipuGr	  	  
	  
Table	  S3.	  Primers	  used	  for	  detecting	  HGT.	  	  




Size	  of	  PCR	  product(s)	  (bp)	   Size	  of	  fragments	  
when	  digested	  
KpnI_fw	   KpnI	   DK1	   TCCAGGTACGTGGCGAAG	   834	   393,	  441	  
KpnI_rev	   	   	   CGTGGAAACCATCGAACAG	   	   	  
EcoRI_fw	   EcoRI	   DK2	   GGTAGTGCGGATCAACCTGT	   968	   425,	  543	  
EcoRI_rev	   	   	   GCTCCGGGTGTTTGACATAG	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  information	  
	  
Figure	  S1.	  Pyocin	  susceptibility	  test.	  The	  pyocin	  isolated	  from	  DK2-­‐P24M2-­‐1987	  (1),	  DK1-­‐P24M2-­‐1992a	  (2),	  
DK1-­‐P24M2-­‐1994a	   (3),	   DK1-­‐P24M2-­‐1995a	   (4),	   DK2-­‐P24M2-­‐1995a	   (5),	   DK1-­‐P24M2-­‐1997a	   (6),	   DK1/2-­‐
P24M2-­‐1997	  (7),	  DK2-­‐P24M2-­‐1999	  (8),	  DK2-­‐P24M2-­‐2002a	  (9),	  DK1/2-­‐P24M2-­‐2002	  (10),	  DK1-­‐P24M2-­‐2003s	  
(11),	  and	  DK2-­‐P24M2-­‐2003a	  (12)	  were	  tested	  against	  the	  sensitive	  control	  stain	  DK2-­‐CF510-­‐2006	  together	  
with	  the	  five	  known	  R-­‐type	  pyocins	  (R1-­‐R5).	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Table	  S1.	  Phenotypic	  characterization	  of	  isolates	  from	  patient	  P24M2.	  1	  
name	   muc/nona	   Genotype	   Region	  1	   Doubling	  time	  (min)	   Morphologyb	   Hypermutatorc	  
DK1-­‐P24M2-­‐1992a	   nm	   DK1	   DK1	   45.5	   green	   ND	  
DK1-­‐P24M2-­‐1992b	   m	   DK1	   DK1	   64.82	   Brown	   -­‐	  
DK1_P24M2-­‐1992c	   m	   DK1	   DK1	   56.7	   green	   ND	  
DK1-­‐P24M2-­‐1994a	   nm	   DK1	   DK1	   50.5	   green	   ND	  
DK1-­‐P24M2-­‐1994b	   nm	   DK1	   DK1	   69.67	   Yellow	   ND	  
DK1-­‐P24M2-­‐1995b	   m	   DK1	   DK1	   34.7	   green	   ND	  
DK1-­‐P24M2-­‐1995a	   m	   DK1	   DK1	   68.7	   green	   ND	  
DK1-­‐P24M2-­‐1997b	   m	   DK1	   DK1	   61.51	   Brown	   ND	  
DK1-­‐P24M2-­‐1997a	   nm	   DK1	   DK1	   66.97	   Green	   ND	  
DK1-­‐P24M2-­‐2003b	   m	   DK1	   DK1	   60.83	   Brown	   -­‐	  
DK1-­‐P24M2-­‐2003a	   nm	   DK1	   DK1	   62.04	   Green	   ND	  
DK2-­‐P24M2-­‐1987	   nm	   DK2	   DK2	   101.85	   Colorless,	  sheen	   -­‐	  
DK2-­‐P24M2-­‐1988	   nm	   DK2	   DK2	   110.31	   Colorless,	  sheen	   ND	  
DK2-­‐P24M2-­‐1992	   nm	   DK2	   DK2	   109.7	   White/colorless,	  sheen	   ND	  
DK2-­‐P24M2-­‐1994	   nm	   DK2	   DK2	   77.6	   Yellow	   +	  
DK2-­‐P24M2-­‐1995a	   nm	   DK2	   DK2	   89.61	   Colorless,	  sheen	   ND	  
DK2-­‐P24M2-­‐1995b	   nm	   DK2	   DK2	   90.4	   Colorless,	  sheen	   ND	  
DK2-­‐P24M2-­‐1995c	   nm	   DK2	   DK2	   84.6	   Yellow/sheen	   ND	  
DK2-­‐P24M2-­‐1995d	   nm	   DK2	   DK2	   80.5	   Yellow/sheen	   ND	  
DK1/2-­‐P24M2-­‐1997	   nm	   DK2	   DK1	   67.35	   Colorless,	  sheen	   -­‐	  
DK2-­‐P24M2-­‐1999	   nm	   DK2	   DK2	   89.4	   Yellow/sheen	   ND	  
DK1/2-­‐P24M2-­‐2002	   nm	   DK2	   DK1	   76.61	   Colorless,	  sheen	   -­‐	  
DK2-­‐P24M2-­‐2002a	   nm	   DK2	   DK2	   54.74	   White/colorless	   ND	  
DK2-­‐P24M2-­‐2002b	   m	   DK2	   DK2	   80.59	   White/colorless	   +	  
DK2-­‐P24M2-­‐2002c	   m	   DK2	   DK2	   67.2	   White/colorless	   ND	  
DK2-­‐P24M2-­‐2002d	   nm	   DK2	   DK2	   48.5	   White/colorless	   ND	  
DK2-­‐P24M2-­‐2002e	   nm	   DK2	   DK2	   ND	   White/colorless	   ND	  
DK2-­‐P24M2-­‐2003a	   nm	   DK2	   DK2	   96.95	   White/colorless	   -­‐	  
DK2-­‐P24M2-­‐2003b	   nm	   DK2	   DK2	   80.74	   White/colorless	   ND	  
DK2-­‐P24M2-­‐2003c	   m	   DK2	   DK2	   111.83	   White/colorless	   -­‐	  
a	  muc/non;	  m,	  mucoid;	  nm,	  non-­‐mucoid	  2	  
b	  Color	  of	  colonies	  grown	  on	  LB	  agar	  plates.	  Sheen;	  visible	  metallic	  irident	  sheen	  when	  grown	  on	  LB	  agar.	  3	  
c	  Hypermutation	  was	  determined	  based	  on	  sequencing	  data	  showing	  elavated	  mutation	  rate	  and/or	  4	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Table	  S3.	  Tobramycin	  MIC	  values	  of	  DK1,	  DK2,	  and	  DK1/2	  strains	  14	  
Strain	   Tobramycin	  MIC	  
(µg/mL)	  
PAO1	   0.25	  
DK1/2-­‐P24M2-­‐1997	   16	  
DK1/2-­‐P24M2-­‐1997wbpZ(wt)	   16	  
DK1/2-­‐P24M2-­‐2002	   8	  
DK1/2-­‐P24M2-­‐2002wbpZ(wt)	   8	  
DK1-­‐P24M2-­‐2003a	   0.5	  
DK1-­‐P24M2-­‐2003awbpZ	   0.5	  
DK2-­‐P24M2-­‐2003a	   4	  
DK2-­‐P24M2-­‐2003awbpZ	   4	  
	  15	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Table	  S4.	  Primers	  used	  in	  this	  study	  17	  
Primers	   Oligonucleotide	  sequence	  (5’-­‐3’)	   Reference	  
wbpZ-­‐fw-­‐SacI	   GAGAGAGCTCGCATCCAGAGCCGTCGCCAG	   This	  study	  
wbpZ-­‐rev-­‐XbaI	   ACATTTAGATCGTCGGGGTGATGCGCTAC	   This	  study	  
M_fw_SacI	   GAGAGAGCTCACTTCGGTCAGGCCTTCAAT	   This	  study	  
M_rev_XbaI	   ACATTTAGACTGCACGTCCGACAGTTG	   This	  study	  
I_fw_SacI	   GAGAGAGCTCATAGACAGGCCAGGGGACTT	   This	  study	  
I_rev_XbaI	   ACATTTAGAAAAAAGCGCCGATTGTACTG	   This	  study	  
	  18	  
